2599 lines
736 KiB
Text
2599 lines
736 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-toc">
|
|
<meta name="ncbi_acc" content="NBK565358">
|
|
<meta name="ncbi_domain" content="niceng185er6">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK565358/?report=reader">
|
|
<meta name="ncbi_pagename" content="Evidence review for the clinical and cost-effectiveness of drug-eluting stents - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="toc">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Evidence review for the clinical and cost-effectiveness of drug-eluting stents - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="1">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE,NOIMAGEINDEX">
|
|
<meta name="author" content="National Guideline Centre (UK)">
|
|
<meta name="citation_title" content="Evidence review for the clinical and cost-effectiveness of drug-eluting stents">
|
|
<meta name="citation_publisher" content="National Institute for Health and Care Excellence (NICE)">
|
|
<meta name="citation_date" content="2020/11">
|
|
<meta name="citation_author" content="National Guideline Centre (UK)">
|
|
<meta name="citation_pmid" content="33301274">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK565358/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Evidence review for the clinical and cost-effectiveness of drug-eluting stents">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Institute for Health and Care Excellence (NICE)">
|
|
<meta name="DC.Contributor" content="National Guideline Centre (UK)">
|
|
<meta name="DC.Date" content="2020/11">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK565358/">
|
|
<meta name="og:title" content="Evidence review for the clinical and cost-effectiveness of drug-eluting stents">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK565358/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-niceng185er6-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/niceng185er6/toc/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK565358/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8C348D7D717A710000000000B30083.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK565358/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-cmap-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK565358/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK565358/&text=Evidence%20review%20for%20the%20clinical%20and%20cost-effectiveness%20of%20drug-eluting%20stents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-cmap-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">In Page Navigation</div></div><div class="cnt lol f1"><a href="/books/n/niceercollect/?report=reader">NICE Evidence Reviews Collection</a><a class="current">Title Information</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK565358/?report=classic">Switch to classic view</a><a href="/books/n/niceng185er6/pdf/">PDF (3.2M)</a><a href="/books/n/niceng185er6/toc/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK565358%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8C348D7D717A710000000000B30083.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style"><div class="fm-sec bkr_bottom_sep"><div class="bkr_thumb"><a href="https://www.nice.org.uk" title="National Institute for Health and Care Excellence (NICE)" class="img_link icnblk_img" ref="pagearea=logo&targetsite=external&targetcat=link&targettype=publisher"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-niceng185er6-lrg.png" alt="Cover of Evidence review for the clinical and cost-effectiveness of drug-eluting stents" /></a></div><div class="bkr_bib"><h1 id="_NBK565358_"><span itemprop="name">Evidence review for the clinical and cost-effectiveness of drug-eluting stents</span></h1><div class="subtitle">Acute coronary syndromes</div><p><b>Evidence review F</b></p><p><i>NICE Guideline, No. 185</i></p><p class="contrib-group"><h4>Authors</h4><span itemprop="author">National Guideline Centre (UK)</span>.</p><div class="half_rhythm">London: <a href="https://www.nice.org.uk" ref="pagearea=meta&targetsite=external&targetcat=link&targettype=publisher"><span itemprop="publisher">National Institute for Health and Care Excellence (NICE)</span></a>; <span itemprop="datePublished">2020 Nov</span>.<div class="small">ISBN-13: <span itemprop="isbn">978-1-4731-3902-2</span></div></div><div><a href="/books/about/copyright/">Copyright</a> © NICE 2020.</div></div><div class="bkr_clear"></div></div><div id="niceng185er6.s1"><h2 id="_niceng185er6_s1_">1. Drug eluting stents</h2><div id="niceng185er6.s1.1"><h3>1.1. Review question: What is the clinical and cost effectiveness of drug-eluting stents in adults with acute coronary syndromes, including those with unstable angina or NSTEMI undergoing percutaneous coronary intervention and those with STEMI undergoing primary percutaneous coronary intervention?</h3></div><div id="niceng185er6.s1.2"><h3>1.2. Introduction</h3><p>In 2008 drug-eluting stents were recommended in certain circumstances by NICE technology appraisal 152 ‘Drug-eluting stents for the treatment of coronary artery disease’:
|
|
<ul><li class="half_rhythm"><div>Drug-eluting stents are recommended for use in percutaneous coronary intervention for the treatment of coronary artery disease, within their instructions for use, only if:
|
|
<ul class="circle"><li class="half_rhythm"><div>the target artery to be treated has less than a 3-mm calibre or the lesion is longer than 15 mm, and</div></li><li class="half_rhythm"><div>the price difference between drug-eluting stents and bare-metal stents is no more than £300.<a class="bibr" href="#niceng185er6.ref81" rid="niceng185er6.ref81"><sup>81</sup></a></div></li></ul></div></li></ul></p><p>This was on the basis of a systematic review of the evidence and cost effectiveness modelling. However, since then drug-eluting stents have continued to develop and new studies have been published. Audit data from 2016 reported that 92% of PCIs used stents and 90% used drug eluting stents and this varied only slightly by indication (that is, it was 89% in PPCI for STEMI).</p><p>This guideline will review the evidence for drug eluting stents compared to bare metal stents in people with ACS and partially update and replace the recommendations from TA152. It is important to note that TA152 covered all PCI whereas this guideline will only be updating recommendations in relation to people with ACS.</p></div><div id="niceng185er6.s1.3"><h3>1.3. PICO table</h3><p>For full details see the review protocol in <a href="#niceng185er6.appa">appendix A</a>.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er6tab1"><a href="/books/NBK565358/table/niceng185er6.tab1/?report=objectonly" target="object" title="Table 1" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er6tab1" rid-ob="figobniceng185er6tab1"><img class="small-thumb" src="/books/NBK565358/table/niceng185er6.tab1/?report=thumb" src-large="/books/NBK565358/table/niceng185er6.tab1/?report=previmg" alt="Table 1. PICO characteristics of review question." /></a><div class="icnblk_cntnt"><h4 id="niceng185er6.tab1"><a href="/books/NBK565358/table/niceng185er6.tab1/?report=objectonly" target="object" rid-ob="figobniceng185er6tab1">Table 1</a></h4><p class="float-caption no_bottom_margin">PICO characteristics of review question. </p></div></div></div><div id="niceng185er6.s1.4"><h3>1.4. Methods and process</h3><p>This evidence review was developed using the methods and process described in Developing NICE guidelines: the manual.<a class="bibr" href="#niceng185er6.ref28" rid="niceng185er6.ref28"><sup>28</sup></a> Methods specific to this review question are described in the review protocol in <a href="#niceng185er6.appa">appendix A</a>.</p><p>Declarations of interest were recorded according to NICE’s 2014 conflicts of interest policy.</p></div><div id="niceng185er6.s1.5"><h3>1.5. Clinical evidence</h3><div id="niceng185er6.s1.5.1"><h4>1.5.1. Included studies</h4><p>Twenty-nine trials (fifty papers) were included in the review;<a class="bibr" href="#niceng185er6.ref7" rid="niceng185er6.ref7"><sup>7</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er6.ref13" rid="niceng185er6.ref13"><sup>13</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er6.ref14" rid="niceng185er6.ref14"><sup>14</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er6.ref17" rid="niceng185er6.ref17"><sup>17</sup></a><sup>–</sup><a class="bibr" href="#niceng185er6.ref19" rid="niceng185er6.ref19"><sup>19</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er6.ref22" rid="niceng185er6.ref22"><sup>22</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er6.ref27" rid="niceng185er6.ref27"><sup>27</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er6.ref32" rid="niceng185er6.ref32"><sup>32</sup></a><sup>–</sup><a class="bibr" href="#niceng185er6.ref36" rid="niceng185er6.ref36"><sup>36</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er6.ref46" rid="niceng185er6.ref46"><sup>46</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er6.ref47" rid="niceng185er6.ref47"><sup>47</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er6.ref55" rid="niceng185er6.ref55"><sup>55</sup></a><sup>–</sup><a class="bibr" href="#niceng185er6.ref57" rid="niceng185er6.ref57"><sup>57</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er6.ref61" rid="niceng185er6.ref61"><sup>61</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er6.ref67" rid="niceng185er6.ref67"><sup>67</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er6.ref73" rid="niceng185er6.ref73"><sup>73</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er6.ref75" rid="niceng185er6.ref75"><sup>75</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er6.ref76" rid="niceng185er6.ref76"><sup>76</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er6.ref88" rid="niceng185er6.ref88"><sup>88</sup></a><sup>–</sup><a class="bibr" href="#niceng185er6.ref91" rid="niceng185er6.ref91"><sup>91</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er6.ref94" rid="niceng185er6.ref94"><sup>94</sup></a><sup>–</sup><a class="bibr" href="#niceng185er6.ref96" rid="niceng185er6.ref96"><sup>96</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er6.ref100" rid="niceng185er6.ref100"><sup>100</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er6.ref102" rid="niceng185er6.ref102"><sup>102</sup></a><sup>–</sup><a class="bibr" href="#niceng185er6.ref105" rid="niceng185er6.ref105"><sup>105</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er6.ref109" rid="niceng185er6.ref109"><sup>109</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er6.ref111" rid="niceng185er6.ref111"><sup>111</sup></a><sup>–</sup><a class="bibr" href="#niceng185er6.ref114" rid="niceng185er6.ref114"><sup>114</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er6.ref116" rid="niceng185er6.ref116"><sup>116</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er6.ref121" rid="niceng185er6.ref121"><sup>121</sup></a><sup>–</sup><a class="bibr" href="#niceng185er6.ref126" rid="niceng185er6.ref126"><sup>126</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er6.ref128" rid="niceng185er6.ref128"><sup>128</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er6.ref131" rid="niceng185er6.ref131"><sup>131</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er6.ref133" rid="niceng185er6.ref133"><sup>133</sup></a> that evaluated drug-eluting stents versus bare metal stents. Evidence from these studies is summarised in the clinical evidence summary below (<a class="figpopup" href="/books/NBK565358/table/niceng185er6.tab4/?report=objectonly" target="object" rid-figpopup="figniceng185er6tab4" rid-ob="figobniceng185er6tab4">Table 4</a>).</p><p>One relevant Cochrane review was identified for this evidence review.<a class="bibr" href="#niceng185er6.ref42" rid="niceng185er6.ref42"><sup>42</sup></a> This Cochrane review’s PICO was similar to the PICO developed by the guideline committee. However, the Cochrane review did not have an upper limit for the outcome time-points. As seen in <a class="figpopup" href="/books/NBK565358/table/niceng185er6.tab1/?report=objectonly" target="object" rid-figpopup="figniceng185er6tab1" rid-ob="figobniceng185er6tab1">Table 1</a>, the guideline committee agreed on reviewing outcome data that was reported up to 3 years. The studies included in the Cochrane were reviewed and included if applicable.</p><p>See also the study selection flow chart in <a href="#niceng185er6.appc">appendix C</a>, study evidence tables in <a href="#niceng185er6.appd">appendix D</a>, forest plots in <a href="#niceng185er6.appe">appendix E</a> and GRADE tables in <a href="#niceng185er6.apph">appendix H</a>.</p></div><div id="niceng185er6.s1.5.2"><h4>1.5.2. Excluded studies</h4><p>See the excluded studies list in <a href="#niceng185er6.appi">appendix I</a>.</p></div><div id="niceng185er6.s1.5.3"><h4>1.5.3. Summary of clinical studies included in the evidence review</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er6tab2"><a href="/books/NBK565358/table/niceng185er6.tab2/?report=objectonly" target="object" title="Table 2" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er6tab2" rid-ob="figobniceng185er6tab2"><img class="small-thumb" src="/books/NBK565358/table/niceng185er6.tab2/?report=thumb" src-large="/books/NBK565358/table/niceng185er6.tab2/?report=previmg" alt="Table 2. Summary of evaluated outcomes in included studies." /></a><div class="icnblk_cntnt"><h4 id="niceng185er6.tab2"><a href="/books/NBK565358/table/niceng185er6.tab2/?report=objectonly" target="object" rid-ob="figobniceng185er6tab2">Table 2</a></h4><p class="float-caption no_bottom_margin">Summary of evaluated outcomes in included studies. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er6tab3"><a href="/books/NBK565358/table/niceng185er6.tab3/?report=objectonly" target="object" title="Table 3" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er6tab3" rid-ob="figobniceng185er6tab3"><img class="small-thumb" src="/books/NBK565358/table/niceng185er6.tab3/?report=thumb" src-large="/books/NBK565358/table/niceng185er6.tab3/?report=previmg" alt="Table 3. Summary of studies included in the evidence review." /></a><div class="icnblk_cntnt"><h4 id="niceng185er6.tab3"><a href="/books/NBK565358/table/niceng185er6.tab3/?report=objectonly" target="object" rid-ob="figobniceng185er6tab3">Table 3</a></h4><p class="float-caption no_bottom_margin">Summary of studies included in the evidence review. </p></div></div><p>See <a href="#niceng185er6.appd">appendix D</a> for full evidence tables.</p></div><div id="niceng185er6.s1.5.4"><h4>1.5.4. Quality assessment of clinical studies included in the evidence review</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er6tab4"><a href="/books/NBK565358/table/niceng185er6.tab4/?report=objectonly" target="object" title="Table 4" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er6tab4" rid-ob="figobniceng185er6tab4"><img class="small-thumb" src="/books/NBK565358/table/niceng185er6.tab4/?report=thumb" src-large="/books/NBK565358/table/niceng185er6.tab4/?report=previmg" alt="Table 4. Clinical evidence summary: Drug eluting stents (DES) versus bare metal stents (BMS)." /></a><div class="icnblk_cntnt"><h4 id="niceng185er6.tab4"><a href="/books/NBK565358/table/niceng185er6.tab4/?report=objectonly" target="object" rid-ob="figobniceng185er6tab4">Table 4</a></h4><p class="float-caption no_bottom_margin">Clinical evidence summary: Drug eluting stents (DES) versus bare metal stents (BMS). </p></div></div><p>See <a href="#niceng185er6.appf">appendix F</a> for full GRADE tables.</p></div></div><div id="niceng185er6.s1.6"><h3>1.6. Economic evidence</h3><div id="niceng185er6.s1.6.1"><h4>1.6.1. Included studies</h4><p>Five health economic studies with the relevant comparison were included in this review.<a class="bibr" href="#niceng185er6.ref24" rid="niceng185er6.ref24"><sup>24</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er6.ref48" rid="niceng185er6.ref48"><sup>48</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er6.ref81" rid="niceng185er6.ref81"><sup>81</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er6.ref93" rid="niceng185er6.ref93"><sup>93</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er6.ref106" rid="niceng185er6.ref106"><sup>106</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er6.ref135" rid="niceng185er6.ref135"><sup>135</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er6.ref137" rid="niceng185er6.ref137"><sup>137</sup></a> Note that two papers were identified for one study as one of these (Hill 2007<a class="bibr" href="#niceng185er6.ref48" rid="niceng185er6.ref48"><sup>48</sup></a>) is the analysis undertaken to inform TA152.<a class="bibr" href="#niceng185er6.ref81" rid="niceng185er6.ref81"><sup>81</sup></a> These are summarised in the health economic evidence profile below (<a class="figpopup" href="/books/NBK565358/table/niceng185er6.tab5/?report=objectonly" target="object" rid-figpopup="figniceng185er6tab5" rid-ob="figobniceng185er6tab5">Table 5</a>) and the health economic evidence tables in <a href="#niceng185er6.apph">Appendix H</a>:.</p></div><div id="niceng185er6.s1.6.2"><h4>1.6.2. Excluded studies</h4><p>Fifteen economic studies relating to this review question were excluded due to a combination of methodological limitations and the availability of more applicable evidence.<a class="bibr" href="#niceng185er6.ref8" rid="niceng185er6.ref8"><sup>8</sup></a><sup>–</sup><a class="bibr" href="#niceng185er6.ref10" rid="niceng185er6.ref10"><sup>10</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er6.ref20" rid="niceng185er6.ref20"><sup>20</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er6.ref21" rid="niceng185er6.ref21"><sup>21</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er6.ref39" rid="niceng185er6.ref39"><sup>39</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er6.ref45" rid="niceng185er6.ref45"><sup>45</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er6.ref52" rid="niceng185er6.ref52"><sup>52</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er6.ref54" rid="niceng185er6.ref54"><sup>54</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er6.ref65" rid="niceng185er6.ref65"><sup>65</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er6.ref69" rid="niceng185er6.ref69"><sup>69</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er6.ref87" rid="niceng185er6.ref87"><sup>87</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er6.ref117" rid="niceng185er6.ref117"><sup>117</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er6.ref118" rid="niceng185er6.ref118"><sup>118</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng185er6.ref129" rid="niceng185er6.ref129"><sup>129</sup></a> These are listed in <a href="#niceng185er6.appi">Appendix I</a>:, with reasons for exclusion given. Generally, these were studies that were published before the technology appraisal analysis, used treatment effects that were from clinical studies that did not meet the inclusion criteria or did not use QALYs.</p><p>See also the health economic study selection flow chart in <a href="#niceng185er6.appg">Appendix G</a>:.</p></div><div id="niceng185er6.s1.6.3"><h4>1.6.3. Summary of studies included in the economic evidence review</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er6tab5"><a href="/books/NBK565358/table/niceng185er6.tab5/?report=objectonly" target="object" title="Table 5" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er6tab5" rid-ob="figobniceng185er6tab5"><img class="small-thumb" src="/books/NBK565358/table/niceng185er6.tab5/?report=thumb" src-large="/books/NBK565358/table/niceng185er6.tab5/?report=previmg" alt="Table 5. Health economic evidence profile: drug-eluting stents versus bare metal stents." /></a><div class="icnblk_cntnt"><h4 id="niceng185er6.tab5"><a href="/books/NBK565358/table/niceng185er6.tab5/?report=objectonly" target="object" rid-ob="figobniceng185er6tab5">Table 5</a></h4><p class="float-caption no_bottom_margin">Health economic evidence profile: drug-eluting stents versus bare metal stents. </p></div></div><p>The tables below show additional cost effectiveness results from Hill 2007 (this analysis informed NICE TA152).<a class="bibr" href="#niceng185er6.ref48" rid="niceng185er6.ref48"><sup>48</sup></a></p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er6tab6"><a href="/books/NBK565358/table/niceng185er6.tab6/?report=objectonly" target="object" title="Table 6" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er6tab6" rid-ob="figobniceng185er6tab6"><img class="small-thumb" src="/books/NBK565358/table/niceng185er6.tab6/?report=thumb" src-large="/books/NBK565358/table/niceng185er6.tab6/?report=previmg" alt="Table 6. Hill 2007 cost-effectiveness results for non-elective PCI patients." /></a><div class="icnblk_cntnt"><h4 id="niceng185er6.tab6"><a href="/books/NBK565358/table/niceng185er6.tab6/?report=objectonly" target="object" rid-ob="figobniceng185er6tab6">Table 6</a></h4><p class="float-caption no_bottom_margin">Hill 2007 cost-effectiveness results for non-elective PCI patients. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er6tab7"><a href="/books/NBK565358/table/niceng185er6.tab7/?report=objectonly" target="object" title="Table 7" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er6tab7" rid-ob="figobniceng185er6tab7"><img class="small-thumb" src="/books/NBK565358/table/niceng185er6.tab7/?report=thumb" src-large="/books/NBK565358/table/niceng185er6.tab7/?report=previmg" alt="Table 7. Hill 2007 cost–effectiveness results for all non-elective patients (using mean number of stents implanted, 1.46 stents) by absolute risk of TVR and level of price premium for DES." /></a><div class="icnblk_cntnt"><h4 id="niceng185er6.tab7"><a href="/books/NBK565358/table/niceng185er6.tab7/?report=objectonly" target="object" rid-ob="figobniceng185er6tab7">Table 7</a></h4><p class="float-caption no_bottom_margin">Hill 2007 cost–effectiveness results for all non-elective patients (using mean number of stents implanted, 1.46 stents) by absolute risk of TVR and level of price premium for DES. </p></div></div><p><a class="figpopup" href="/books/NBK565358/table/niceng185er6.tab8/?report=objectonly" target="object" rid-figpopup="figniceng185er6tab8" rid-ob="figobniceng185er6tab8">Table 8</a> summarises the stent prices used in the health economic studies. Current UK stent costs are provided in <a class="figpopup" href="/books/NBK565358/table/niceng185er6.tab10/?report=objectonly" target="object" rid-figpopup="figniceng185er6tab10" rid-ob="figobniceng185er6tab10">Table 10</a>.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er6tab8"><a href="/books/NBK565358/table/niceng185er6.tab8/?report=objectonly" target="object" title="Table 8" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er6tab8" rid-ob="figobniceng185er6tab8"><img class="small-thumb" src="/books/NBK565358/table/niceng185er6.tab8/?report=thumb" src-large="/books/NBK565358/table/niceng185er6.tab8/?report=previmg" alt="Table 8. Stent costs used in studies." /></a><div class="icnblk_cntnt"><h4 id="niceng185er6.tab8"><a href="/books/NBK565358/table/niceng185er6.tab8/?report=objectonly" target="object" rid-ob="figobniceng185er6tab8">Table 8</a></h4><p class="float-caption no_bottom_margin">Stent costs used in studies. </p></div></div><p><a class="figpopup" href="/books/NBK565358/table/niceng185er6.tab9/?report=objectonly" target="object" rid-figpopup="figniceng185er6tab9" rid-ob="figobniceng185er6tab9">Table 9</a> summarises the treatment effects from the NGC systematic review and meta analyses reports in section 1.5 and the relevant treatment effects in the included economic analyses to aid interpretation. For models these are the reported treatment effects applied in the models. For within trial analyses these are the relative treatment effects from the relevant RCT or RCT subgroup. Specific details are provided under the table.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er6tab9"><a href="/books/NBK565358/table/niceng185er6.tab9/?report=objectonly" target="object" title="Table 9" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er6tab9" rid-ob="figobniceng185er6tab9"><img class="small-thumb" src="/books/NBK565358/table/niceng185er6.tab9/?report=thumb" src-large="/books/NBK565358/table/niceng185er6.tab9/?report=previmg" alt="Table 9. Comparison of NGC meta-analysis results and treatment effects in economic studies." /></a><div class="icnblk_cntnt"><h4 id="niceng185er6.tab9"><a href="/books/NBK565358/table/niceng185er6.tab9/?report=objectonly" target="object" rid-ob="figobniceng185er6tab9">Table 9</a></h4><p class="float-caption no_bottom_margin">Comparison of NGC meta-analysis results and treatment effects in economic studies. </p></div></div></div><div id="niceng185er6.s1.6.4"><h4>1.6.4. Health economic modelling</h4><p>This area was not prioritised for new cost-effectiveness analysis.</p></div><div id="niceng185er6.s1.6.5"><h4>1.6.5. Unit costs</h4><p>Relevant unit costs are provided below to aid consideration of cost effectiveness.</p><p><a class="figpopup" href="/books/NBK565358/table/niceng185er6.tab10/?report=objectonly" target="object" rid-figpopup="figniceng185er6tab10" rid-ob="figobniceng185er6tab10">Table 10</a> shows coronary stent costs from the NHS Supply Chain and local hospital estimates. Data about the usage of different types of drug eluting stents in the NHS was obtained the British Cardiovascular Intervention Society (BCIS) from 1st April 2017 to 31st March 2018 for people undergoing PCI for ACS. This was to inform calculation of a weighted average to reflect what types of stents are often used in practice. Data was not available on the different types of bare metal stents that are used in the NHS. In addition, committee members highlighted that their local costs were considerably lower than those in the NHS supply chain catalogue. As a result, average local costs and average NHS supply chain costs are provided based on weighted averages for drug-eluting stents.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er6tab10"><a href="/books/NBK565358/table/niceng185er6.tab10/?report=objectonly" target="object" title="Table 10" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er6tab10" rid-ob="figobniceng185er6tab10"><img class="small-thumb" src="/books/NBK565358/table/niceng185er6.tab10/?report=thumb" src-large="/books/NBK565358/table/niceng185er6.tab10/?report=previmg" alt="Table 10. UK unit costs of coronary stents: local costs and equivalent NHS supply chain costs." /></a><div class="icnblk_cntnt"><h4 id="niceng185er6.tab10"><a href="/books/NBK565358/table/niceng185er6.tab10/?report=objectonly" target="object" rid-ob="figobniceng185er6tab10">Table 10</a></h4><p class="float-caption no_bottom_margin">UK unit costs of coronary stents: local costs and equivalent NHS supply chain costs. </p></div></div></div></div><div id="niceng185er6.s1.7"><h3>1.7. Evidence statements</h3><div id="niceng185er6.s1.7.1"><h4>1.7.1. Clinical evidence statements</h4><ul><li class="half_rhythm"><div>There was a clinically important benefit of drug eluting stents (DES) compared to bare metal stents (BMS) for all-cause mortality at 1 year (14049 participants in 22 studies, moderate quality evidence) and at 1-3 years (12999 participants in 12 studies, low quality evidence)</div></li><li class="half_rhythm"><div>There was a clinically important benefit of DES compared to BMS for cardiac mortality at 1 year (12117 participants in 14 studies, moderate quality evidence) and at 1-3 years (12416 participants in 10 studies, low quality evidence)</div></li><li class="half_rhythm"><div>There was a clinically important benefit of DES compared to BMS for target vessel failure up to 1 year (2041 participants in 4 studies, very low quality evidence) and at 1-3 years (703 participants in 3 studies, moderate quality evidence)</div></li><li class="half_rhythm"><div>There was a clinically important benefit of DES compared to BMS for target vessel revascularisation up to 1 year (12858 participants in 18 studies, moderate quality evidence) and at 1-3 years (15141 participants in 3 studies, moderate quality evidence)</div></li><li class="half_rhythm"><div>There was no clinically important difference of DES compared to BMS for definite or probable stent thrombosis up to 1 year (11405 participants in 12 studies, low quality evidence) and at 1-3 years (14390 participants in 12 studies, low quality evidence)</div></li><li class="half_rhythm"><div>There was a clinically important benefit of DES compared to BMS for myocardial infarction (MI) up to 1 year (10780 participants in 20 studies, moderate quality evidence) and at 1-3 years (9456 participants in 10 studies, low quality evidence)</div></li><li class="half_rhythm"><div>At 1 year, there was no clinically important difference of DES compared to BMS for bleeding (unspecified, 1467 participants in 2 studies, very low quality evidence), major bleeding (7395 participants in 6 studies, low quality evidence), minor bleeding (6595 participants in 5 studies, low quality evidence).</div></li><li class="half_rhythm"><div>There was no clinically important difference of DES compared to BMS for major bleeding (5104 participants in 2 studies, very low quality evidence) or for minor bleeding (2314 participants in 1 study, very low quality evidence) at 1-3 years.</div></li><li class="half_rhythm"><div>At 1 year, there was no clinically important difference of DES compared to BMS for in segment minimal luminal diameter (MLD; 346 participants in 2 studies, moderate quality evidence), for in stent MLD (1103 participants in 5 studies, moderate quality evidence), in lesion MLD (695 participants in 2 studies, low quality evidence), MLD proximal edge (37 participants in 1 study, low quality evidence), MLD distal edge (40 participants in 1 study, very low quality evidence) and MLD unspecified (5273 participants in 7 studies, very low quality evidence).</div></li></ul></div><div id="niceng185er6.s1.7.2"><h4>1.7.2. Health economic evidence statements</h4><ul><li class="half_rhythm"><div>One cost-utility analysis found that in people with STEMI undergoing PCI bare metal stents was dominant (less costly and more effective) compared to drug-eluting stents. This analysis was assessed as partially applicable with potentially serious limitations.</div></li><li class="half_rhythm"><div>One cost-utility analysis found that in people with ACS undergoing PCI drug-eluting stents was not cost effective compared to bare metal stents (ICER: £244,400 - £376,100 per QALY gained). This analysis was assessed as partially applicable with potentially serious limitations.</div></li><li class="half_rhythm"><div>One cost-utility analysis found that in people with STEMI undergoing PCI drug-eluting stents was cost effective compared to bare metal stents (ICER: £4,180 per QALY gained. This analysis was assessed as partially applicable with potentially serious limitations.</div></li><li class="half_rhythm"><div>One cost effectiveness analysis found that in people with STEMI, NSTEMI, unstable or stable angina undergoing PCI drug eluting stents was dominant (less costly and more effective) compared to bare metal stents. This analysis was assessed as partially applicable with potentially serious limitations.</div></li><li class="half_rhythm"><div>One cost-utility analysis found that in people with stable coronary artery disease or ACS undergoing PCI with at least one stent with a diameter ≥3mm and ≤15 mm lesion, drug eluting stents was cost effective compared to bare metal stents (ICER: £15,105 per QALY gained). This analysis was assessed as partially applicable with potentially serious limitations.</div></li></ul></div></div><div id="niceng185er6.s1.8"><h3>1.8. The committee’s discussion of the evidence</h3><div id="niceng185er6.s1.8.1"><h4>1.8.1. Interpreting the evidence</h4><div id="niceng185er6.s1.8.1.1"><h5>1.8.1.1. The outcomes that matter most</h5><p>The committee agreed that the following outcomes were critical for decision-making: all-cause mortality, cardiac mortality, target vessel failure, target lesion revascularisation (TLR), target vessel revascularisation (TVR), stent thrombosis, myocardial infarction and health-related quality of life. In the analyses, TLR outcome data was combined with TVR outcome data as the committee noted that by definition TVR encompasses TLR. The committee acknowledged that outcomes such as TLR and TVR were surrogate indicators of clinical effectiveness, but felt that they represent an important sense check for the clinical outcome measures.</p><p>The committee also agreed that the outcomes major bleeding, minor bleeding and minimal lumen diameter, were important for decision-making.</p><p>Outcome data was meta-analysed according to the pre-specified time-points agreed by the committee. These were ‘early’ (before one year or at one year) and ‘late’ (more than one year, until 3 years) reporting of the outcomes of interest.</p><p>Outcome data was identified for the majority of the outcomes. There was outcome data for all of the important and critical outcomes, except for health-related quality of life (a critical outcome).</p></div><div id="niceng185er6.s1.8.1.2"><h5>1.8.1.2. The quality of the evidence</h5><p>Twenty-nine randomised controlled trials were included in this review. One relevant Cochrane review was identified for this evidence review. The search strategy and search dates were updated. Papers included in the Cochrane review were assessed and included if they satisfied the PICO criteria for this review.</p><p>Overall, the evidence was graded from very low to moderate quality. There was serious risk of bias for a majority of the outcomes due to inadequate information reported in the studies about the process of randomisation. There were also concerns about the presence of imprecision for a majority of the evidence that was graded as very low or low quality.</p><p>There are many different types of DES containing a variety of pharmacological agents and polymer coatings. The committee elected to consider these as a single class as this would otherwise involve assessment of highly fragmented data. Differences in effectiveness between the various agents/stents cannot be excluded by this review, but the committee believe that any such variation would be small.</p></div><div id="niceng185er6.s1.8.1.3"><h5>1.8.1.3. Benefits and harms</h5><p>The evidence suggested benefits of using drug-eluting stents (DES) in terms of all-cause mortality, cardiac mortality, myocardial infarction, target vessel failure, target vessel revascularisation and MI up to 1 year and 1-3 years. However, the committee noted uncertainty in the evidence for several of these outcomes including those for all-cause and cardiac mortality, and this uncertainty was taken into account during decision-making. The data for bleeding risk, both major and minor, showed no difference between drug-eluting and bare metal stents.</p><p>The committee had not anticipated seeing any major difference in mortality, and although there was no definitive evidence of a mortality benefit some members felt there was a signal favouring DES in terms of mortality in the longer term.</p><p>The committee agreed there was no evidence of harm with DES and evidence of benefit, albeit with less certainty for some outcomes than others. They also noted the cost-effectiveness data described below and recommended the use of DES in people with acute STEMI undergoing revascularisation by primary PCI and people with unstable angina and NSTEMI undergoing revascularisation by PCI.</p></div></div><div id="niceng185er6.s1.8.2"><h4>1.8.2. Cost effectiveness and resource use</h4><p>Five economic evaluations were included for this review. These weren’t consistent in their conclusions regarding the cost-effectiveness of DES compared to BMS in people with ACS but they also varied in terms of their methods. The committee considered the methods in detail in the context of the clinical review above in order to come to a conclusion regarding the cost effectiveness of DES compared to BMS.</p><p>The analysis that informed NICE technology appraisal 152 which this review is partially updating found that DES were not cost-effective for non-elective patients overall (which was assumed to equate to ACS). Drug-eluting stents were found to be cost effective under some limited circumstances where cost differences between DES and BMS were reduced to £300 and the risk of revascularisation was high. The committee highlighted that DES have evolved since the time of this analysis and much more evidence is available now about the benefits of DES than at the time of the technology appraisal. The analysis only included treatment effects of target-vessel revascularisation whereas the clinical review found other effects, such as a reduction in MI and potentially a mortality benefit. The clinical review also found evidence of effects beyond 1 year but this analysis only employed a 1 year time horizon. The committee agreed that both these things may mean that health effects have not been fully captured. It was noted that the treatment effect for target-vessel revascularisation applied in this analysis was greater than that estimated in the clinical review for this update; however the longer term treatment effects and effects on other outcomes could outweigh this. The cost of DES has considerably reduced since the publication of this technology appraisal, which used costs ranging from £997 to £1,045 and a difference with BMS of around £700. Our estimates of current average costs for DES ranged from £250 to £380, with a difference of £170 to £300. It was agreed it was therefore likely that this analysis would under estimate the benefits of DES as understood from the current clinical evidence base and may overestimate the costs.</p><p>One other included analysis also suggested DES might not be cost effective for people with STEMI. This was based on an analysis of patient-level data from the TYPHOON RCT that was included in the clinical evidence review. In this analysis DES had higher costs and slightly lower QALYs. However, it was noted that the QALY loss with DES in this study appeared potentially inconsistent with the key clinical endpoints from the TYPHOON trial which suggested that DES had lower mortality, target-vessel revascularisation and stent thrombosis and it was unclear what was driving the slight QALY loss. In addition, methods appear to indicate that other cardiac and non-cardiac adverse events were also incorporated in the analysis and the committee agreed that many of these would not be related to the choice of stent and it was unclear if this was appropriate and how inclusion of these events were effecting QALYs. As noted above, the clinical review found evidence of effects beyond 1 year, and this analysis only employed a 1 year time horizon, which means health effects such as mortality may not have been fully captured. Given these issues the committee were concerned the conclusions of this analysis were not reliable.</p><p>The remaining 3 included analyses suggested that DES are cost effective compared to BMS. A model comparing two types of DES (paclitaxel and sirolimus stents) with each other and with BMS in people with ACS or stable angina undergoing PCI found DES dominated BMS with lower costs and an increase in life years. This analysis from a 2008 Norwegian perspective incorporated revascularisation, MI and mortality, used a lifetime horizon and applied treatment effects for 5 years. This was deemed appropriate by the committee as the clinical evidence review showed longer-term treatment effects and also a small mortality benefit, which indicates that people should be modelled over a lifetime to capture the difference in life years gained. Treatment effects were derived from a meta-analysis of 35 RCTs that included studies that were excluded from our clinical evidence review and it was somewhat difficult to assess the impact of this as the time points and outcomes used in the model did not exactly match those used in our review. However, relative treatment effects generally seemed similar or less favourable and the committee agreed that it didn’t seem likely that the benefits were being overestimated. In addition the baseline risks were also derived from the overall coronary artery disease population and were lower than seen in the clinical evidence review which is also unlikely to favour DES. In addition, the cost difference was higher than the current UK estimates, with the difference ranging from £312 to £408 for the two types of DES. QALYs were not estimated but given the life years are higher with DES this was not considered likely to impact conclusions.</p><p>A study comparing DES with BMS in a subgroup of people with stable disease or ACS undergoing PCI with at least one stent with a diameter >3mm and ≤15 mm lesion at baseline from the BASKET-PROVE RCT found that DES were cost-effective with an ICER of £15,105 per QALY gained. The within-trial analysis from a 2013 Swiss perspective used EQ-5D data collected over a 2 year follow-up period to estimate QALY gains. It was noted that QALY gains were quite small in this study. One limitation was that the analysis included people with stable disease and did not report the proportion that was ACS, however the BASKET-PROVE RCT reported that 64% had an ACS. Also, the time horizon of 2 years may not fully capture differences in costs and health outcomes, as the clinical evidence review showed differences in effects at 3 years. It was also unclear if survival was incorporated when calculating QALYs. One benefit was that this analysis showed that DES were cost-effective in a lower risk group, a group of people that the previous TA excluded from their recommendation. Therefore, this may indicate that DES are more cost-effective for a wider population. The difference in costs between DES and BMS was quite low, at £151. This is slightly less than current UK estimates.</p><p>An analysis based on the EXAMINATION RCT which was included in the clinical review also found that DES were cost effective in people with STEMI with an ICER of £4,180 per QALY gained. This analysis took a 2016 Spanish perspective and used 5-year patient level data from the RCT and a modelled extrapolation to a lifetime perspective. It incorporated mortality, MI, stent thrombosis and revascularisation. The committee noted that the NICE technology appraisal assumed a 1 month reduction in quality of life after having PCI, whereas this Spanish analysis applied a 1 year reduction. The committee noted that it is hard to determine how long quality of life would be impacted, however they agreed that the impact would be closer to 1 year and that 1 month was likely to be too short. The committee agreed that the QALY loss applied for 1 year for having repeat MI or stent thrombosis was appropriate. The committee noted that relative treatment effects in EXAMINATION trial were similar to those seen in our clinical review and the study was conducted in three European countries similar to the UK. It was agreed that this analysis was the most applicable and had the least methodological limitations of all the included analyses. They highlighted that the EXAMINATION trial had a broad inclusion criterion to ensure it was an all-comers population and so baseline risk and treatment effects were likely to most accurately reflect the real world. The committee agreed it was likely to be reasonable to generalise the conclusions from this analysis to the UA/NSTEMI population undergoing PCI.</p><p>In summary, although NICE technology appraisal 152 only found DES to be cost-effective under certain circumstances, newer analyses that incorporated other treatment effects and adopted longer time horizon generally found DES to be cost-effective. The committee concluded that there was sufficient evidence that DES are cost effective to support a recommendation for use of DES in people with ACS.</p><p>The committee noted that the use of DES is common practice. Audit data obtained from BCIS showed that from April 2017 to March 2018 91% of all PCIs used a stent during the procedure. Of these procedures that used stents, 97% used DES. Therefore, the committee concluded that a recommendation for DES would not be a change in practice and would not result in a substantial resource impact to the NHS in the England.</p></div><div id="niceng185er6.s1.8.3"><h4>1.8.3. Other factors the committee took into account</h4><p>The committee noted that design of DES has changed, and by implication improved, since they were first introduced whereas bare-metal stents have not changed appreciably. Some of the studies considered in this review used older versions of DES and it was therefore considered that the benefits of currently used DES might be greater than indicated by the results presented here.</p></div></div></div><div id="niceng185er6.rl.r1"><h2 id="_niceng185er6_rl_r1_">References</h2><dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>1.</dt><dd><div class="bk_ref" id="niceng185er6.ref1">Ahmed
|
|
K, Jeong
|
|
MH, Chakraborty
|
|
R, Ahmed
|
|
S, Hong
|
|
YJ, Sim
|
|
DS
|
|
et al. Coronary stents in patients with st-elevation myocardial infarction and chronic kidney disease undergoing primary percutaneous coronary intervention. Sunhwangi. 2012; 42(12):830–8 [<a href="/pmc/articles/PMC3539049/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3539049</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23323121" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23323121</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>2.</dt><dd><div class="bk_ref" id="niceng185er6.ref2">Alfonso
|
|
F, Perez-Vizcayno
|
|
MJ, Hernandez
|
|
R, Fernandez
|
|
C, Escaned
|
|
J, Banuelos
|
|
C
|
|
et al. Sirolimus-eluting stents versus bare-metal stents in patients with in-stent restenosis: Results of a pooled analysis of two randomized studies. Catheterization and Cardiovascular Interventions. 2008; 72(4):459–467 [<a href="https://pubmed.ncbi.nlm.nih.gov/18814274" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18814274</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>3.</dt><dd><div class="bk_ref" id="niceng185er6.ref3">Aoki
|
|
J, Lansky
|
|
AJ, Mehran
|
|
R, Moses
|
|
J, Bertrand
|
|
ME, McLaurin
|
|
BT
|
|
et al. Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the Acute Catheterization and Urgent Intervention Triage Strategy trial. Circulation. 2009; 119(5):687–98 [<a href="https://pubmed.ncbi.nlm.nih.gov/19171852" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19171852</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>4.</dt><dd><div class="bk_ref" id="niceng185er6.ref4">Ardissino
|
|
D, Cavallini
|
|
C, Bramucci
|
|
E, Indolfi
|
|
C, Marzocchi
|
|
A, Manari
|
|
A
|
|
et al. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: A randomized trial. JAMA. 2004; 292(22):2727–34 [<a href="https://pubmed.ncbi.nlm.nih.gov/15585732" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15585732</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>5.</dt><dd><div class="bk_ref" id="niceng185er6.ref5">Ariotti
|
|
S, Adamo
|
|
M, Costa
|
|
F, Patialiakas
|
|
A, Briguori
|
|
C, Thury
|
|
A
|
|
et al. Is bare-metal stent implantation still justifiable in high bleeding risk patients undergoing percutaneous coronary intervention? A pre-specified analysis from the ZEUS Trial. JACC: Cardiovascular Interventions. 2016; 9(5):426–36 [<a href="https://pubmed.ncbi.nlm.nih.gov/26965932" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26965932</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>6.</dt><dd><div class="bk_ref" id="niceng185er6.ref6">Arroyo
|
|
D, Togni
|
|
M, Puricel
|
|
S, Gerard
|
|
B, Sonja
|
|
L, Corpataux
|
|
N
|
|
et al. Comparison of everolimus-eluting and biolimus-eluting coronary stents with everolimus-eluting bioresorbable scaffold: study protocol of the randomized controlled EVERBIO II trial. Trials. 2014; 15:9 [<a href="/pmc/articles/PMC3926690/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3926690</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24398143" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24398143</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>7.</dt><dd><div class="bk_ref" id="niceng185er6.ref7">Atary
|
|
JZ, van der Hoeven
|
|
BL, Liem
|
|
SS, Jukema
|
|
JW, van der Bom
|
|
JG, Atsma
|
|
DE
|
|
et al. Three-year outcome of sirolimus-eluting versus bare-metal stents for the treatment of ST-segment elevation myocardial infarction (from the MISSION! Intervention Study). American Journal of Cardiology. 2010; 106(1):4–12 [<a href="https://pubmed.ncbi.nlm.nih.gov/20609639" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20609639</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>8.</dt><dd><div class="bk_ref" id="niceng185er6.ref8">Bagust
|
|
A, Grayson
|
|
AD, Palmer
|
|
ND, Perry
|
|
RA, Walley
|
|
T. Cost effectiveness of drug eluting coronary artery stenting in a UK setting: Cost-utility study. Heart. 2006; 92(1):68–74 [<a href="/pmc/articles/PMC1861007/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1861007</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15831599" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15831599</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>9.</dt><dd><div class="bk_ref" id="niceng185er6.ref9">Baschet
|
|
L, Bourguignon
|
|
S, Marque
|
|
S, Durand-Zaleski
|
|
I, Teiger
|
|
E, Wilquin
|
|
F
|
|
et al. Cost-effectiveness of drug-eluting stents versus bare-metal stents in patients undergoing percutaneous coronary intervention. Open Heart. 2016; 3(2):e000445 [<a href="/pmc/articles/PMC5013343/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5013343</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27621830" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27621830</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>10.</dt><dd><div class="bk_ref" id="niceng185er6.ref10">Baumler
|
|
M, Stargardt
|
|
T, Schreyogg
|
|
J, Busse
|
|
R. Cost effectiveness of drug-eluting stents in acute myocardial infarction patients in Germany: results from administrative data using a propensity score-matching approach. Applied Health Economics and Health Policy. 2012; 10(4):235–248 [<a href="https://pubmed.ncbi.nlm.nih.gov/22574616" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22574616</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>11.</dt><dd><div class="bk_ref" id="niceng185er6.ref11">Belkacemi
|
|
A, Agostoni
|
|
P, Nathoe
|
|
H, Shao
|
|
C, Sangiorgi
|
|
G, Voskuil
|
|
M
|
|
et al. Results of the drug-eluting balloon in acute STEMI (DEB-AMI) trial: A multicenter randomised comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus DES in primary PCI with 6-month angiographic, intravascular, functional and 12-month clinical outcomes. EuroIntervention. 2012; 8(Suppl N):N25</div></dd></dl><dl class="bkr_refwrap"><dt>12.</dt><dd><div class="bk_ref" id="niceng185er6.ref12">Belkacemi
|
|
A, Agostoni
|
|
P, Nathoe
|
|
HM, Voskuil
|
|
M, Shao
|
|
C, Van Belle
|
|
E
|
|
et al. First results of the DEB-AMI (drug eluting balloon in acute ST-segment elevation myocardial infarction) trial: A multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in primary percutaneous coronary intervention with 6-month angiographic, intravascular, functional, and clinical outcomes. Journal of the American College of Cardiology. 2012; 59(25):2327–37 [<a href="https://pubmed.ncbi.nlm.nih.gov/22503057" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22503057</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>13.</dt><dd><div class="bk_ref" id="niceng185er6.ref13">Boden
|
|
H, Van Der Hoeven
|
|
BL, Atary
|
|
JZ, Liem
|
|
SS, Van Der Wall
|
|
EE, Schalij
|
|
MJ. 5-year outcomes of the MISSION intervention study; A randomized comparison of sirolimus-eluting to bare-metal stent implantation in patients with STEMI. European Heart Journal. 2011; 32:(Suppl 1):654</div></dd></dl><dl class="bkr_refwrap"><dt>14.</dt><dd><div class="bk_ref" id="niceng185er6.ref14">Boden
|
|
H, van der Hoeven
|
|
BL, Liem
|
|
SS, Atary
|
|
JZ, Cannegieter
|
|
SC, Atsma
|
|
DE
|
|
et al. Five-year clinical follow-up from the MISSION! Intervention Study: Sirolimus-eluting stent versus bare metal stent implantation in patients with ST-segment elevation myocardial infarction, a randomised controlled trial. EuroIntervention. 2012; 7(9):1021–9 [<a href="https://pubmed.ncbi.nlm.nih.gov/22207227" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22207227</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>15.</dt><dd><div class="bk_ref" id="niceng185er6.ref15">Bonaa
|
|
KH, Mannsverk
|
|
J, Wiseth
|
|
R, Aaberge
|
|
L, Myreng
|
|
Y, Nygard
|
|
O
|
|
et al. Drug-eluting or bare-metal stents for coronary artery disease. New England Journal of Medicine. 2016; 375(13):1242–52 [<a href="https://pubmed.ncbi.nlm.nih.gov/27572953" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27572953</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>16.</dt><dd><div class="bk_ref" id="niceng185er6.ref16">Brener
|
|
SJ, Ertelt
|
|
K, Mehran
|
|
R, Genereux
|
|
P, Xu
|
|
K, Witzenbichler
|
|
B
|
|
et al. Predictors and impact of target vessel revascularization after stent implantation for acute ST-segment elevation myocardial infarction: lessons from HORIZONS-AMI. American Heart Journal. 2015; 169(2):242–8 [<a href="https://pubmed.ncbi.nlm.nih.gov/25641533" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25641533</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>17.</dt><dd><div class="bk_ref" id="niceng185er6.ref17">Brilakis
|
|
ES, Edson
|
|
R, Bhatt
|
|
DL, Goldman
|
|
S, Holmes
|
|
DR, Jr., Rao
|
|
SV
|
|
et al. Drug-eluting stents versus bare-metal stents in saphenous vein grafts: A double-blind, randomised trial. Lancet. 2018; 391(10134):1997–2007 [<a href="/pmc/articles/PMC6402785/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6402785</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29759512" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29759512</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>18.</dt><dd><div class="bk_ref" id="niceng185er6.ref18">Brilakis
|
|
ES, Lichtenwalter
|
|
C, Abdel-karim
|
|
AR, de Lemos
|
|
JA, Obel
|
|
O, Addo
|
|
T
|
|
et al. Continued benefit from paclitaxel-eluting compared with bare-metal stent implantation in saphenous vein graft lesions during long-term follow-up of the SOS (Stenting of Saphenous Vein Grafts) trial. JACC: Cardiovascular Interventions. 2011; 4(2):176–82 [<a href="https://pubmed.ncbi.nlm.nih.gov/21349456" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21349456</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>19.</dt><dd><div class="bk_ref" id="niceng185er6.ref19">Brilakis
|
|
ES, Lichtenwalter
|
|
C, de Lemos
|
|
JA, Roesle
|
|
M, Obel
|
|
O, Haagen
|
|
D
|
|
et al. A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions. The SOS (Stenting Of Saphenous Vein Grafts) trial. Journal of the American College of Cardiology. 2009; 53(11):919–928 [<a href="https://pubmed.ncbi.nlm.nih.gov/19281920" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19281920</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>20.</dt><dd><div class="bk_ref" id="niceng185er6.ref20">Brophy
|
|
J, Erickson
|
|
L. An economic analysis of drug eluting coronary stents: a Quebec perspective. Montreal. (AETMIS) AdEdTedMdIeS, 2004. Available from: <a href="http://www.aetmis.gouv.qc.ca/" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">http://www<wbr style="display:inline-block"></wbr>​.aetmis.gouv.qc.ca/</a></div></dd></dl><dl class="bkr_refwrap"><dt>21.</dt><dd><div class="bk_ref" id="niceng185er6.ref21">Brophy
|
|
JM, Erickson
|
|
LJ. Cost-effectiveness of drug-eluting coronary stents in Quebec, Canada. International Journal of Technology Assessment in Health Care. 2005; 21(3):326–333 [<a href="https://pubmed.ncbi.nlm.nih.gov/16110712" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16110712</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>22.</dt><dd><div class="bk_ref" id="niceng185er6.ref22">Brugaletta
|
|
S, Sabate
|
|
M, Cequier
|
|
A, Iniguez
|
|
A, Serra
|
|
A, Hernandez-Antolin
|
|
R
|
|
et al. Impact of everolimus-eluting stents on stent thrombosis as compared to conventional bare metal stents in patients with ST-segment elevation myocardial infarction. Insights from the EXAMINATION trial. European Heart Journal. 2012; 33:(Suppl 1):175</div></dd></dl><dl class="bkr_refwrap"><dt>23.</dt><dd><div class="bk_ref" id="niceng185er6.ref23">Brugaletta
|
|
S, Sabate
|
|
M, Martin-Yuste
|
|
V, Masotti
|
|
M, Shiratori
|
|
Y, Alvarez-Contreras
|
|
L
|
|
et al. Predictors and clinical implications of stent thrombosis in patients with ST-segment elevation myocardial infarction: Insights from the EXAMINATION trial. International Journal of Cardiology. 2013; 168(3):2632–6 [<a href="https://pubmed.ncbi.nlm.nih.gov/23578890" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23578890</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>24.</dt><dd><div class="bk_ref" id="niceng185er6.ref24">Canoui-Poitrine
|
|
F, Jeanblanc
|
|
G, Alberti
|
|
C, Armoogum
|
|
P, Cebrian
|
|
A, Carrie
|
|
D
|
|
et al. Cost effectiveness of sirolimus-eluting stents compared with bare metal stents in acute myocardial infarction: insights from the TYPHOON trial. Applied Health Economics and Health Policy. 2009; 7(1):19–29 [<a href="https://pubmed.ncbi.nlm.nih.gov/19558192" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19558192</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>25.</dt><dd><div class="bk_ref" id="niceng185er6.ref25">Carrie
|
|
D, Menown
|
|
I, Oldroyd
|
|
K, Copt
|
|
S, Talwar
|
|
S, Maillard
|
|
L
|
|
et al. Safety and efficacy of polymer-free biolimus A9-coated versus bare-metal stents in orally anticoagulated patients: 2-year results of the LEADERS FREE oral anticoagulation substudy. JACC: Cardiovascular Interventions. 2017; 10(16):1633–1642 [<a href="https://pubmed.ncbi.nlm.nih.gov/28838473" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28838473</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>26.</dt><dd><div class="bk_ref" id="niceng185er6.ref26">Chacko
|
|
R, Mulhearn
|
|
M, Novack
|
|
V, Novack
|
|
L, Mauri
|
|
L, Cohen
|
|
SA
|
|
et al. Impact of target lesion and nontarget lesion cardiac events on 5-year clinical outcomes after sirolimus-eluting or bare-metal stenting. JACC: Cardiovascular Interventions. 2009; 2(6):498–503 [<a href="https://pubmed.ncbi.nlm.nih.gov/19539252" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19539252</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>27.</dt><dd><div class="bk_ref" id="niceng185er6.ref27">Chechi
|
|
T, Vittori
|
|
G, Biondi Zoccai
|
|
GG, Vecchio
|
|
S, Falchetti
|
|
E, Spaziani
|
|
G
|
|
et al. Single-center randomized evaluation of paclitaxel-eluting versus conventional stent in acute myocardial infarction (SELECTION). Journal of Interventional Cardiology. 2007; 20(4):282–91 [<a href="https://pubmed.ncbi.nlm.nih.gov/17680858" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17680858</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>28.</dt><dd><div class="bk_ref" id="niceng185er6.ref28">Cochrane Handbook for Systematic Reviews of Interventions 5.0.2 [updated September 2009]. Higgins J, Green S. The Cochrane Collaboration. 2009. Available from: <a href="http://www.cochrane-handbook.org" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">www<wbr style="display:inline-block"></wbr>​.cochrane-handbook.org</a></div></dd></dl><dl class="bkr_refwrap"><dt>29.</dt><dd><div class="bk_ref" id="niceng185er6.ref29">Costa
|
|
RA, Abizaid
|
|
A, Lotan
|
|
C, Dudek
|
|
D, Silber
|
|
S, Dizon
|
|
JM
|
|
et al. Impact of thrombus burden on outcomes after standard versus mesh-covered stents in acute myocardial infarction (from the MGuard for acute ST elevation reperfusion trial). American Journal of Cardiology. 2015; 115(2):161–6 [<a href="https://pubmed.ncbi.nlm.nih.gov/25465924" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25465924</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>30.</dt><dd><div class="bk_ref" id="niceng185er6.ref30">Crimi
|
|
G, Leonardi
|
|
S, Costa
|
|
F, Adamo
|
|
M, Ariotti
|
|
S, Valgimigli
|
|
M. Role of stent type and of duration of dual antiplatelet therapy in patients with chronic kidney disease undergoing percutaneous coronary interventions. Is bare metal stent implantation still a justifiable choice? A post-hoc analysis of the all comer PRODIGY trial. International Journal of Cardiology. 2016; 212:110–7 [<a href="https://pubmed.ncbi.nlm.nih.gov/27038714" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27038714</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>31.</dt><dd><div class="bk_ref" id="niceng185er6.ref31">Darkahian
|
|
M, Peighambari
|
|
MM. Comparison of the mid-term outcome between drug-eluting stent and bare metal stent implantation in patients undergoing primary PCI in Rajaie Heart Center January 2012- April 2013. Iranian Heart Journal. 2014; 15(2):12–19</div></dd></dl><dl class="bkr_refwrap"><dt>32.</dt><dd><div class="bk_ref" id="niceng185er6.ref32">de Belder
|
|
A, de la Torre Hernandez
|
|
JM, Lopez-Palop
|
|
R, O’Kane
|
|
P, Hernandez Hernandez
|
|
F, Strange
|
|
J
|
|
et al. A prospective randomized trial of everolimus-eluting stents versus bare-metal stents in octogenarians: The XIMA Trial (Xience or Vision Stents for the Management of Angina in the Elderly). Journal of the American College of Cardiology. 2014; 63(14):1371–5 [<a href="https://pubmed.ncbi.nlm.nih.gov/24216285" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24216285</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>33.</dt><dd><div class="bk_ref" id="niceng185er6.ref33">Di Lorenzo
|
|
E, De Luca
|
|
G, Sauro
|
|
R, Varricchio
|
|
A, Capasso
|
|
M, Lanzillo
|
|
T
|
|
et al. The PASEO (PaclitAxel or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty) randomized trial. JACC: Cardiovascular Interventions. 2009; 2(6):515–23 [<a href="https://pubmed.ncbi.nlm.nih.gov/19539255" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19539255</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>34.</dt><dd><div class="bk_ref" id="niceng185er6.ref34">Di Lorenzo
|
|
E, Sauro
|
|
R, Varricchio
|
|
A, Capasso
|
|
M, Lanzillo
|
|
T, Manganelli
|
|
F
|
|
et al. Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: four year results of the PaclitAxel or Sirolimus-Eluting stent vs bare metal stent in primary angiOplasty (PASEO) randomized trial. American Heart Journal. 2009; 158(4):e43–50 [<a href="https://pubmed.ncbi.nlm.nih.gov/19781402" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19781402</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>35.</dt><dd><div class="bk_ref" id="niceng185er6.ref35">Diaz de la Llera
|
|
LS, Ballesteros
|
|
S, Nevado
|
|
J, Fernandez
|
|
M, Villa
|
|
M, Sanchez
|
|
A
|
|
et al. Sirolimus-eluting stents compared with standard stents in the treatment of patients with primary angioplasty. American Heart Journal. 2007; 154(1):164.e1–6 [<a href="https://pubmed.ncbi.nlm.nih.gov/17584571" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17584571</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>36.</dt><dd><div class="bk_ref" id="niceng185er6.ref36">Dirksen
|
|
MT, Vink
|
|
MA, Suttorp
|
|
MJ, Tijssen
|
|
JG, Patterson
|
|
MS, Slagboom
|
|
T
|
|
et al. Two year follow-up after primary PCI with a paclitaxel-eluting stent versus a bare-metal stent for acute ST-elevation myocardial infarction (the PASSION trial): A follow-up study. EuroIntervention. 2008; 4(1):64–70 [<a href="https://pubmed.ncbi.nlm.nih.gov/19112781" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19112781</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>37.</dt><dd><div class="bk_ref" id="niceng185er6.ref37">Dominguez Franco
|
|
AJ, Alonso Briales
|
|
JH, Jimenez Navarro
|
|
MF, Hernandez Garcia
|
|
JM, Garcia Pinilla
|
|
JM, Perez Caravante
|
|
M
|
|
et al. Clinical impact of drug-eluting stents in an unselected population of diabetic patients. Clinical Cardiology. 2008; 31(4):165–71 [<a href="/pmc/articles/PMC6652838/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6652838</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18404726" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18404726</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>38.</dt><dd><div class="bk_ref" id="niceng185er6.ref38">Dudek
|
|
D, Mehran
|
|
R, Dziewierz
|
|
A, Witzenbichler
|
|
B, Brodie
|
|
BR, Kornowski
|
|
R
|
|
et al. Impact of advanced age on the safety and effectiveness of paclitaxel-eluting stent implantation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: The HORIZONS-AMI trial. Catheterization and Cardiovascular Interventions. 2013; 82(6):869–77 [<a href="https://pubmed.ncbi.nlm.nih.gov/23359554" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23359554</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>39.</dt><dd><div class="bk_ref" id="niceng185er6.ref39">Ekman
|
|
M, Sjogren
|
|
I, James
|
|
S. Cost-effectiveness of the Taxus paclitaxel-eluting stent in the Swedish healthcare system. Scandinavian Cardiovascular Journal. 2006; 40(1):17–24 [<a href="https://pubmed.ncbi.nlm.nih.gov/16448993" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16448993</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>40.</dt><dd><div class="bk_ref" id="niceng185er6.ref40">Ellis
|
|
SG, Stone
|
|
GW, Cox
|
|
DA, Hermiller
|
|
J, O’Shaughnessy
|
|
C, Mann
|
|
T
|
|
et al. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent). JACC: Cardiovascular Interventions. 2009; 2(12):1248–59 [<a href="https://pubmed.ncbi.nlm.nih.gov/20129552" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20129552</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>41.</dt><dd><div class="bk_ref" id="niceng185er6.ref41">Erglis
|
|
A, Narbute
|
|
I, Kumsars
|
|
I, Jegere
|
|
S, Mintale
|
|
I, Zakke
|
|
I
|
|
et al. A randomized comparison of paclitaxel-eluting stents versus bare-metal stents for treatment of unprotected left main coronary artery stenosis. Journal of the American College of Cardiology. 2007; 50(6):491–7 [<a href="https://pubmed.ncbi.nlm.nih.gov/17678730" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17678730</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>42.</dt><dd><div class="bk_ref" id="niceng185er6.ref42">Feinberg
|
|
J, Nielsen
|
|
EE, Greenhalgh
|
|
J, Hounsome
|
|
J, Sethi
|
|
NJ, Safi
|
|
S
|
|
et al. Drug-eluting stents versus bare‐metal stents for acute coronary syndrome. Cochrane Database of Systematic Reviews
|
|
2017, Issue 8. Art. No.: CD012481. DOI: 10.1002/14651858.CD012481.pub2. [<a href="/pmc/articles/PMC6483499/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6483499</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28832903" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28832903</span></a>] [<a href="http://dx.crossref.org/10.1002/14651858.CD012481.pub2" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">CrossRef</a>]</div></dd></dl><dl class="bkr_refwrap"><dt>43.</dt><dd><div class="bk_ref" id="niceng185er6.ref43">Garg
|
|
S, Sarno
|
|
G, Gutierrez-Chico
|
|
JL, Garcia-Garcia
|
|
HM, Gomez-Lara
|
|
J, Serruys
|
|
PW
|
|
et al. Five-year outcomes of percutaneous coronary intervention compared to bypass surgery in patients with multivessel disease involving the proximal left anterior descending artery: An ARTS-II sub-study. EuroIntervention. 2011; 6(9):1060–7 [<a href="https://pubmed.ncbi.nlm.nih.gov/21518677" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21518677</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>44.</dt><dd><div class="bk_ref" id="niceng185er6.ref44">Garot
|
|
P, Morice
|
|
MC, Tresukosol
|
|
D, Pocock
|
|
SJ, Meredith
|
|
IT, Abizaid
|
|
A
|
|
et al. 2-year outcomes of high bleeding risk patients after polymer-free drug-coated stents. Journal of the American College of Cardiology. 2017; 69(2):162–171 [<a href="https://pubmed.ncbi.nlm.nih.gov/27806919" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27806919</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>45.</dt><dd><div class="bk_ref" id="niceng185er6.ref45">Goeree
|
|
R, Bowen
|
|
JM, Blackhouse
|
|
G, Lazzam
|
|
C, Cohen
|
|
E, Chiu
|
|
M
|
|
et al. Economic evaluation of drug-eluting stents compared to bare metal stents using a large prospective study in Ontario. International Journal of Technology Assessment in Health Care. 2009; 25(2):196–207 [<a href="https://pubmed.ncbi.nlm.nih.gov/19331710" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19331710</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>46.</dt><dd><div class="bk_ref" id="niceng185er6.ref46">Guagliumi
|
|
G, Sirbu
|
|
V, Bezerra
|
|
H, Biondi-Zoccai
|
|
G, Fiocca
|
|
L, Musumeci
|
|
G
|
|
et al. Strut coverage and vessel wall response to zotarolimus-eluting and bare-metal stents implanted in patients with ST-segment elevation myocardial infarction: the OCTAMI (Optical Coherence Tomography in Acute Myocardial Infarction) Study. JACC: Cardiovascular Interventions. 2010; 3(6):680–7 [<a href="https://pubmed.ncbi.nlm.nih.gov/20630463" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20630463</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>47.</dt><dd><div class="bk_ref" id="niceng185er6.ref47">Han
|
|
YL, Wang
|
|
SL, Jing
|
|
QM, Yu
|
|
HB, Wang
|
|
B, Ma
|
|
YY
|
|
et al. Midterm outcomes of prospective, randomized, single-center study of the Janus tacrolimus-eluting stent for treatment of native coronary artery lesions. Chinese Medical Journal. 2007; 120(7):552–6 [<a href="https://pubmed.ncbi.nlm.nih.gov/17442201" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17442201</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>48.</dt><dd><div class="bk_ref" id="niceng185er6.ref48">Hill
|
|
RA, Boland
|
|
A, Dickson
|
|
R, Dundar
|
|
Y, Haycox
|
|
A, McLeod
|
|
C
|
|
et al. Drug-eluting stents: A systematic review and economic evaluation. Health Technology Assessment. 2007; 11(46):1–242 [<a href="https://pubmed.ncbi.nlm.nih.gov/17999841" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17999841</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>49.</dt><dd><div class="bk_ref" id="niceng185er6.ref49">Holmvang
|
|
L, Kelbaek
|
|
H, Kaltoft
|
|
A, Thuesen
|
|
L, Lassen
|
|
JF, Clemmensen
|
|
P
|
|
et al. Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 5 years follow-up from the randomized DEDICATION trial (Drug Elution and Distal Protection in Acute Myocardial Infarction). JACC: Cardiovascular Interventions. 2013; 6(6):548–53 [<a href="https://pubmed.ncbi.nlm.nih.gov/23683734" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23683734</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>50.</dt><dd><div class="bk_ref" id="niceng185er6.ref50">Ielasi
|
|
A, Brugaletta
|
|
S, Silvestro
|
|
A, Cequier
|
|
A, Iniguez
|
|
A, Serra
|
|
A
|
|
et al. Everolimus-eluting stent versus bare-metal stent in elderly (>=75 years) versus non-elderly (<75 years) patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Insights from the examination trial. International Journal of Cardiology. 2015; 179:73–8 [<a href="https://pubmed.ncbi.nlm.nih.gov/25464418" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25464418</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>51.</dt><dd><div class="bk_ref" id="niceng185er6.ref51">Ischinger
|
|
T. European study of Axxion and Glycocalix long-term evaluation. Herz. 2006; 31(6):596</div></dd></dl><dl class="bkr_refwrap"><dt>52.</dt><dd><div class="bk_ref" id="niceng185er6.ref52">Jahn
|
|
B, Pfeiffer
|
|
KP, Theurl
|
|
E, Tarride
|
|
JE, Goeree
|
|
R. Capacity constraints and cost-effectiveness: A discrete event simulation for drug-eluting stents. Medical Decision Making. 2010; 30(1):16–28 [<a href="https://pubmed.ncbi.nlm.nih.gov/19789389" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19789389</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>53.</dt><dd><div class="bk_ref" id="niceng185er6.ref53">Jimenez-Quevedo
|
|
P, Hernando
|
|
L, Gomez-Hospital
|
|
JA, Iniguez
|
|
A, SanRoman
|
|
A, Alfonso
|
|
F
|
|
et al. Sirolimus-eluting stent versus bare metal stent in diabetic patients: The final five-year follow-up of the DIABETES trial. EuroIntervention. 2013; 9(3):328–35 [<a href="https://pubmed.ncbi.nlm.nih.gov/23518240" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23518240</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>54.</dt><dd><div class="bk_ref" id="niceng185er6.ref54">Kaiser
|
|
C, Brunner-La Rocca
|
|
HP, Buser
|
|
PT, Bonetti
|
|
PO, Osswald
|
|
S, Linka
|
|
A
|
|
et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: Randomised Basel Stent Kosten Effektivitats Trial (BASKET) Lancet. 2005; 366(9489):921–929 [<a href="https://pubmed.ncbi.nlm.nih.gov/16154019" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16154019</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>55.</dt><dd><div class="bk_ref" id="niceng185er6.ref55">Kaiser
|
|
C, Galatius
|
|
S, Erne
|
|
P, Eberli
|
|
F, Alber
|
|
H, Rickli
|
|
H
|
|
et al. Drug-eluting versus bare-metal stents in large coronary arteries. New England Journal of Medicine. 2010; 363(24):2310–2319 [<a href="https://pubmed.ncbi.nlm.nih.gov/21080780" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21080780</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>56.</dt><dd><div class="bk_ref" id="niceng185er6.ref56">Kaiser
|
|
C, Galatius
|
|
S, Jeger
|
|
R, Gilgen
|
|
N, Skov Jensen
|
|
J, Naber
|
|
C
|
|
et al. Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitats Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial. Circulation. 2015; 131(1):74–81 [<a href="https://pubmed.ncbi.nlm.nih.gov/25411159" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25411159</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>57.</dt><dd><div class="bk_ref" id="niceng185er6.ref57">Kaltoft
|
|
A, Kelbaek
|
|
H, Thuesen
|
|
L, Lassen
|
|
JF, Clemmensen
|
|
P, Klovgaard
|
|
L
|
|
et al. Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 3-year follow-up of the randomized DEDICATION (Drug Elution and Distal Protection in Acute Myocardial Infarction) Trial. Journal of the American College of Cardiology. 2010; 56(8):641–5 [<a href="https://pubmed.ncbi.nlm.nih.gov/20688033" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20688033</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>58.</dt><dd><div class="bk_ref" id="niceng185er6.ref58">Kandzari
|
|
DE, Leon
|
|
MB, Meredith
|
|
I, Fajadet
|
|
J, Wijns
|
|
W, Mauri
|
|
L. Final 5-year outcomes from the ENDEAVOR zotarolimus-eluting stent clinical trial program: Comparison of safety and efficacy with first-generation drug-eluting and bare-metal stents. JACC: Cardiovascular Interventions. 2013; 6(5):504–12 [<a href="https://pubmed.ncbi.nlm.nih.gov/23602459" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23602459</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>59.</dt><dd><div class="bk_ref" id="niceng185er6.ref59">Kaul
|
|
U, Bangalore
|
|
S, Seth
|
|
A, Arambam
|
|
P, Abhaichand
|
|
RK, Patel
|
|
TM
|
|
et al. Paclitaxel-eluting versus everolimus-eluting coronary stents in diabetes. New England Journal of Medicine. 2015; 373(18):1709–19 [<a href="https://pubmed.ncbi.nlm.nih.gov/26466202" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26466202</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>60.</dt><dd><div class="bk_ref" id="niceng185er6.ref60">Kelbaek
|
|
H, Klovgaard
|
|
L, Helqvist
|
|
S, Lassen
|
|
JF, Krusell
|
|
LR, Engstrom
|
|
T
|
|
et al. Long-term outcome in patients treated with sirolimus-eluting stents in complex coronary artery lesions: 3-year results of the SCANDSTENT (Stenting Coronary Arteries in Non-Stress/Benestent Disease) trial. Journal of the American College of Cardiology. 2008; 51(21):2011–6 [<a href="https://pubmed.ncbi.nlm.nih.gov/18498953" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18498953</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>61.</dt><dd><div class="bk_ref" id="niceng185er6.ref61">Kelbaek
|
|
H, Thuesen
|
|
L, Helqvist
|
|
S, Clemmensen
|
|
P, Klovgaard
|
|
L, Kaltoft
|
|
A
|
|
et al. Drug-eluting versus bare metal stents in patients with ST-segment-elevation myocardial infarction: eight-month follow-up in the Drug Elution and Distal Protection in Acute Myocardial Infarction (DEDICATION) trial. Circulation. 2008; 118(11):1155–62 [<a href="https://pubmed.ncbi.nlm.nih.gov/18725489" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18725489</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>62.</dt><dd><div class="bk_ref" id="niceng185er6.ref62">Kim
|
|
SS, Hong
|
|
YJ, Jeong
|
|
MH, Kim
|
|
W, Kim
|
|
HK, Ko
|
|
JS
|
|
et al. Two-year clinical outcome after abciximab-coated stent implantation in patients with coronary artery disease. Circulation Journal. 2010; 74(3):442–8 [<a href="https://pubmed.ncbi.nlm.nih.gov/20103970" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20103970</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>63.</dt><dd><div class="bk_ref" id="niceng185er6.ref63">Konig
|
|
A, Leibig
|
|
M, Rieber
|
|
J, Schiele
|
|
TM, Theisen
|
|
K, Siebert
|
|
U
|
|
et al. Randomized comparison of dexamethasone-eluting stents with bare metal stent implantation in patients with acute coronary syndrome: serial angiographic and sonographic analysis. American Heart Journal. 2007; 153(6):979.e1–8 [<a href="https://pubmed.ncbi.nlm.nih.gov/17540198" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17540198</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>64.</dt><dd><div class="bk_ref" id="niceng185er6.ref64">Kurz
|
|
DJ, Bernheim
|
|
AM, Tuller
|
|
D, Zbinden
|
|
R, Jeger
|
|
R, Kaiser
|
|
C
|
|
et al. Improved outcomes of elderly patients treated with drug-eluting versus bare metal stents in large coronary arteries: results from the BAsel Stent Kosten-Effektivitats Trial PROspective Validation Examination randomized trial. American Heart Journal. 2015; 170(4):787–795.e1 [<a href="https://pubmed.ncbi.nlm.nih.gov/26386803" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 26386803</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>65.</dt><dd><div class="bk_ref" id="niceng185er6.ref65">Kuukasjarvi
|
|
P, Rasanen
|
|
P, Malmivaara
|
|
A, Aronen
|
|
P, Sintonen
|
|
H. Economic evaluation of drug-eluting stents: A systematic literature review and model-based cost-utility analysis. International Journal of Technology Assessment in Health Care. 2007; 23(4):473–479 [<a href="https://pubmed.ncbi.nlm.nih.gov/17937836" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17937836</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>66.</dt><dd><div class="bk_ref" id="niceng185er6.ref66">La Manna
|
|
A, Prati
|
|
F, Capodanno
|
|
D, Di Salvo
|
|
M, Sanfilippo
|
|
A, Barrano
|
|
G
|
|
et al. Head-to-head comparison of early vessel healing by optical coherence tomography after implantation of different stents in the same patient. Journal of Cardiovascular Medicine. 2011; 12(5):328–333 [<a href="https://pubmed.ncbi.nlm.nih.gov/20962664" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20962664</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>67.</dt><dd><div class="bk_ref" id="niceng185er6.ref67">Laarman
|
|
GJ, Suttorp
|
|
MJ, Dirksen
|
|
MT, van Heerebeek
|
|
L, Kiemeneij
|
|
F, Slagboom
|
|
T
|
|
et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. New England Journal of Medicine. 2006; 355(11):1105–13 [<a href="https://pubmed.ncbi.nlm.nih.gov/16971717" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16971717</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>68.</dt><dd><div class="bk_ref" id="niceng185er6.ref68">Ledwoch
|
|
J, Fuernau
|
|
G, Desch
|
|
S, Eitel
|
|
I, Jung
|
|
C, de Waha
|
|
S
|
|
et al. Drug-eluting stents versus bare-metal stents in acute myocardial infarction with cardiogenic shock. Heart. 2017; 103(15):1177–1184 [<a href="https://pubmed.ncbi.nlm.nih.gov/28174212" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28174212</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>69.</dt><dd><div class="bk_ref" id="niceng185er6.ref69">Lee
|
|
S, Baek
|
|
K, Chun
|
|
K. Cost-effectiveness of drug-eluting vs. bare-metal stents in patients with coronary artery disease from the Korean National Health Insurance Database. Yonsei Medical Journal. 2014; 55(6):1533–1541 [<a href="/pmc/articles/PMC4205692/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4205692</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25323889" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25323889</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>70.</dt><dd><div class="bk_ref" id="niceng185er6.ref70">Lemos
|
|
PA, Moulin
|
|
B, Perin
|
|
MA, Oliveira
|
|
LA, Arruda
|
|
JA, Lima
|
|
VC
|
|
et al. Late clinical outcomes after implantation of drug-eluting stents coated with biodegradable polymers: 3-year follow-up of the PAINT randomised trial. EuroIntervention. 2012; 8(1):117–9 [<a href="https://pubmed.ncbi.nlm.nih.gov/22580255" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22580255</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>71.</dt><dd><div class="bk_ref" id="niceng185er6.ref71">Lemos
|
|
PA, Moulin
|
|
B, Perin
|
|
MA, Oliveira
|
|
LA, Arruda
|
|
JA, Lima
|
|
VC
|
|
et al. Randomized evaluation of two drug-eluting stents with identical metallic platform and biodegradable polymer but different agents (paclitaxel or sirolimus) compared against bare stents: 1-year results of the PAINT trial. Catheterization and Cardiovascular Interventions. 2009; 74(5):665–73 [<a href="https://pubmed.ncbi.nlm.nih.gov/19670303" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19670303</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>72.</dt><dd><div class="bk_ref" id="niceng185er6.ref72">Li
|
|
SY, Fu
|
|
X, Liu
|
|
J, Wu
|
|
W, Gu
|
|
X, Ma
|
|
N. Randomized study to evaluate sirolimus-eluting stents implanted at coronary small vessel lesions. American Journal of Cardiology. 2004; 94(6A):218E</div></dd></dl><dl class="bkr_refwrap"><dt>73.</dt><dd><div class="bk_ref" id="niceng185er6.ref73">Magro
|
|
M, Raber
|
|
L, Heg
|
|
D, Taniwaki
|
|
M, Kelbaek
|
|
H, Ostojic
|
|
M
|
|
et al. The MI SYNTAX score for risk stratification in patients undergoing primary percutaneous coronary intervention for treatment of acute myocardial infarction: A substudy of the COMFORTABLE AMI trial. International Journal of Cardiology. 2014; 175(2):314–22 [<a href="https://pubmed.ncbi.nlm.nih.gov/24882698" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24882698</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>74.</dt><dd><div class="bk_ref" id="niceng185er6.ref74">Mehilli
|
|
J, Pache
|
|
J, Abdel-Wahab
|
|
M, Schulz
|
|
S, Byrne
|
|
RA, Tiroch
|
|
K
|
|
et al. Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): A randomised controlled superiority trial. Lancet. 2011; 378(9796):1071–8 [<a href="https://pubmed.ncbi.nlm.nih.gov/21872918" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21872918</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>75.</dt><dd><div class="bk_ref" id="niceng185er6.ref75">Mehran
|
|
R, Brodie
|
|
B, Cox
|
|
DA, Grines
|
|
CL, Rutherford
|
|
B, Bhatt
|
|
DL
|
|
et al. The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale. American Heart Journal. 2008; 156(1):44–56 [<a href="https://pubmed.ncbi.nlm.nih.gov/18585496" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18585496</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>76.</dt><dd><div class="bk_ref" id="niceng185er6.ref76">Menichelli
|
|
M, Parma
|
|
A, Pucci
|
|
E, Fiorilli
|
|
R, De Felice
|
|
F, Nazzaro
|
|
M
|
|
et al. Randomized trial of sirolimus-eluting stent versus bare-metal stent in acute myocardial infarction (SESAMI). Journal of the American College of Cardiology. 2007; 49(19):1924–30 [<a href="https://pubmed.ncbi.nlm.nih.gov/17498576" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17498576</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>77.</dt><dd><div class="bk_ref" id="niceng185er6.ref77">Menozzi
|
|
A, Solinas
|
|
E, Ortolani
|
|
P, Repetto
|
|
A, Saia
|
|
F, Piovaccari
|
|
G
|
|
et al. Twenty-four months clinical outcomes of sirolimus-eluting stents for the treatment of small coronary arteries: The long-term SES-SMART clinical study. European Heart Journal. 2009; 30(17):2095–2101 [<a href="https://pubmed.ncbi.nlm.nih.gov/19508994" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19508994</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>78.</dt><dd><div class="bk_ref" id="niceng185er6.ref78">Morice
|
|
MC, Talwar
|
|
S, Gaemperli
|
|
O, Richardt
|
|
G, Eberli
|
|
F, Meredith
|
|
I
|
|
et al. Drug-coated versus bare-metal stents for elderly patients: A predefined sub-study of the LEADERS FREE trial. International Journal of Cardiology. 2017; 243:110–115 [<a href="https://pubmed.ncbi.nlm.nih.gov/28579168" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28579168</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>79.</dt><dd><div class="bk_ref" id="niceng185er6.ref79">Musto
|
|
C, Fiorilli
|
|
R, De Felice
|
|
F, Patti
|
|
G, Nazzaro
|
|
MS, Scappaticci
|
|
M
|
|
et al. Long-term outcome of sirolimus-eluting vs bare-metal stent in the setting of acute myocardial infarction: 5-year results of the SESAMI trial. International Journal of Cardiology. 2013; 166(2):399–403 [<a href="https://pubmed.ncbi.nlm.nih.gov/22093961" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22093961</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>80.</dt><dd><div class="bk_ref" id="niceng185er6.ref80">National Institute for Health and Care Excellence. Developing NICE guidelines: the manual [updated October 2018]. London. National Institute for Health and Care Excellence, 2014. Available from: <a href="http://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20overview" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">http://www<wbr style="display:inline-block"></wbr>​.nice.org.uk<wbr style="display:inline-block"></wbr>​/article/PMG20/chapter<wbr style="display:inline-block"></wbr>​/1%20Introduction%20and%20overview</a></div></dd></dl><dl class="bkr_refwrap"><dt>81.</dt><dd><div class="bk_ref" id="niceng185er6.ref81">National Institute for Health and Clinical Excellence. Drug-eluting stents for the treatment of coronary artery disease: part review of the NICE technology appraisal guidance 71. NICE technology appraisal guidance 152. London. National Institute of Health and Clincial Excellence, 2008. Available from: <a href="http://guidance.nice.org.uk/TA152" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">http://guidance<wbr style="display:inline-block"></wbr>​.nice.org.uk/TA152</a></div></dd></dl><dl class="bkr_refwrap"><dt>82.</dt><dd><div class="bk_ref" id="niceng185er6.ref82">NHS Supply Chain Catalogue. 2018. Available from: <a href="http://www.supplychain.nhs.uk/" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">http://www<wbr style="display:inline-block"></wbr>​.supplychain.nhs.uk/</a> Last accessed: 28/02/2019</div></dd></dl><dl class="bkr_refwrap"><dt>83.</dt><dd><div class="bk_ref" id="niceng185er6.ref83">Organisation for Economic Co-operation and Development (OECD). Purchasing power parities (PPP). 2012. Available from: <a href="http://www.oecd.org/sdd/prices-ppp/" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">http://www<wbr style="display:inline-block"></wbr>​.oecd.org/sdd/prices-ppp/</a> Last accessed: 18/01/2019</div></dd></dl><dl class="bkr_refwrap"><dt>84.</dt><dd><div class="bk_ref" id="niceng185er6.ref84">Park
|
|
SD, Yoon
|
|
CH, Oh
|
|
IY, Suh
|
|
JW, Cho
|
|
YS, Youn
|
|
TJ
|
|
et al. Comparison of a drug-eluting balloon first and then bare metal stent with a drug-eluting stent for treatment of de novo lesions: study protocol of a randomized controlled trial. Trials. 2013; 14:38 [<a href="/pmc/articles/PMC3598714/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3598714</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23394404" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23394404</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>85.</dt><dd><div class="bk_ref" id="niceng185er6.ref85">Pedersen
|
|
SH, Pfisterer
|
|
M, Kaiser
|
|
C, Jensen
|
|
JS, Alber
|
|
H, Rickenbacher
|
|
P
|
|
et al. Drug-eluting stents and bare metal stents in patients with NSTE-ACS: 2-year outcome from the randomised BASKET-PROVE trial. EuroIntervention. 2014; 10(1):58–64 [<a href="https://pubmed.ncbi.nlm.nih.gov/24694667" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24694667</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>86.</dt><dd><div class="bk_ref" id="niceng185er6.ref86">Pitt
|
|
JE, Reeve
|
|
R, Watkin
|
|
H, Whitlam
|
|
G, Pulikal
|
|
J, Ment
|
|
N
|
|
et al. Drug eluting versus bare metal stents in acute ST elevation myocardial infarction (DEVINE) ‐ a randomised control trial. European Heart Journal. 2007; 28:(Suppl 1):206</div></dd></dl><dl class="bkr_refwrap"><dt>87.</dt><dd><div class="bk_ref" id="niceng185er6.ref87">Poder
|
|
TG, Erraji
|
|
J, Coulibaly
|
|
LP, Koffi
|
|
K. Percutaneous coronary intervention with second-generation drug-eluting stent versus bare-metal stent: Systematic review and cost-benefit analysis. PloS One. 2017; 12(5):e0177476 [<a href="/pmc/articles/PMC5428949/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5428949</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28498849" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28498849</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>88.</dt><dd><div class="bk_ref" id="niceng185er6.ref88">Raber
|
|
L, Kelbaek
|
|
H, Baumbach
|
|
A, Tuller
|
|
D, Ostojic
|
|
M, Juni
|
|
P
|
|
et al. Long‐term clinical outcomes of biolimus‐eluting stents with biodegradable versus bare‐metal stents in patients with acute STEMI: 5 year results of the randomized COMFORTABLE AMI trial. European Heart Journal. 2016; 37:(Suppl 1):35</div></dd></dl><dl class="bkr_refwrap"><dt>89.</dt><dd><div class="bk_ref" id="niceng185er6.ref89">Raber
|
|
L, Kelbaek
|
|
H, Ostoijc
|
|
M, Baumbach
|
|
A, Tuller
|
|
D, von Birgelen
|
|
C
|
|
et al. Comparison of biolimus eluted from an erodible stent coating with bare metal stents in acute ST-elevation myocardial infarction (COMFORTABLE AMI trial): Rationale and design. EuroIntervention. 2012; 7(12):1435–43 [<a href="https://pubmed.ncbi.nlm.nih.gov/22301368" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22301368</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>90.</dt><dd><div class="bk_ref" id="niceng185er6.ref90">Raber
|
|
L, Kelbaek
|
|
H, Ostojic
|
|
M, Baumbach
|
|
A, Heg
|
|
D, Tuller
|
|
D
|
|
et al. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: The COMFORTABLE AMI randomized trial. JAMA. 2012; 308(8):777–87 [<a href="https://pubmed.ncbi.nlm.nih.gov/22910755" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22910755</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>91.</dt><dd><div class="bk_ref" id="niceng185er6.ref91">Raber
|
|
L, Kelbaek
|
|
H, Taniwaki
|
|
M, Ostojic
|
|
M, Heg
|
|
D, Baumbach
|
|
A
|
|
et al. Biolimus-eluting stents with biodegradable polymer versus bare-metal stents in acute myocardial infarction: two-year clinical results of the COMFORTABLE AMI trial. Circulation: Cardiovascular Interventions. 2014; 7(3):355–64 [<a href="https://pubmed.ncbi.nlm.nih.gov/24847017" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24847017</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>92.</dt><dd><div class="bk_ref" id="niceng185er6.ref92">Rebeiz
|
|
AG, Zoghbi
|
|
E, Harb
|
|
R, Youhanna
|
|
S, Skouri
|
|
HN, Dimassi
|
|
A
|
|
et al. Comparison of the systemic levels of inflammatory markers after percutaneous coronary intervention with bare metal versus sirolimus-eluting stents. Journal of Interventional Cardiology. 2009; 22(2):169–74 [<a href="https://pubmed.ncbi.nlm.nih.gov/19245380" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19245380</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>93.</dt><dd><div class="bk_ref" id="niceng185er6.ref93">Remak
|
|
E, Manson
|
|
S, Hutton
|
|
J, Brasseur
|
|
P, Olivier
|
|
E, Gershlick
|
|
A. Cost-effectiveness of the Endeavor stent in de novo native coronary artery lesions updated with contemporary data. EuroIntervention. 2010; 5(7):826–832 [<a href="https://pubmed.ncbi.nlm.nih.gov/20142198" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20142198</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>94.</dt><dd><div class="bk_ref" id="niceng185er6.ref94">Remkes
|
|
WS, Badings
|
|
EA, Hermanides
|
|
RS, Rasoul
|
|
S, Dambrink
|
|
J-HE, Koopmans
|
|
PC
|
|
et al. Randomised comparison of drug-eluting versus bare-metal stenting in patients with non-ST elevation myocardial infarction. Open Heart. 2016; 3(2):e000455 [<a href="/pmc/articles/PMC5133402/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5133402</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27933192" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27933192</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>95.</dt><dd><div class="bk_ref" id="niceng185er6.ref95">Ribamar Costa
|
|
J, Jr., Abizaid
|
|
A, Sousa
|
|
A, Siqueira
|
|
D, Chamie
|
|
D, Feres
|
|
F
|
|
et al. Serial greyscale and radiofrequency intravascular ultrasound assessment of plaque modification and vessel geometry at proximal and distal edges of bare metal and first-generation drug-eluting stents. EuroIntervention. 2012; 8(2):225–34 [<a href="https://pubmed.ncbi.nlm.nih.gov/22717925" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22717925</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>96.</dt><dd><div class="bk_ref" id="niceng185er6.ref96">Ribichini
|
|
F, Tomai
|
|
F, De Luca
|
|
G, Boccuzzi
|
|
G, Presbitero
|
|
P, Pesarini
|
|
G
|
|
et al. Immunosuppressive therapy with oral prednisone to prevent restenosis after PCI. A multicenter randomized trial. American Journal of Medicine. 2011; 124(5):434–43 [<a href="https://pubmed.ncbi.nlm.nih.gov/21531233" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21531233</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>97.</dt><dd><div class="bk_ref" id="niceng185er6.ref97">Ribichini
|
|
F, Tomai
|
|
F, De Luca
|
|
G, Boccuzzi
|
|
G, Presbitero
|
|
P, Pesarini
|
|
G
|
|
et al. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: Cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale. Journal of Cardiovascular Medicine. 2009; 10(2):192–9 [<a href="https://pubmed.ncbi.nlm.nih.gov/19377384" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19377384</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>98.</dt><dd><div class="bk_ref" id="niceng185er6.ref98">Ribichini
|
|
F, Tomai
|
|
F, Pesarini
|
|
G, Zivelonghi
|
|
C, Rognoni
|
|
A, De Luca
|
|
G
|
|
et al. Long-term clinical follow-up of the multicentre, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: Cortisone plus BMS or DES veRsus BMS alone to EliminAte Restenosis (CEREA-DES). European Heart Journal. 2013; 34(23):1740–8 [<a href="https://pubmed.ncbi.nlm.nih.gov/23492671" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23492671</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>99.</dt><dd><div class="bk_ref" id="niceng185er6.ref99">Rodriguez
|
|
AE, Maree
|
|
A, Tarragona
|
|
S, Fernandez-Pereira
|
|
C, Santaera
|
|
O, Rodriguez Granillo
|
|
AM
|
|
et al. Percutaneous coronary intervention with oral sirolimus and bare metal stents has comparable safety and efficacy to treatment with drug eluting stents, but with significant cost saving: Long-term follow-up results from the randomised, controlled ORAR III (Oral Rapamycin in ARgentina) study. EuroIntervention. 2009; 5(2):255–64 [<a href="https://pubmed.ncbi.nlm.nih.gov/20449934" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20449934</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>100.</dt><dd><div class="bk_ref" id="niceng185er6.ref100">Rodriguez
|
|
AE, Vigo
|
|
CF, Delacasa
|
|
A, Mieres
|
|
J, Fernandez-Pereira
|
|
C, Bernardi
|
|
V
|
|
et al. Efficacy and safety of a double-coated paclitaxel-eluting coronary stent: The EUCATAX trial. Catheterization and Cardiovascular Interventions. 2011; 77(3):335–42 [<a href="https://pubmed.ncbi.nlm.nih.gov/20824769" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20824769</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>101.</dt><dd><div class="bk_ref" id="niceng185er6.ref101">Rubartelli
|
|
P, Petronio
|
|
AS, Guiducci
|
|
V, Sganzerla
|
|
P, Bolognese
|
|
L, Galli
|
|
M
|
|
et al. Comparison of sirolimus-eluting and bare metal stent for treatment of patients with total coronary occlusions: Results of the GISSOC II-GISE multicentre randomized trial. European Heart Journal. 2010; 31(16):2014–20 [<a href="https://pubmed.ncbi.nlm.nih.gov/20566487" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20566487</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>102.</dt><dd><div class="bk_ref" id="niceng185er6.ref102">Sabate
|
|
M, Brugaletta
|
|
S, Cequier
|
|
A, Iniguez
|
|
A, Serra
|
|
A, Hernadez-Antolin
|
|
R
|
|
et al. The EXAMINATION trial (Everolimus-Eluting Stents Versus Bare-Metal Stents in ST-Segment Elevation Myocardial Infarction): 2-year results from a multicenter randomized controlled trial. JACC: Cardiovascular Interventions. 2014; 7(1):64–71 [<a href="https://pubmed.ncbi.nlm.nih.gov/24332423" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24332423</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>103.</dt><dd><div class="bk_ref" id="niceng185er6.ref103">Sabate
|
|
M, Cequier
|
|
A, Iniguez
|
|
A, Serra
|
|
A, Hernandez-Antolin
|
|
R, Mainar
|
|
V
|
|
et al. Rationale and design of the EXAMINATION trial: A randomised comparison between everolimus-eluting stents and cobalt-chromium bare-metal stents in ST-elevation myocardial infarction. EuroIntervention. 2011; 7(8):977–84 [<a href="https://pubmed.ncbi.nlm.nih.gov/22115622" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22115622</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>104.</dt><dd><div class="bk_ref" id="niceng185er6.ref104">Sabate
|
|
M, Cequier
|
|
A, Iniguez
|
|
A, Serra
|
|
A, Hernandez-Antolin
|
|
R, Mainar
|
|
V
|
|
et al. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet. 2012; 380(9852):1482–90 [<a href="https://pubmed.ncbi.nlm.nih.gov/22951305" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22951305</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>105.</dt><dd><div class="bk_ref" id="niceng185er6.ref105">Sanchez
|
|
PL, Gimeno
|
|
F, Ancillo
|
|
P, Sanz
|
|
JJ, Alonso-Briales
|
|
JH, Bosa
|
|
F
|
|
et al. Role of the paclitaxel-eluting stent and tirofiban in patients with ST-elevation myocardial infarction undergoing postfibrinolysis angioplasty: the GRACIA-3 randomized clinical trial. Circulation: Cardiovascular Interventions. 2010; 3(4):297–307 [<a href="https://pubmed.ncbi.nlm.nih.gov/20716757" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20716757</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>106.</dt><dd><div class="bk_ref" id="niceng185er6.ref106">Schur
|
|
N, Brugaletta
|
|
S, Cequier
|
|
A, Iniguez
|
|
A, Serra
|
|
A, Jimenez-Quevedo
|
|
P
|
|
et al. Cost-effectiveness of everolimus-eluting versus bare-metal stents in ST-segment elevation myocardial infarction: An analysis from the EXAMINATION randomized controlled trial. PloS One. 2018; 13(8):e0201985 [<a href="/pmc/articles/PMC6095536/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6095536</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30114230" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 30114230</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>107.</dt><dd><div class="bk_ref" id="niceng185er6.ref107">Silber
|
|
S, Gutierrez-Chico
|
|
JL, Behrens
|
|
S, Witzenbichler
|
|
B, Wiemer
|
|
M, Hoffmann
|
|
S
|
|
et al. Effect of paclitaxel elution from reservoirs with bioabsorbable polymer compared to a bare metal stent for the elective percutaneous treatment of de novo coronary stenosis: The EUROSTAR-II randomised clinical trial. EuroIntervention. 2011; 7(1):64–73 [<a href="https://pubmed.ncbi.nlm.nih.gov/21550905" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21550905</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>108.</dt><dd><div class="bk_ref" id="niceng185er6.ref108">Sinning
|
|
JM, Baumgart
|
|
D, Werner
|
|
N, Klauss
|
|
V, Baer
|
|
FM, Hartmann
|
|
F
|
|
et al. Five-year results of the Multicenter Randomized Controlled Open-Label Study of the CYPHER Sirolimus-Eluting Stent in the Treatment of Diabetic Patients with De Novo Native Coronary Artery Lesions (SCORPIUS) study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients. American Heart Journal. 2012; 163(3):446–53, 453.e1 [<a href="https://pubmed.ncbi.nlm.nih.gov/22424016" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22424016</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>109.</dt><dd><div class="bk_ref" id="niceng185er6.ref109">Spaulding
|
|
C, Henry
|
|
P, Teiger
|
|
E, Beatt
|
|
K, Bramucci
|
|
E, Carrie
|
|
D
|
|
et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. New England Journal of Medicine. 2006; 355(11):1093–104 [<a href="https://pubmed.ncbi.nlm.nih.gov/16971716" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16971716</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>110.</dt><dd><div class="bk_ref" id="niceng185er6.ref110">Spaulding
|
|
C, Teiger
|
|
E, Commeau
|
|
P, Varenne
|
|
O, Bramucci
|
|
E, Slama
|
|
M
|
|
et al. Four-year follow-up of TYPHOON (trial to assess the use of the CYPHer sirolimus-eluting coronary stent in acute myocardial infarction treated with BallOON angioplasty). JACC: Cardiovascular Interventions. 2011; 4(1):14–23 [<a href="https://pubmed.ncbi.nlm.nih.gov/21251624" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21251624</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>111.</dt><dd><div class="bk_ref" id="niceng185er6.ref111">Steinwender
|
|
C, Hofmann
|
|
R, Kypta
|
|
A, Kammler
|
|
J, Kerschner
|
|
K, Grund
|
|
M
|
|
et al. In-stent restenosis in bare metal stents versus sirolimus-eluting stents after primary coronary intervention for acute myocardial infarction and subsequent transcoronary transplantation of autologous stem cells. Clinical Cardiology. 2008; 31(8):356–359 [<a href="/pmc/articles/PMC6653443/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6653443</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18727076" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18727076</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>112.</dt><dd><div class="bk_ref" id="niceng185er6.ref112">Stone
|
|
GW, Lansky
|
|
AJ, Pocock
|
|
SJ, Gersh
|
|
BJ, Dangas
|
|
G, Wong
|
|
SC
|
|
et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. New England Journal of Medicine. 2009; 360(19):1946–59 [<a href="https://pubmed.ncbi.nlm.nih.gov/19420364" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19420364</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>113.</dt><dd><div class="bk_ref" id="niceng185er6.ref113">Stone
|
|
GW, Parise
|
|
H, Witzenbichler
|
|
B, Kirtane
|
|
A, Guagliumi
|
|
G, Peruga
|
|
JZ
|
|
et al. Selection criteria for drug-eluting versus bare-metal stents and the impact of routine angiographic follow-up: 2-year insights from the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial. Journal of the American College of Cardiology. 2010; 56(19):1597–604 [<a href="https://pubmed.ncbi.nlm.nih.gov/20888162" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20888162</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>114.</dt><dd><div class="bk_ref" id="niceng185er6.ref114">Stone
|
|
GW, Witzenbichler
|
|
B, Guagliumi
|
|
G, Peruga
|
|
JZ, Brodie
|
|
BR, Dudek
|
|
D
|
|
et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet. 2011; 377(9784):2193–204 [<a href="https://pubmed.ncbi.nlm.nih.gov/21665265" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21665265</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>115.</dt><dd><div class="bk_ref" id="niceng185er6.ref115">Storger
|
|
H, Grube
|
|
E, Hofmann
|
|
M, Schwarz
|
|
F, Haase
|
|
J. Clinical experiences using everolimus-eluting stents in patients with coronary artery disease. Journal of Interventional Cardiology. 2004; 17(6):387–90 [<a href="https://pubmed.ncbi.nlm.nih.gov/15546290" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15546290</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>116.</dt><dd><div class="bk_ref" id="niceng185er6.ref116">Strozzi
|
|
M, Anic
|
|
D. Comparison of stent graft, sirolimus stent, and bare metal stent implanted in patients with acute coronary syndrome: Clinical and angiographic follow-up. Croatian Medical Journal. 2007; 48(3):348–52 [<a href="/pmc/articles/PMC2080548/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2080548</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17589978" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17589978</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>117.</dt><dd><div class="bk_ref" id="niceng185er6.ref117">Suh
|
|
HS, Song
|
|
HJ, Jang
|
|
EJ, Kim
|
|
JS, Choi
|
|
D, Lee
|
|
SM. Use of drug-eluting stents versus bare-metal stents in Korea: A cost-minimization analysis using population data. Journal of Preventive Medicine and Public Health. 2013; 46(4):201–209 [<a href="/pmc/articles/PMC3740225/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3740225</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23946878" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23946878</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>118.</dt><dd><div class="bk_ref" id="niceng185er6.ref118">Tarricone
|
|
R, Marchetti
|
|
M, Lamotte
|
|
M, Annemans
|
|
L, de Jong
|
|
P. What reimbursement for coronary revascularization with drug-eluting stents. European Journal of Health Economics. 2004; 5(4):309–316 [<a href="https://pubmed.ncbi.nlm.nih.gov/15759170" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15759170</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>119.</dt><dd><div class="bk_ref" id="niceng185er6.ref119">Tierala
|
|
I, Syvanne
|
|
M, Kupari
|
|
M. Randomised comparison of a paclitaxel‐eluting and a bare metal stent in STEMI‐PCI. American Journal of Cardiology. 2006; 98(Meeting abstract):78M</div></dd></dl><dl class="bkr_refwrap"><dt>120.</dt><dd><div class="bk_ref" id="niceng185er6.ref120">Tomai
|
|
F, Ribichini
|
|
F, De Luca
|
|
L, Petrolini
|
|
A, Ghini
|
|
AS, Weltert
|
|
L
|
|
et al. Randomized comparison of xience v and multi-link vision coronary stents in the same multivessel patient with chronic kidney disease (RENAL-DES) study. Circulation. 2014; 129(10):1104–1112 [<a href="https://pubmed.ncbi.nlm.nih.gov/24357403" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24357403</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>121.</dt><dd><div class="bk_ref" id="niceng185er6.ref121">Valgimigli
|
|
M, Campo
|
|
G, Gambetti
|
|
S, Bolognese
|
|
L, Ribichini
|
|
F, Colangelo
|
|
S
|
|
et al. Three-year follow-up of the MULTIcentre evaluation of Single high-dose Bolus TiRofiban versus Abciximab with Sirolimus-eluting STEnt or Bare-Metal Stent in Acute Myocardial Infarction StudY (MULTISTRATEGY). International Journal of Cardiology. 2013; 165(1):134–141 [<a href="https://pubmed.ncbi.nlm.nih.gov/21864917" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21864917</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>122.</dt><dd><div class="bk_ref" id="niceng185er6.ref122">Valgimigli
|
|
M, Campo
|
|
G, Percoco
|
|
G, Bolognese
|
|
L, Vassanelli
|
|
C, Colangelo
|
|
S
|
|
et al. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: The MULTISTRATEGY randomized trial. JAMA. 2008; 299(15):1788–99 [<a href="https://pubmed.ncbi.nlm.nih.gov/18375998" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18375998</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>123.</dt><dd><div class="bk_ref" id="niceng185er6.ref123">Valgimigli
|
|
M, Campo
|
|
G, Percoco
|
|
G, Monti
|
|
M, Ferrari
|
|
F, Tumscitz
|
|
C
|
|
et al. Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention Design and rationale for the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia study (PRODIGY). American Heart Journal. 2010; 160(5):804–811 [<a href="https://pubmed.ncbi.nlm.nih.gov/21095265" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21095265</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>124.</dt><dd><div class="bk_ref" id="niceng185er6.ref124">Valgimigli
|
|
M, Patialiakas
|
|
A, Thury
|
|
A, Colangelo
|
|
S, Campo
|
|
G, Tebaldi
|
|
M
|
|
et al. Randomized comparison of Zotarolimus-Eluting Endeavor Sprint versus bare-metal stent implantation in uncertain drug-eluting stent candidates: rationale, design, and characterization of the patient population for the Zotarolimus-eluting Endeavor Sprint stent in uncertain DES candidates study. American Heart Journal. 2013; 166(5):831–8 [<a href="https://pubmed.ncbi.nlm.nih.gov/24176438" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24176438</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>125.</dt><dd><div class="bk_ref" id="niceng185er6.ref125">Valgimigli
|
|
M, Patialiakas
|
|
A, Thury
|
|
A, McFadden
|
|
E, Colangelo
|
|
S, Campo
|
|
G
|
|
et al. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. Journal of the American College of Cardiology. 2015; 65(8):805–815 [<a href="https://pubmed.ncbi.nlm.nih.gov/25720624" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25720624</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>126.</dt><dd><div class="bk_ref" id="niceng185er6.ref126">Valgimigli
|
|
M, Tebaldi
|
|
M, Borghesi
|
|
M, Vranckx
|
|
P, Campo
|
|
G, Tumscitz
|
|
C
|
|
et al. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: A pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY). JACC: Cardiovascular Interventions. 2014; 7(1):20–8 [<a href="https://pubmed.ncbi.nlm.nih.gov/24332420" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24332420</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>127.</dt><dd><div class="bk_ref" id="niceng185er6.ref127">Van den Branden
|
|
BJ, Rahel
|
|
BM, Laarman
|
|
GJ, Slagboom
|
|
T, Kelder
|
|
JC, Ten Berg
|
|
JM
|
|
et al. Five-year clinical outcome after primary stenting of totally occluded native coronary arteries: A randomised comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions (PRISON II study). EuroIntervention. 2012; 7(10):1189–96 [<a href="https://pubmed.ncbi.nlm.nih.gov/22030323" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22030323</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>128.</dt><dd><div class="bk_ref" id="niceng185er6.ref128">van der Hoeven
|
|
BL, Liem
|
|
SS, Jukema
|
|
JW, Suraphakdee
|
|
N, Putter
|
|
H, Dijkstra
|
|
J
|
|
et al. Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study. Journal of the American College of Cardiology. 2008; 51(6):618–26 [<a href="https://pubmed.ncbi.nlm.nih.gov/18261680" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18261680</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>129.</dt><dd><div class="bk_ref" id="niceng185er6.ref129">van Hout
|
|
BA, Serruys
|
|
PW, Lemos
|
|
PA, van den Brand
|
|
MJ, van Es
|
|
G, Lindeboom
|
|
WK
|
|
et al. One year cost effectiveness of sirolimus eluting stents compared with bare metal stents in the treatment of single native de novo coronary lesions: An analysis from the RAVEL trial. Heart. 2005; 91(4):507–512 [<a href="/pmc/articles/PMC1768841/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1768841</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15772214" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15772214</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>130.</dt><dd><div class="bk_ref" id="niceng185er6.ref130">Vink
|
|
MA, Dirksen
|
|
MT, Suttorp
|
|
MJ, Tijssen
|
|
JG, van Etten
|
|
J, Patterson
|
|
MS
|
|
et al. 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: A follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial. JACC: Cardiovascular Interventions. 2011; 4(1):24–9 [<a href="https://pubmed.ncbi.nlm.nih.gov/21251625" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21251625</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>131.</dt><dd><div class="bk_ref" id="niceng185er6.ref131">Violini
|
|
R, Musto
|
|
C, De Felice
|
|
F, Nazzaro
|
|
MS, Cifarelli
|
|
A, Petitti
|
|
T
|
|
et al. Maintenance of long-term clinical benefit with sirolimus-eluting stents in patients with ST-segment elevation myocardial infarction 3-year results of the SESAMI (sirolimus-eluting stent versus bare-metal stent in acute myocardial infarction) trial. Journal of the American College of Cardiology. 2010; 55(8):810–4 [<a href="https://pubmed.ncbi.nlm.nih.gov/20170821" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20170821</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>132.</dt><dd><div class="bk_ref" id="niceng185er6.ref132">Wiemer
|
|
M, Serruys
|
|
PW, Miquel-Hebert
|
|
K, Neumann
|
|
FJ, Piek
|
|
JJ, Grube
|
|
E
|
|
et al. Five-year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: The SPIRIT FIRST trial. Catheterization and Cardiovascular Interventions. 2010; 75(7):997–1003 [<a href="https://pubmed.ncbi.nlm.nih.gov/20517959" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20517959</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>133.</dt><dd><div class="bk_ref" id="niceng185er6.ref133">Wijnbergen
|
|
I, Helmes
|
|
H, Tijssen
|
|
J, Brueren
|
|
G, Peels
|
|
K, van Dantzig
|
|
JM
|
|
et al. Comparison of drug-eluting and bare-metal stents for primary percutaneous coronary intervention with or without abciximab in ST-segment elevation myocardial infarction: DEBATER: The Eindhoven reperfusion study. JACC: Cardiovascular Interventions. 2012; 5(3):313–22 [<a href="https://pubmed.ncbi.nlm.nih.gov/22440498" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22440498</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>134.</dt><dd><div class="bk_ref" id="niceng185er6.ref134">Wijnbergen
|
|
I, Tijssen
|
|
J, Brueren
|
|
G, Peels
|
|
K, van Dantzig
|
|
JM, Veer
|
|
MV
|
|
et al. Long-term comparison of sirolimus-eluting and bare-metal stents in ST-segment elevation myocardial infarction. Coronary Artery Disease. 2014; 25(5):378–83 [<a href="https://pubmed.ncbi.nlm.nih.gov/24736301" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24736301</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>135.</dt><dd><div class="bk_ref" id="niceng185er6.ref135">Wisloff
|
|
T, Atar
|
|
D, Sonbo Kristiansen
|
|
I. Cost effectiveness of drug-eluting stents as compared with bare metal stents in patients with coronary artery disease. American Journal of Therapeutics. 2013; 20(6):596–601 [<a href="https://pubmed.ncbi.nlm.nih.gov/21822114" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21822114</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>136.</dt><dd><div class="bk_ref" id="niceng185er6.ref136">Witzenbichler
|
|
B, Wohrle
|
|
J, Guagliumi
|
|
G, Peruga
|
|
JZ, Brodie
|
|
BR, Dudek
|
|
D
|
|
et al. Paclitaxel-eluting stents compared with bare metal stents in diabetic patients with acute myocardial infarction: the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. Circulation: Cardiovascular Interventions. 2011; 4(2):130–8 [<a href="https://pubmed.ncbi.nlm.nih.gov/21364152" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21364152</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>137.</dt><dd><div class="bk_ref" id="niceng185er6.ref137">Zbinden
|
|
R, von Felten
|
|
S, Wein
|
|
B, Tueller
|
|
D, Kurz
|
|
DJ, Reho
|
|
I
|
|
et al. Impact of stent diameter and length on in-stent restenosis after DES vs BMS implantation in patients needing large coronary stents-A clinical and health-economic evaluation. Cardiovascular Therapeutics. 2017; 35(1):19–25 [<a href="https://pubmed.ncbi.nlm.nih.gov/27662632" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27662632</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>138.</dt><dd><div class="bk_ref" id="niceng185er6.ref138">Zellweger
|
|
MJ, Kaiser
|
|
C, Brunner-La Rocca
|
|
HP, Buser
|
|
PT, Osswald
|
|
S, Weiss
|
|
P
|
|
et al. Value and limitations of target-vessel ischemia in predicting late clinical events after drug-eluting stent implantation. Journal of Nuclear Medicine. 2008; 49(4):550–6 [<a href="https://pubmed.ncbi.nlm.nih.gov/18344439" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18344439</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>139.</dt><dd><div class="bk_ref" id="niceng185er6.ref139">Zellweger
|
|
MJ, Kaiser
|
|
C, Jeger
|
|
R, Brunner-La Rocca
|
|
HP, Buser
|
|
P, Bader
|
|
F
|
|
et al. Coronary artery disease progression late after successful stent implantation. Journal of the American College of Cardiology. 2012; 59(9):793–9 [<a href="https://pubmed.ncbi.nlm.nih.gov/22361397" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22361397</span></a>]</div></dd></dl></dl></div><div id="appendixesappgroup1"><h2 id="_appendixesappgroup1_">Appendices</h2><div id="niceng185er6.appa"><h3>Appendix A. Review protocols</h3><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er6appatab1"><a href="/books/NBK565358/table/niceng185er6.appa.tab1/?report=objectonly" target="object" title="Table 11" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er6appatab1" rid-ob="figobniceng185er6appatab1"><img class="small-thumb" src="/books/NBK565358/table/niceng185er6.appa.tab1/?report=thumb" src-large="/books/NBK565358/table/niceng185er6.appa.tab1/?report=previmg" alt="Table 11. Review protocol: Clinical and cost-effectiveness of drug-eluting stents." /></a><div class="icnblk_cntnt"><h4 id="niceng185er6.appa.tab1"><a href="/books/NBK565358/table/niceng185er6.appa.tab1/?report=objectonly" target="object" rid-ob="figobniceng185er6appatab1">Table 11</a></h4><p class="float-caption no_bottom_margin">Review protocol: Clinical and cost-effectiveness of drug-eluting stents. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er6appatab2"><a href="/books/NBK565358/table/niceng185er6.appa.tab2/?report=objectonly" target="object" title="Table 12" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er6appatab2" rid-ob="figobniceng185er6appatab2"><img class="small-thumb" src="/books/NBK565358/table/niceng185er6.appa.tab2/?report=thumb" src-large="/books/NBK565358/table/niceng185er6.appa.tab2/?report=previmg" alt="Table 12. Health economic review protocol." /></a><div class="icnblk_cntnt"><h4 id="niceng185er6.appa.tab2"><a href="/books/NBK565358/table/niceng185er6.appa.tab2/?report=objectonly" target="object" rid-ob="figobniceng185er6appatab2">Table 12</a></h4><p class="float-caption no_bottom_margin">Health economic review protocol. </p></div></div></div><div id="niceng185er6.appb"><h3>Appendix B. Literature search strategies</h3><p>The literature searches for this review are detailed below and complied with the methodology outlined in Developing NICE guidelines: the manual.<a class="bibr" href="#niceng185er6.ref80" rid="niceng185er6.ref80"><sup>80</sup></a></p><p>For more information, please see the Methods report published as part of the accompanying documents for this guideline.</p><div id="niceng185er6.appb.s1"><h4>B.1. Clinical search literature search strategy</h4><p>Searches were constructed using a PICO framework where population (P) terms were combined with Intervention (I) and in some cases Comparison (C) terms. Outcomes (O) are rarely used in search strategies for interventions as these concepts may not be well described in title, abstract or indexes and therefore difficult to retrieve. Search filters were applied to the search where appropriate.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er6appbtab1"><a href="/books/NBK565358/table/niceng185er6.appb.tab1/?report=objectonly" target="object" title="Table 13" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er6appbtab1" rid-ob="figobniceng185er6appbtab1"><img class="small-thumb" src="/books/NBK565358/table/niceng185er6.appb.tab1/?report=thumb" src-large="/books/NBK565358/table/niceng185er6.appb.tab1/?report=previmg" alt="Table 13. Database date parameters and filters used." /></a><div class="icnblk_cntnt"><h4 id="niceng185er6.appb.tab1"><a href="/books/NBK565358/table/niceng185er6.appb.tab1/?report=objectonly" target="object" rid-ob="figobniceng185er6appbtab1">Table 13</a></h4><p class="float-caption no_bottom_margin">Database date parameters and filters used. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er6appbtab2"><a href="/books/NBK565358/table/niceng185er6.appb.tab2/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er6appbtab2" rid-ob="figobniceng185er6appbtab2"><img class="small-thumb" src="/books/NBK565358/table/niceng185er6.appb.tab2/?report=thumb" src-large="/books/NBK565358/table/niceng185er6.appb.tab2/?report=previmg" alt="Medline (Ovid) search terms." /></a><div class="icnblk_cntnt"><h4 id="niceng185er6.appb.tab2"><a href="/books/NBK565358/table/niceng185er6.appb.tab2/?report=objectonly" target="object" rid-ob="figobniceng185er6appbtab2">Table</a></h4><p class="float-caption no_bottom_margin">Medline (Ovid) search terms. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er6appbtab3"><a href="/books/NBK565358/table/niceng185er6.appb.tab3/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er6appbtab3" rid-ob="figobniceng185er6appbtab3"><img class="small-thumb" src="/books/NBK565358/table/niceng185er6.appb.tab3/?report=thumb" src-large="/books/NBK565358/table/niceng185er6.appb.tab3/?report=previmg" alt="Embase (Ovid) search terms." /></a><div class="icnblk_cntnt"><h4 id="niceng185er6.appb.tab3"><a href="/books/NBK565358/table/niceng185er6.appb.tab3/?report=objectonly" target="object" rid-ob="figobniceng185er6appbtab3">Table</a></h4><p class="float-caption no_bottom_margin">Embase (Ovid) search terms. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er6appbtab4"><a href="/books/NBK565358/table/niceng185er6.appb.tab4/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er6appbtab4" rid-ob="figobniceng185er6appbtab4"><img class="small-thumb" src="/books/NBK565358/table/niceng185er6.appb.tab4/?report=thumb" src-large="/books/NBK565358/table/niceng185er6.appb.tab4/?report=previmg" alt="Cochrane Library (Wiley) search terms." /></a><div class="icnblk_cntnt"><h4 id="niceng185er6.appb.tab4"><a href="/books/NBK565358/table/niceng185er6.appb.tab4/?report=objectonly" target="object" rid-ob="figobniceng185er6appbtab4">Table</a></h4><p class="float-caption no_bottom_margin">Cochrane Library (Wiley) search terms. </p></div></div></div><div id="niceng185er6.appb.s2"><h4>B.2. Health Economics literature search strategy</h4><p>Health economic evidence was identified by conducting a search relating to acute coronary syndromes population combined with terms for interventions in NHS Economic Evaluation Database (NHS EED – this ceased to be updated after March 2015) and the Health Technology Assessment database (HTA) with no date restrictions. NHS EED and HTA databases are hosted by the Centre for Research and Dissemination (CRD). Additional searches were run on Medline and Embase using a filter for health economics studies.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er6appbtab5"><a href="/books/NBK565358/table/niceng185er6.appb.tab5/?report=objectonly" target="object" title="Table 14" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er6appbtab5" rid-ob="figobniceng185er6appbtab5"><img class="small-thumb" src="/books/NBK565358/table/niceng185er6.appb.tab5/?report=thumb" src-large="/books/NBK565358/table/niceng185er6.appb.tab5/?report=previmg" alt="Table 14. Database date parameters and filters used." /></a><div class="icnblk_cntnt"><h4 id="niceng185er6.appb.tab5"><a href="/books/NBK565358/table/niceng185er6.appb.tab5/?report=objectonly" target="object" rid-ob="figobniceng185er6appbtab5">Table 14</a></h4><p class="float-caption no_bottom_margin">Database date parameters and filters used. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er6appbtab6"><a href="/books/NBK565358/table/niceng185er6.appb.tab6/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er6appbtab6" rid-ob="figobniceng185er6appbtab6"><img class="small-thumb" src="/books/NBK565358/table/niceng185er6.appb.tab6/?report=thumb" src-large="/books/NBK565358/table/niceng185er6.appb.tab6/?report=previmg" alt="Medline (Ovid) search terms." /></a><div class="icnblk_cntnt"><h4 id="niceng185er6.appb.tab6"><a href="/books/NBK565358/table/niceng185er6.appb.tab6/?report=objectonly" target="object" rid-ob="figobniceng185er6appbtab6">Table</a></h4><p class="float-caption no_bottom_margin">Medline (Ovid) search terms. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er6appbtab7"><a href="/books/NBK565358/table/niceng185er6.appb.tab7/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er6appbtab7" rid-ob="figobniceng185er6appbtab7"><img class="small-thumb" src="/books/NBK565358/table/niceng185er6.appb.tab7/?report=thumb" src-large="/books/NBK565358/table/niceng185er6.appb.tab7/?report=previmg" alt="Embase (Ovid) search terms." /></a><div class="icnblk_cntnt"><h4 id="niceng185er6.appb.tab7"><a href="/books/NBK565358/table/niceng185er6.appb.tab7/?report=objectonly" target="object" rid-ob="figobniceng185er6appbtab7">Table</a></h4><p class="float-caption no_bottom_margin">Embase (Ovid) search terms. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er6appbtab8"><a href="/books/NBK565358/table/niceng185er6.appb.tab8/?report=objectonly" target="object" title="Table" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er6appbtab8" rid-ob="figobniceng185er6appbtab8"><img class="small-thumb" src="/books/NBK565358/table/niceng185er6.appb.tab8/?report=thumb" src-large="/books/NBK565358/table/niceng185er6.appb.tab8/?report=previmg" alt="NHS EED and HTA (CRD) search terms." /></a><div class="icnblk_cntnt"><h4 id="niceng185er6.appb.tab8"><a href="/books/NBK565358/table/niceng185er6.appb.tab8/?report=objectonly" target="object" rid-ob="figobniceng185er6appbtab8">Table</a></h4><p class="float-caption no_bottom_margin">NHS EED and HTA (CRD) search terms. </p></div></div></div></div><div id="niceng185er6.appc"><h3>Appendix C. Clinical evidence selection</h3><div id="niceng185er6.appc.fig1" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%201.%20Flow%20chart%20of%20clinical%20study%20selection%20for%20the%20review%20of%20drug-eluting%20stents%20in%20adults%20with%20acute%20coronary%20syndromes%2C%20including%20those%20with%20unstable%20angina%20or%20NSTEMI%20undergoing%20percutaneous%20coronary%20intervention%20and%20those%20with%20STEMI%20undergoing%20primary%20percutaneous%20coronary%20intervention.&p=BOOKS&id=565358_niceng185er6appcf1.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK565358/bin/niceng185er6appcf1.jpg" alt="Figure 1. Flow chart of clinical study selection for the review of drug-eluting stents in adults with acute coronary syndromes, including those with unstable angina or NSTEMI undergoing percutaneous coronary intervention and those with STEMI undergoing primary percutaneous coronary intervention." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 1</span><span class="title">Flow chart of clinical study selection for the review of drug-eluting stents in adults with acute coronary syndromes, including those with unstable angina or NSTEMI undergoing percutaneous coronary intervention and those with STEMI undergoing primary percutaneous coronary intervention</span></h3></div></div><div id="niceng185er6.appd"><h3>Appendix D. Clinical evidence tables</h3><p id="niceng185er6.appd.et1"><a href="/books/NBK565358/bin/niceng185er6-appd-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (966K)</span></p></div><div id="niceng185er6.appe"><h3>Appendix E. Forest plots</h3><div id="niceng185er6.appe.s1"><h4>E.1. Drug-eluting stents (DES) versus bare metal stents (BMS)</h4><p id="niceng185er6.appe.fig1"><a href="/books/NBK565358/figure/niceng185er6.appe.fig1/?report=objectonly" target="object" rid-ob="figobniceng185er6appefig1" class="figpopup">Figure 2. All-cause mortality (≤1 year)</a></p><p id="niceng185er6.appe.fig2"><a href="/books/NBK565358/figure/niceng185er6.appe.fig2/?report=objectonly" target="object" rid-ob="figobniceng185er6appefig2" class="figpopup">Figure 3. All-cause mortality (>1-3 years)</a></p><p id="niceng185er6.appe.fig3"><a href="/books/NBK565358/figure/niceng185er6.appe.fig3/?report=objectonly" target="object" rid-ob="figobniceng185er6appefig3" class="figpopup">Figure 4. Cardiac mortality (≤1 year)</a></p><p id="niceng185er6.appe.fig4"><a href="/books/NBK565358/figure/niceng185er6.appe.fig4/?report=objectonly" target="object" rid-ob="figobniceng185er6appefig4" class="figpopup">Figure 5. Cardiac mortality (>1-3 years)</a></p><p id="niceng185er6.appe.fig5"><a href="/books/NBK565358/figure/niceng185er6.appe.fig5/?report=objectonly" target="object" rid-ob="figobniceng185er6appefig5" class="figpopup">Figure 6. Target vessel failure (≤1 year)</a></p><p id="niceng185er6.appe.fig6"><a href="/books/NBK565358/figure/niceng185er6.appe.fig6/?report=objectonly" target="object" rid-ob="figobniceng185er6appefig6" class="figpopup">Figure 7. Target vessel failure (>1-3 years)</a></p><p id="niceng185er6.appe.fig7"><a href="/books/NBK565358/figure/niceng185er6.appe.fig7/?report=objectonly" target="object" rid-ob="figobniceng185er6appefig7" class="figpopup">Figure 8. Target vessel revascularisation (≤1 year)</a></p><p id="niceng185er6.appe.fig8"><a href="/books/NBK565358/figure/niceng185er6.appe.fig8/?report=objectonly" target="object" rid-ob="figobniceng185er6appefig8" class="figpopup">Figure 9. Target vessel revascularisation (>1-3 years)</a></p><p id="niceng185er6.appe.fig9"><a href="/books/NBK565358/figure/niceng185er6.appe.fig9/?report=objectonly" target="object" rid-ob="figobniceng185er6appefig9" class="figpopup">Figure 10. Stent thrombosis – definite or probable (≤1 year)</a></p><p id="niceng185er6.appe.fig10"><a href="/books/NBK565358/figure/niceng185er6.appe.fig10/?report=objectonly" target="object" rid-ob="figobniceng185er6appefig10" class="figpopup">Figure 11. Stent thrombosis – definite or probable (>1-3 years)</a></p><p id="niceng185er6.appe.fig11"><a href="/books/NBK565358/figure/niceng185er6.appe.fig11/?report=objectonly" target="object" rid-ob="figobniceng185er6appefig11" class="figpopup">Figure 12. Myocardial infarction (≤1 year)</a></p><p id="niceng185er6.appe.fig12"><a href="/books/NBK565358/figure/niceng185er6.appe.fig12/?report=objectonly" target="object" rid-ob="figobniceng185er6appefig12" class="figpopup">Figure 13. Myocardial infarction (>1-3 years)</a></p><p id="niceng185er6.appe.fig13"><a href="/books/NBK565358/figure/niceng185er6.appe.fig13/?report=objectonly" target="object" rid-ob="figobniceng185er6appefig13" class="figpopup">Figure 14. Bleeding(≤1 year)</a></p><p id="niceng185er6.appe.fig14"><a href="/books/NBK565358/figure/niceng185er6.appe.fig14/?report=objectonly" target="object" rid-ob="figobniceng185er6appefig14" class="figpopup">Figure 15. Bleeding (major) (>1-3 years)</a></p><p id="niceng185er6.appe.fig15"><a href="/books/NBK565358/figure/niceng185er6.appe.fig15/?report=objectonly" target="object" rid-ob="figobniceng185er6appefig15" class="figpopup">Figure 16. Bleeding (minor) (>1-3 years)</a></p><p id="niceng185er6.appe.fig16"><a href="/books/NBK565358/figure/niceng185er6.appe.fig16/?report=objectonly" target="object" rid-ob="figobniceng185er6appefig16" class="figpopup">Figure 17. Minimal luminal diameter (≤1 year)</a></p><p id="niceng185er6.appe.fig17"><a href="/books/NBK565358/figure/niceng185er6.appe.fig17/?report=objectonly" target="object" rid-ob="figobniceng185er6appefig17" class="figpopup">Figure 18. Minimal luminal diameter – unspecified (≤1 year)</a></p><div id="niceng185er6.appe.s1.1"><h5>E.1.1. Minimal important differences for continuous outcomes</h5><p>The MID values reported in <a class="figpopup" href="/books/NBK565358/table/niceng185er6.appe.tab1/?report=objectonly" target="object" rid-figpopup="figniceng185er6appetab1" rid-ob="figobniceng185er6appetab1">Table 15</a> were used to assess imprecision for the various continuous outcomes included in this evidence review.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er6appetab1"><a href="/books/NBK565358/table/niceng185er6.appe.tab1/?report=objectonly" target="object" title="Table 15" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er6appetab1" rid-ob="figobniceng185er6appetab1"><img class="small-thumb" src="/books/NBK565358/table/niceng185er6.appe.tab1/?report=thumb" src-large="/books/NBK565358/table/niceng185er6.appe.tab1/?report=previmg" alt="Table 15. Minimal important difference: DES versus BMS." /></a><div class="icnblk_cntnt"><h4 id="niceng185er6.appe.tab1"><a href="/books/NBK565358/table/niceng185er6.appe.tab1/?report=objectonly" target="object" rid-ob="figobniceng185er6appetab1">Table 15</a></h4><p class="float-caption no_bottom_margin">Minimal important difference: DES versus BMS. </p></div></div></div></div></div><div id="niceng185er6.appf"><h3>Appendix F. GRADE tables</h3><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er6appftab1"><a href="/books/NBK565358/table/niceng185er6.appf.tab1/?report=objectonly" target="object" title="Table 16" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er6appftab1" rid-ob="figobniceng185er6appftab1"><img class="small-thumb" src="/books/NBK565358/table/niceng185er6.appf.tab1/?report=thumb" src-large="/books/NBK565358/table/niceng185er6.appf.tab1/?report=previmg" alt="Table 16. Clinical evidence profile: Drug eluting stents (DES) versus bare metal stents (BMS)." /></a><div class="icnblk_cntnt"><h4 id="niceng185er6.appf.tab1"><a href="/books/NBK565358/table/niceng185er6.appf.tab1/?report=objectonly" target="object" rid-ob="figobniceng185er6appftab1">Table 16</a></h4><p class="float-caption no_bottom_margin">Clinical evidence profile: Drug eluting stents (DES) versus bare metal stents (BMS). </p></div></div></div><div id="niceng185er6.appg"><h3>Appendix G. Health economic evidence selection</h3><div id="niceng185er6.appg.fig1" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2019.%20Flow%20chart%20of%20health%20economic%20study%20selection%20for%20the%20guideline.&p=BOOKS&id=565358_niceng185er6appgf1.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img src="/books/NBK565358/bin/niceng185er6appgf1.jpg" alt="Figure 19. Flow chart of health economic study selection for the guideline." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 19</span><span class="title">Flow chart of health economic study selection for the guideline</span></h3><div class="caption"><p>* Non-relevant population, intervention, comparison, design or setting; non-English language</p><p>Review A = dual-antiplatelet therapy; Review B = early invasive investigation for UA/NSTEMI; Review C = antithrombins in UA/NSTEMI; Review D = bivalirudin in STEMI; Review E = multi-vessel PCI; Review F = drugeluting stents; Review G = combination of antiplatelets and anticoagulants; Review H = beta-blocker therapy.</p></div></div></div><div id="niceng185er6.apph"><h3>Appendix H. Health economic evidence tables</h3><p id="niceng185er6.apph.et1"><a href="/books/NBK565358/bin/niceng185er6-apph-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (317K)</span></p></div><div id="niceng185er6.appi"><h3>Appendix I. Excluded studies</h3><div id="niceng185er6.appi.s1"><h4>I.1. Excluded clinical studies</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er6appitab1"><a href="/books/NBK565358/table/niceng185er6.appi.tab1/?report=objectonly" target="object" title="Table 17" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er6appitab1" rid-ob="figobniceng185er6appitab1"><img class="small-thumb" src="/books/NBK565358/table/niceng185er6.appi.tab1/?report=thumb" src-large="/books/NBK565358/table/niceng185er6.appi.tab1/?report=previmg" alt="Table 17. Studies excluded from the clinical review." /></a><div class="icnblk_cntnt"><h4 id="niceng185er6.appi.tab1"><a href="/books/NBK565358/table/niceng185er6.appi.tab1/?report=objectonly" target="object" rid-ob="figobniceng185er6appitab1">Table 17</a></h4><p class="float-caption no_bottom_margin">Studies excluded from the clinical review. </p></div></div></div><div id="niceng185er6.appi.s2"><h4>I.2. Excluded health economic studies</h4><p>Published health economic studies that met the inclusion criteria (relevant population, comparators, economic study design, published 2003 or later and not from non-OECD country or USA) but that were excluded following appraisal of applicability and methodological quality are listed below. See the health economic protocol for more details.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng185er6appitab2"><a href="/books/NBK565358/table/niceng185er6.appi.tab2/?report=objectonly" target="object" title="Table 18" class="img_link icnblk_img figpopup" rid-figpopup="figniceng185er6appitab2" rid-ob="figobniceng185er6appitab2"><img class="small-thumb" src="/books/NBK565358/table/niceng185er6.appi.tab2/?report=thumb" src-large="/books/NBK565358/table/niceng185er6.appi.tab2/?report=previmg" alt="Table 18. Studies excluded from the health economic review." /></a><div class="icnblk_cntnt"><h4 id="niceng185er6.appi.tab2"><a href="/books/NBK565358/table/niceng185er6.appi.tab2/?report=objectonly" target="object" rid-ob="figobniceng185er6appitab2">Table 18</a></h4><p class="float-caption no_bottom_margin">Studies excluded from the health economic review. </p></div></div></div></div></div></div><div class="fm-sec"><div><p>Final</p></div><div><p>Intervention evidence review</p><p>This evidence review was developed by the National Guideline Centre based at the Royal College of Physicians</p></div><div><p><b>Disclaimer</b>: The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and, where appropriate, their carer or guardian.</p><p>Local commissioners and providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.</p><p>NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the <a href="http://wales.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Welsh Government</a>, <a href="http://www.scotland.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Scottish Government</a>, and <a href="http://www.northernireland.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Northern Ireland Executive</a>. All NICE guidance is subject to regular review and may be updated or withdrawn.</p></div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © NICE 2020.</div><div class="small"><span class="label">Bookshelf ID: NBK565358</span><span class="label">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/33301274" title="PubMed record of this title" ref="pagearea=meta&targetsite=entrez&targetcat=link&targettype=pubmed">33301274</a></span></div></div><div class="small-screen-prev"></div><div class="small-screen-next"></div></article><article data-type="table-wrap" id="figobniceng185er6tab1"><div id="niceng185er6.tab1" class="table"><h3><span class="label">Table 1</span><span class="title">PICO characteristics of review question</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565358/table/niceng185er6.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er6.tab1_lrgtbl__"><table><tbody><tr><th id="hd_b_niceng185er6.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Population</th><td headers="hd_b_niceng185er6.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Patients with UA/NSTEMI and those with STEMI intended for treatment with a stent</td></tr><tr><th id="hd_b_niceng185er6.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Intervention(s)</th><td headers="hd_b_niceng185er6.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Drug eluting stents including:
|
|
<ul><li class="half_rhythm"><div>Sirolimus</div></li><li class="half_rhythm"><div>Everolimus</div></li><li class="half_rhythm"><div>Paclitaxel</div></li><li class="half_rhythm"><div>Rapamycin</div></li><li class="half_rhythm"><div>Paclitaxel & Cilostazol</div></li><li class="half_rhythm"><div>Ridaforolimus</div></li><li class="half_rhythm"><div>Novolimus</div></li><li class="half_rhythm"><div>Zotarolimus</div></li></ul></td></tr><tr><th id="hd_b_niceng185er6.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparison(s)</th><td headers="hd_b_niceng185er6.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Bare metal stents including:
|
|
<ul><li class="half_rhythm"><div>Cobalt Chronium</div></li><li class="half_rhythm"><div>Platinium Chronium</div></li><li class="half_rhythm"><div>Stainless Steel</div></li></ul></td></tr><tr><th id="hd_b_niceng185er6.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcomes</th><td headers="hd_b_niceng185er6.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>CRITICAL</b>
|
|
</p>
|
|
<p>Time points: early ≤1 and later >1-3 year
|
|
<ul><li class="half_rhythm"><div>All-cause mortality</div></li><li class="half_rhythm"><div>Cardiac mortality</div></li><li class="half_rhythm"><div>TVF- target vessel failure</div></li><li class="half_rhythm"><div>TLR and TVR – target lesion and target vessel revascularisation</div></li><li class="half_rhythm"><div>Stent thrombosis (definite and/or probable) (record if assessed using optical coherence tomography (OCT), Intravascular ultrasound (IVUS) or angiography)</div></li><li class="half_rhythm"><div>Myocardial infarction</div></li><li class="half_rhythm"><div>Health-related quality of life including EQ5D and SF-36.</div></li></ul></p>
|
|
<p><b>MPORTANT</b>
|
|
<ul><li class="half_rhythm"><div class="half_rhythm">Bleeding- Where possible, bleeding outcomes will be categorised into:
|
|
<ul class="circle"><li class="half_rhythm"><div>Major bleeding (including BARC 3-5 and as reported by author)</div></li><li class="half_rhythm"><div>Minor bleeding (including BARC 2, TIMI and as reported by author).</div></li></ul></div><div class="half_rhythm">The following hierarchy of bleeding scales will be used:
|
|
<ul class="circle"><li class="half_rhythm"><div>BARC</div></li><li class="half_rhythm"><div>Author’s definition</div></li><li class="half_rhythm"><div>TIMI</div></li><li class="half_rhythm"><div>GUSTO</div></li></ul></div></li><li class="half_rhythm"><div class="half_rhythm">MLD - Minimal lumen diameter (measuring how much restenosis there is)-surrogate marker for TLR and TVR</div></li></ul></p>
|
|
</td></tr><tr><th id="hd_b_niceng185er6.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Study design</th><td headers="hd_b_niceng185er6.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">
|
|
<ul><li class="half_rhythm"><div>Randomised Controlled Trials (RCT)</div></li><li class="half_rhythm"><div>Systematic Reviews (SR) of RCTs</div></li></ul></td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng185er6tab2"><div id="niceng185er6.tab2" class="table"><h3><span class="label">Table 2</span><span class="title">Summary of evaluated outcomes in included studies</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565358/table/niceng185er6.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er6.tab2_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng185er6.tab2_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_niceng185er6.tab2_1_1_1_1" style="text-align:left;vertical-align:bottom;">Study</th><th id="hd_h_niceng185er6.tab2_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_niceng185er6.tab2_1_1_1_2" style="text-align:left;vertical-align:top;">No. of participa nts</th><th id="hd_h_niceng185er6.tab2_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_niceng185er6.tab2_1_1_1_3" style="text-align:left;vertical-align:top;">Country</th><th id="hd_h_niceng185er6.tab2_1_1_1_4" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">All-cause mortality</th><th id="hd_h_niceng185er6.tab2_1_1_1_5" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Cardiac mortality</th><th id="hd_h_niceng185er6.tab2_1_1_1_6" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">TVF</th><th id="hd_h_niceng185er6.tab2_1_1_1_7" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">TLR/TVR</th><th id="hd_h_niceng185er6.tab2_1_1_1_8" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">MI</th><th id="hd_h_niceng185er6.tab2_1_1_1_9" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Stent thrombosis</th><th id="hd_h_niceng185er6.tab2_1_1_1_10" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">MLD</th><th id="hd_h_niceng185er6.tab2_1_1_1_11" colspan="2" rowspan="1" style="text-align:left;vertical-align:top;">Bleeding</th></tr><tr><th headers="hd_h_niceng185er6.tab2_1_1_1_4" id="hd_h_niceng185er6.tab2_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 yr</th><th headers="hd_h_niceng185er6.tab2_1_1_1_4" id="hd_h_niceng185er6.tab2_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">+1 yr</th><th headers="hd_h_niceng185er6.tab2_1_1_1_5" id="hd_h_niceng185er6.tab2_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 yr</th><th headers="hd_h_niceng185er6.tab2_1_1_1_5" id="hd_h_niceng185er6.tab2_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">+1 yr</th><th headers="hd_h_niceng185er6.tab2_1_1_1_6" id="hd_h_niceng185er6.tab2_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 yr</th><th headers="hd_h_niceng185er6.tab2_1_1_1_6" id="hd_h_niceng185er6.tab2_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">+1 yr</th><th headers="hd_h_niceng185er6.tab2_1_1_1_7" id="hd_h_niceng185er6.tab2_1_1_2_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 yr</th><th headers="hd_h_niceng185er6.tab2_1_1_1_7" id="hd_h_niceng185er6.tab2_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">+1 yr</th><th headers="hd_h_niceng185er6.tab2_1_1_1_8" id="hd_h_niceng185er6.tab2_1_1_2_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 yr</th><th headers="hd_h_niceng185er6.tab2_1_1_1_8" id="hd_h_niceng185er6.tab2_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">+1 yr</th><th headers="hd_h_niceng185er6.tab2_1_1_1_9" id="hd_h_niceng185er6.tab2_1_1_2_11" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 yr</th><th headers="hd_h_niceng185er6.tab2_1_1_1_9" id="hd_h_niceng185er6.tab2_1_1_2_12" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">+1 yr</th><th headers="hd_h_niceng185er6.tab2_1_1_1_10" id="hd_h_niceng185er6.tab2_1_1_2_13" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 yr</th><th headers="hd_h_niceng185er6.tab2_1_1_1_10" id="hd_h_niceng185er6.tab2_1_1_2_14" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">+1 yr</th><th headers="hd_h_niceng185er6.tab2_1_1_1_11" id="hd_h_niceng185er6.tab2_1_1_2_15" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 yr</th><th headers="hd_h_niceng185er6.tab2_1_1_1_11" id="hd_h_niceng185er6.tab2_1_1_2_16" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">+1 yr</th></tr></thead><tbody><tr><td headers="hd_h_niceng185er6.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Brilakis 2009<a class="bibr" href="#niceng185er6.ref19" rid="niceng185er6.ref19"><sup>19</sup></a>: SOS</b>
|
|
</td><td headers="hd_h_niceng185er6.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">80</td><td headers="hd_h_niceng185er6.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">USA, Greece</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_1" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_2" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_5" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_6" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_7" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_8" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_9" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_10" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_11" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_12" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_13" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_14" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_15" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_16" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td></tr><tr><td headers="hd_h_niceng185er6.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Brilakis 2018<a class="bibr" href="#niceng185er6.ref17" rid="niceng185er6.ref17"><sup>17</sup></a>: DIVA</b>
|
|
</td><td headers="hd_h_niceng185er6.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">597</td><td headers="hd_h_niceng185er6.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">USA</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_1" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_2" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_3" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_4" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_7" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_8" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_9" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_10" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_11" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_12" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_13" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_14" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_15" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_16" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td></tr><tr><td headers="hd_h_niceng185er6.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Chechi 2007</b>
|
|
<a class="bibr" href="#niceng185er6.ref27" rid="niceng185er6.ref27">
|
|
<sup>27</sup>
|
|
</a>
|
|
</td><td headers="hd_h_niceng185er6.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">80</td><td headers="hd_h_niceng185er6.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Italy</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_1" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_7" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_9" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_11" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_12" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_13" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_14" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_15" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_16" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td></tr><tr><td headers="hd_h_niceng185er6.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>de Belder 2014<a class="bibr" href="#niceng185er6.ref32" rid="niceng185er6.ref32"><sup>32</sup></a>: XIMA</b>
|
|
</td><td headers="hd_h_niceng185er6.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">800</td><td headers="hd_h_niceng185er6.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">UK, Spain</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_1" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_3" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_7" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_9" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_11" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_12" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_13" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_14" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_15" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_16" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td></tr><tr><td headers="hd_h_niceng185er6.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Di Lorenzo 2009<a class="bibr" href="#niceng185er6.ref34" rid="niceng185er6.ref34"><sup>34</sup></a>: PASEO</b>
|
|
</td><td headers="hd_h_niceng185er6.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">270</td><td headers="hd_h_niceng185er6.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Italy</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_1" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_2" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_7" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_8" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_9" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_10" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_11" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_12" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_13" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_14" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_15" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_16" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td></tr><tr><td headers="hd_h_niceng185er6.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Diaz de la Llera 2007</b>
|
|
<a class="bibr" href="#niceng185er6.ref35" rid="niceng185er6.ref35">
|
|
<sup>35</sup>
|
|
</a>
|
|
</td><td headers="hd_h_niceng185er6.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">120</td><td headers="hd_h_niceng185er6.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Spain</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_1" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_7" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_11" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_12" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_13" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_14" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_15" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_16" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td></tr><tr><td headers="hd_h_niceng185er6.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Guagliumi 2010<a class="bibr" href="#niceng185er6.ref46" rid="niceng185er6.ref46"><sup>46</sup></a>: OCTAMI</b>
|
|
</td><td headers="hd_h_niceng185er6.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">44</td><td headers="hd_h_niceng185er6.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">USA, Italy</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_1" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_7" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_9" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_11" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_12" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_13" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_14" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_15" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_16" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td></tr><tr><td headers="hd_h_niceng185er6.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Han 2007</b>
|
|
<a class="bibr" href="#niceng185er6.ref47" rid="niceng185er6.ref47">
|
|
<sup>47</sup>
|
|
</a>
|
|
</td><td headers="hd_h_niceng185er6.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">200</td><td headers="hd_h_niceng185er6.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Chile</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_3" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_9" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_11" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_12" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_13" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_14" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_15" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_16" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td></tr><tr><td headers="hd_h_niceng185er6.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Kaiser 2010<a class="bibr" href="#niceng185er6.ref55" rid="niceng185er6.ref55"><sup>55</sup></a>: BASKETPROVE</b>
|
|
</td><td headers="hd_h_niceng185er6.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2314</td><td headers="hd_h_niceng185er6.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Multinational</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_2" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_4" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_8" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_11" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_12" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_13" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_14" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_15" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_16" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td></tr><tr><td headers="hd_h_niceng185er6.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Kaiser 2015<a class="bibr" href="#niceng185er6.ref56" rid="niceng185er6.ref56"><sup>56</sup></a>: BASKETPROVE II</b>
|
|
</td><td headers="hd_h_niceng185er6.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2291</td><td headers="hd_h_niceng185er6.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Multinational</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_2" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_4" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_8" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_10" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_11" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_12" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_13" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_14" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_15" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_16" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td></tr><tr><td headers="hd_h_niceng185er6.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Kelbaek 2008<a class="bibr" href="#niceng185er6.ref61" rid="niceng185er6.ref61"><sup>61</sup></a>: DEDICATION</b>
|
|
</td><td headers="hd_h_niceng185er6.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">626</td><td headers="hd_h_niceng185er6.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Denmark</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_1" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_2" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_3" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_4" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_7" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_8" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_9" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_10" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_11" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_12" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_13" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_14" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_15" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_16" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td></tr><tr><td headers="hd_h_niceng185er6.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Laarman 2006<a class="bibr" href="#niceng185er6.ref67" rid="niceng185er6.ref67"><sup>67</sup></a>: PASSION</b>
|
|
</td><td headers="hd_h_niceng185er6.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">619</td><td headers="hd_h_niceng185er6.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Netherlands</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_1" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_2" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_3" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_4" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_7" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_8" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_9" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_10" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_11" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_12" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_13" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_14" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_15" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_16" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td></tr><tr><td headers="hd_h_niceng185er6.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Menichelli 2007<a class="bibr" href="#niceng185er6.ref76" rid="niceng185er6.ref76"><sup>76</sup></a>: SESAMI</b>
|
|
</td><td headers="hd_h_niceng185er6.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">320</td><td headers="hd_h_niceng185er6.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Italy</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_1" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_2" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_7" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_8" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_9" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_10" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_11" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_12" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_13" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_14" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_15" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_16" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td></tr><tr><td headers="hd_h_niceng185er6.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Raber 2012<a class="bibr" href="#niceng185er6.ref90" rid="niceng185er6.ref90"><sup>90</sup></a>: COMFORTABLE</b>
|
|
</td><td headers="hd_h_niceng185er6.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1161</td><td headers="hd_h_niceng185er6.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Multinational</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_1" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_2" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_3" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_4" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_8" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_11" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_12" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_13" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_14" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_15" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_16" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td></tr><tr><td headers="hd_h_niceng185er6.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Remkes 2016<a class="bibr" href="#niceng185er6.ref94" rid="niceng185er6.ref94"><sup>94</sup></a>: ELISA 3 trial</b>
|
|
</td><td headers="hd_h_niceng185er6.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">474</td><td headers="hd_h_niceng185er6.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Netherlands</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_8" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_11" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_12" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_13" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_14" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_15" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_16" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td></tr><tr><td headers="hd_h_niceng185er6.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Ribamar Costa 2012</b>
|
|
<a class="bibr" href="#niceng185er6.ref95" rid="niceng185er6.ref95">
|
|
<sup>95</sup>
|
|
</a>
|
|
</td><td headers="hd_h_niceng185er6.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40</td><td headers="hd_h_niceng185er6.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Brazil</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_1" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_9" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_11" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_12" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_13" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_14" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_15" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_16" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td></tr><tr><td headers="hd_h_niceng185er6.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Ribichini 2011<a class="bibr" href="#niceng185er6.ref96" rid="niceng185er6.ref96"><sup>96</sup></a>: CEREADES</b>
|
|
</td><td headers="hd_h_niceng185er6.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">250</td><td headers="hd_h_niceng185er6.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Italy</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_1" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_3" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_7" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_9" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_11" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_12" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_13" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_14" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_15" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_16" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td></tr><tr><td headers="hd_h_niceng185er6.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Rodriguez 2011<a class="bibr" href="#niceng185er6.ref100" rid="niceng185er6.ref100"><sup>100</sup></a>: EUCATAX</b>
|
|
</td><td headers="hd_h_niceng185er6.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">422</td><td headers="hd_h_niceng185er6.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Argentina</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_1" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_3" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_5" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_7" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_9" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_11" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_12" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_13" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_14" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_15" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_16" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td></tr><tr><td headers="hd_h_niceng185er6.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Sabate 2012<a class="bibr" href="#niceng185er6.ref104" rid="niceng185er6.ref104"><sup>104</sup></a> EXAMINATION</b>
|
|
</td><td headers="hd_h_niceng185er6.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1498</td><td headers="hd_h_niceng185er6.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Spain, Italy, Netherlands</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_1" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_2" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_3" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_4" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_7" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_8" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_11" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_12" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_13" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_14" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_15" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_16" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td></tr><tr><td headers="hd_h_niceng185er6.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Sanchez 2010<a class="bibr" href="#niceng185er6.ref105" rid="niceng185er6.ref105"><sup>105</sup></a>: GRACIA-3</b>
|
|
</td><td headers="hd_h_niceng185er6.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">433</td><td headers="hd_h_niceng185er6.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Spain</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_3" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_9" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_11" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_12" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_13" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_14" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_15" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_16" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td></tr><tr><td headers="hd_h_niceng185er6.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Spaulding 2006<a class="bibr" href="#niceng185er6.ref109" rid="niceng185er6.ref109"><sup>109</sup></a>: TYPHOON</b>
|
|
</td><td headers="hd_h_niceng185er6.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">715</td><td headers="hd_h_niceng185er6.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Multinational</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_1" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_3" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_5" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_9" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_11" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_12" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_13" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_14" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_15" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_16" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td></tr><tr><td headers="hd_h_niceng185er6.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Steinwender 2008</b>
|
|
<a class="bibr" href="#niceng185er6.ref111" rid="niceng185er6.ref111">
|
|
<sup>111</sup>
|
|
</a>
|
|
</td><td headers="hd_h_niceng185er6.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16</td><td headers="hd_h_niceng185er6.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Austria</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_1" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_11" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_12" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_13" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_14" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_15" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_16" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td></tr><tr><td headers="hd_h_niceng185er6.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Stone 2009<a class="bibr" href="#niceng185er6.ref112" rid="niceng185er6.ref112"><sup>112</sup></a>: HORIZONSAMI</b>
|
|
</td><td headers="hd_h_niceng185er6.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3006</td><td headers="hd_h_niceng185er6.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Multinational</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_1" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_2" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_3" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_4" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_7" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_8" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_11" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_12" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_13" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_14" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_15" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_16" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td></tr><tr><td headers="hd_h_niceng185er6.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Strozzi 2007</b>
|
|
<a class="bibr" href="#niceng185er6.ref116" rid="niceng185er6.ref116">
|
|
<sup>116</sup>
|
|
</a>
|
|
</td><td headers="hd_h_niceng185er6.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">119</td><td headers="hd_h_niceng185er6.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Croatia</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_1" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_7" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_9" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_11" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_12" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_13" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_14" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_15" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_16" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td></tr><tr><td headers="hd_h_niceng185er6.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Valgimigli 2008<a class="bibr" href="#niceng185er6.ref122" rid="niceng185er6.ref122"><sup>122</sup></a>: MULTISTRATEGY trial</b>
|
|
</td><td headers="hd_h_niceng185er6.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">744</td><td headers="hd_h_niceng185er6.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Multinational</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_1" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_2" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_3" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_4" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_7" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_8" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_9" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_11" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_12" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_13" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_14" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_15" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_16" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td></tr><tr><td headers="hd_h_niceng185er6.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Valgimigli 2014<a class="bibr" href="#niceng185er6.ref126" rid="niceng185er6.ref126"><sup>126</sup></a>: PRODIGY</b>
|
|
</td><td headers="hd_h_niceng185er6.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2013</td><td headers="hd_h_niceng185er6.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Italy</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_6" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_11" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_12" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_13" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_14" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_15" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_16" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td></tr><tr><td headers="hd_h_niceng185er6.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Valgimigli 2015<a class="bibr" href="#niceng185er6.ref125" rid="niceng185er6.ref125"><sup>125</sup></a>: ZEUS trial</b>
|
|
</td><td headers="hd_h_niceng185er6.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1606</td><td headers="hd_h_niceng185er6.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Multinational</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_1" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_3" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_7" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_9" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_11" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_12" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_13" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_14" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_15" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_16" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td></tr><tr><td headers="hd_h_niceng185er6.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>van der Hoeven 2008<a class="bibr" href="#niceng185er6.ref128" rid="niceng185er6.ref128"><sup>128</sup></a>: MISSION</b>
|
|
</td><td headers="hd_h_niceng185er6.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">310</td><td headers="hd_h_niceng185er6.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Netherlands</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_1" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_2" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_3" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_4" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_5" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_6" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_9" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_10" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_11" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_12" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_13" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_14" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_15" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_16" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td></tr><tr><td headers="hd_h_niceng185er6.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Wijnbergen 2012<a class="bibr" href="#niceng185er6.ref133" rid="niceng185er6.ref133"><sup>133</sup></a>: DEBATER</b>
|
|
</td><td headers="hd_h_niceng185er6.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">907</td><td headers="hd_h_niceng185er6.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Netherlands</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_1" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_4 hd_h_niceng185er6.tab2_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_5 hd_h_niceng185er6.tab2_1_1_2_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_6 hd_h_niceng185er6.tab2_1_1_2_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_7" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_7 hd_h_niceng185er6.tab2_1_1_2_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_8 hd_h_niceng185er6.tab2_1_1_2_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_11" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_9 hd_h_niceng185er6.tab2_1_1_2_12" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_13" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_10 hd_h_niceng185er6.tab2_1_1_2_14" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_15" rowspan="1" colspan="1" style="background-color:#75c599;text-align:left;vertical-align:top;">Y</td><td headers="hd_h_niceng185er6.tab2_1_1_1_11 hd_h_niceng185er6.tab2_1_1_2_16" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Green boxes = study evaluated outcome; Grey boxes = study did not evaluate outcome; Y= yes (evaluated) N=no (not evaluated)</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng185er6tab3"><div id="niceng185er6.tab3" class="table"><h3><span class="label">Table 3</span><span class="title">Summary of studies included in the evidence review</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565358/table/niceng185er6.tab3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er6.tab3_lrgtbl__"><table><thead><tr><th id="hd_h_niceng185er6.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Study</th><th id="hd_h_niceng185er6.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Intervention and comparison</th><th id="hd_h_niceng185er6.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Population</th><th id="hd_h_niceng185er6.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcomes</th><th id="hd_h_niceng185er6.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comments</th></tr></thead><tbody><tr><td headers="hd_h_niceng185er6.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Brilakis 2009<a class="bibr" href="#niceng185er6.ref19" rid="niceng185er6.ref19"><sup>19</sup></a>: SOS trial</p>
|
|
<p>Brilakis, 2011<a class="bibr" href="#niceng185er6.ref18" rid="niceng185er6.ref18"><sup>18</sup></a></p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Intervention (n=39):</p>
|
|
<p>Drug-eluting stents: paclitaxel-eluting stents</p>
|
|
<p>Comparison (n=41):</p>
|
|
<p>Bare metal stents (type of bare metal stent used was unspecified in study)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>n=80</p>
|
|
<p>People with 1 or more 50% to 99% de novo or re-stenotic lesions in an SVG that were between 2.5 and 4.0 mm in diameter and need for percutaneous coronary intervention (PCI)</p>
|
|
<p>Unstable angina: 37.5%</p>
|
|
<p>Non-STEMI: 22.5%</p>
|
|
<p>Age (mean): 66.5 years</p>
|
|
<p>Gender (male to female ratio): 80:0</p>
|
|
<p>Ethnicity: White 94%, Black 2.5%, Hispanic 1.5%</p>
|
|
<p>USA and Greece</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>All-cause mortality at 1 year and 35 months</p>
|
|
<p>Myocardial infarction at 1 year and 35 months</p>
|
|
<p>Target vessel revascularisation at 1 year and 35 months</p>
|
|
<p>Target lesion revascularisation at 1 year and 35 months</p>
|
|
<p>Target vessel failure at 1 year and 35 months</p>
|
|
<p>Stent thrombosis (definite or probable) at 1 year and 35 months</p>
|
|
<p>Minimal luminal diameter (in-segment, proximal edge, in-stent, distal edge) at 1 year and 35 months</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_niceng185er6.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Brilakis 2018<a class="bibr" href="#niceng185er6.ref17" rid="niceng185er6.ref17"><sup>17</sup></a>: DIVA trial</td><td headers="hd_h_niceng185er6.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Intervention (n=292):</p>
|
|
<p>Drug-eluting stents: Any drug-eluting stent that was approved by the US Food and Drug Administration and clinically available at the time of enrolment could be used</p>
|
|
<p>Comparison (n=305):</p>
|
|
<p>Bare metal stents: Any bare metal stent that was approved by the US Food and Drug Administration and clinically available at the time of enrolment could be used</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>n=597</p>
|
|
<p>People with at least one significant de-novo SVG lesion (50–99% stenosis of a 2∙25–4∙5 mm diameter SVG) requiring percutaneous coronary intervention</p>
|
|
<p>Unstable angina: 31%</p>
|
|
<p>NSTEMI: 23.5%</p>
|
|
<p>Age (mean): 68.6 years</p>
|
|
<p>Gender (male to female ratio):</p>
|
|
<p>Ethnicity: White 88.5%, Black 8.5%, Hispanic 5.5%</p>
|
|
<p>USA</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>All-cause mortality at 1 year</p>
|
|
<p>Cardiac mortality at 1 year</p>
|
|
<p>Myocardial infarction at 1 year</p>
|
|
<p>Target vessel revascularisation at 1 year</p>
|
|
<p>Target lesion revascularisation at 1 year</p>
|
|
<p>Stent thrombosis (definite and definite or probable) at 1 year</p>
|
|
<p>Post-procedural bleeding at 1 year</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_niceng185er6.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Chechi 2007<a class="bibr" href="#niceng185er6.ref27" rid="niceng185er6.ref27"><sup>27</sup></a></td><td headers="hd_h_niceng185er6.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Intervention (n=40):</p>
|
|
<p>Drug-eluting stents: paclitaxel-eluting stents</p>
|
|
<p>Comparison (n=40):</p>
|
|
<p>Bare metal stents (type of bare metal stent used was unspecified in study)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>n=80</p>
|
|
<p>People with chest pain persisting for ≥30 minutes associated with ST elevation</p>
|
|
<p>Age (mean): 60.7 years</p>
|
|
<p>Gender (male to female ratio): 66:14</p>
|
|
<p>Ethnicity: Not reported</p>
|
|
<p>Italy</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>All-cause mortality at 7 months</p>
|
|
<p>Target lesion revascularisation at 7 months</p>
|
|
<p>Target vessel revascularisation at 7 months</p>
|
|
<p>Myocardial infarction at 7 months</p>
|
|
<p>Minimal lumen diameter at 7 months</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in Cochrane Review (STEMI patients)</td></tr><tr><td headers="hd_h_niceng185er6.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">de Belder 2014<a class="bibr" href="#niceng185er6.ref32" rid="niceng185er6.ref32"><sup>32</sup></a>: XIMA trial</td><td headers="hd_h_niceng185er6.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Intervention (n=399):</p>
|
|
<p>Drug-eluting stents: everolimus-eluting stents</p>
|
|
<p>Comparison (n=401):</p>
|
|
<p>Bare metal stents (type of bare metal stent used was unspecified in study)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>n=800</p>
|
|
<p>People with non–ST-segment elevation myocardial, infarction, unstable angina, and stable angina</p>
|
|
<p>Age (mean): 83.5 years</p>
|
|
<p>Gender (male to female ratio): 480:320</p>
|
|
<p>Ethnicity: Not reported</p>
|
|
<p>Multinational (United Kingdom and Spain)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>All-cause mortality at 1 year</p>
|
|
<p>Cardiac mortality at 1 year</p>
|
|
<p>Target vessel revascularisation at 1 year</p>
|
|
<p>Myocardial infarction at 1 year</p>
|
|
<p>Major bleeding at 1 year</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in Cochrane Review (STEMI patients)</td></tr><tr><td headers="hd_h_niceng185er6.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Di Lorenzo 2009<a class="bibr" href="#niceng185er6.ref34" rid="niceng185er6.ref34"><sup>34</sup></a>: PASEO trial</p>
|
|
<p>Di Lorenzo 2009<a class="bibr" href="#niceng185er6.ref33" rid="niceng185er6.ref33"><sup>33</sup></a></p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Intervention 1 (n=90):</p>
|
|
<p>Drug-eluting stents: paclitaxel-eluting stents</p>
|
|
<p>Intervention 2 (n=90):</p>
|
|
<p>Drug-eluting stents: sirolimus-eluting stents</p>
|
|
<p>Comparison (n=90):</p>
|
|
<p>Bare metal stents (type of bare metal stent used was unspecified in study)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>n=270</p>
|
|
<p>People with chest pain for more than 30 minutes and ST-segment elevation</p>
|
|
<p>Age (mean): 62.5 years</p>
|
|
<p>Gender (male to female ratio): 190:80</p>
|
|
<p>Ethnicity: Not reported</p>
|
|
<p>Italy</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>All-cause mortality at 1 year, 2 years</p>
|
|
<p>Target lesion vascularisation at 1 year and 2 years</p>
|
|
<p>Myocardial infarction (re-infarction) at 1 year and 2 years</p>
|
|
<p>Stent thrombosis (definite, probable and possible) at one1 year, 2 years</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in Cochrane Review (STEMI patients)</td></tr><tr><td headers="hd_h_niceng185er6.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Diaz de la Llera 2007<a class="bibr" href="#niceng185er6.ref35" rid="niceng185er6.ref35"><sup>35</sup></a></td><td headers="hd_h_niceng185er6.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Intervention (n=60):</p>
|
|
<p>Drug-eluting stents: sirolimus-eluting stents</p>
|
|
<p>Comparison (n=60):</p>
|
|
<p>Bare metal stents (type of bare metal stent used was unspecified in the study)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>n=120</p>
|
|
<p>People with STEMI who were candidates for primary angioplasty</p>
|
|
<p>Age (mean): 64.5 years</p>
|
|
<p>Gender (male to female ratio): 95:19</p>
|
|
<p>Ethnicity: Not reported</p>
|
|
<p>Spain</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>All-cause mortality at 1 year</p>
|
|
<p>Target vessel revascularisation at 1 year</p>
|
|
<p>Stent thrombosis (late and acute or subacute) at 1 year</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in Cochrane Review (STEMI patients)</td></tr><tr><td headers="hd_h_niceng185er6.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Guagliumi 2010<a class="bibr" href="#niceng185er6.ref46" rid="niceng185er6.ref46"><sup>46</sup></a>: OCTAMI trial</td><td headers="hd_h_niceng185er6.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Intervention (n=33):</p>
|
|
<p>Drug-eluting stents: zotarolimus-eluting stents</p>
|
|
<p>Comparison (n=11):</p>
|
|
<p>Bare metal stents (type of bare metal stent used was unspecified in the study)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>n=44</p>
|
|
<p>People presented with STEMI <12 h after symptom onset (prolonged chest pain for more than 20 min, unresponsive to nitroglycerin, and ST-segment elevation</p>
|
|
<p>Age (mean): 61.1 years</p>
|
|
<p>Gender (male to female ratio): 34:10</p>
|
|
<p>Ethnicity: Not reported</p>
|
|
<p>Italy and USA</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>All-cause mortality at 1 year</p>
|
|
<p>Target lesion revascularisation at 1 year</p>
|
|
<p>Target vessel revascularisation at 1 year</p>
|
|
<p>Myocardial infarction at 1 year</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in Cochrane Review (STEMI patients)</td></tr><tr><td headers="hd_h_niceng185er6.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Han 2007<a class="bibr" href="#niceng185er6.ref47" rid="niceng185er6.ref47"><sup>47</sup></a></td><td headers="hd_h_niceng185er6.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Intervention (n=100):</p>
|
|
<p>Drug-eluting stents: tacrolimus-eluting stents</p>
|
|
<p>Comparison (n=100):</p>
|
|
<p>Bare metal stents (type of bare metal stent used was unspecified in the study)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>n=200</p>
|
|
<p>People with symptomatic or documented myocardial ischemia, including acute myocardial infarction</p>
|
|
<p>Age (mean): 58.4 years</p>
|
|
<p>Gender (male to female ratio): 153:47</p>
|
|
<p>Ethnicity: Not reported</p>
|
|
<p>Chile</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Cardiac mortality at 8 months</p>
|
|
<p>Myocardial infarction at 8 months</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in Cochrane Review (STEMI patients)</td></tr><tr><td headers="hd_h_niceng185er6.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Kaiser 2010<a class="bibr" href="#niceng185er6.ref55" rid="niceng185er6.ref55"><sup>55</sup></a>: BASKET-PROVE trial</td><td headers="hd_h_niceng185er6.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Intervention 1 (n=775):</p>
|
|
<p>Drug-eluting stents: first-generation sirolimus-eluting stents</p>
|
|
<p>Intervention 2 (n=774):</p>
|
|
<p>Drug-eluting stents: second-generation everolimus-eluting stent</p>
|
|
<p>Comparison (n=765):</p>
|
|
<p>Bare metal stents – cobalt chromium</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>n=2314</p>
|
|
<p>People who presented with chronic or acute coronary disease, who underwent angioplasty with stenting</p>
|
|
<p>Unstable angina/NSTEMI: 32.3%</p>
|
|
<p>NSTEMI: 32%</p>
|
|
<p>Age (mean): 66.5 years</p>
|
|
<p>Gender (male to female ratio): 1759: 555</p>
|
|
<p>Ethnicity: Not reported</p>
|
|
<p>Switzerland, Denmark, Austria, and Italy</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>All-cause mortality at 2 years</p>
|
|
<p>Cardiac mortality at 2 years</p>
|
|
<p>Myocardial infarction at 2 years</p>
|
|
<p>Target vessel revascularisation at 2 years</p>
|
|
<p>Stent thrombosis (definite; definite or possible) at 2 years</p>
|
|
<p>Major bleeding at 2 years</p>
|
|
<p>Minor bleeding at 2 years</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in Cochrane Review (STEMI patients)</td></tr><tr><td headers="hd_h_niceng185er6.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Kaiser 2015<a class="bibr" href="#niceng185er6.ref56" rid="niceng185er6.ref56"><sup>56</sup></a>: BASKET-PROVE II trial</td><td headers="hd_h_niceng185er6.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Intervention 1 (n=765):</p>
|
|
<p>Drug-eluting stents: second-generation biolimus-A9–eluting biodegradable-polymer stainlesssteel stents</p>
|
|
<p>Intervention 2 (n=765)</p>
|
|
<p>Drug-eluting stents: second-generation everolimus-eluting durable-polymer cobalt-chromium stents</p>
|
|
<p>Comparison (n=761):</p>
|
|
<p>Bare metal stents: newest-generation thin-strut BMS coated with a biocompatible siliconecarbide layer</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>n=2291</p>
|
|
<p>People presenting with chronic or acute coronary artery disease requiring angioplasty and stenting</p>
|
|
<p>STEMI: 29%</p>
|
|
<p>NSTEMI: 34%</p>
|
|
<p>Age (mean): 62.5 years</p>
|
|
<p>Gender (male to female ratio):</p>
|
|
<p>Ethnicity: 1787: 504</p>
|
|
<p>Switzerland, Denmark, Germany, and Austria</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>All-cause mortality at 2 years</p>
|
|
<p>Cardiac mortality at 2 years</p>
|
|
<p>Myocardial infarction at 2 years</p>
|
|
<p>Target vessel revascularisation at 2 years</p>
|
|
<p>Stent thrombosis (definite; definite or possible at 2 years</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in Cochrane Review (STEMI patients)</td></tr><tr><td headers="hd_h_niceng185er6.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Kelbaek 2008<a class="bibr" href="#niceng185er6.ref61" rid="niceng185er6.ref61"><sup>61</sup></a>: DEDICATION trial Kaltoft 2010<a class="bibr" href="#niceng185er6.ref57" rid="niceng185er6.ref57"><sup>57</sup></a></td><td headers="hd_h_niceng185er6.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Intervention (n=313):</p>
|
|
<p>Drug-eluting stents: mixed use of drug eluting stents (47% were sirolimus-eluting, 40% were paclitaxel-eluting, and 13% were zotarolimus-eluting stents</p>
|
|
<p>Comparison (n=313):</p>
|
|
<p>Mixed use of bare metal stents (38% were made of cobalt alloy, 39% were stainless steel stents, and 23% were miscellaneous stainless steel stents</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>n=626</p>
|
|
<p>People with chest pain of >30 minute duration who had a cumulated ST-segment elevation</p>
|
|
<p>Age (mean): 62.05 years</p>
|
|
<p>Gender (male to female ratio): 458:168</p>
|
|
<p>Ethnicity: Not reported</p>
|
|
<p>Denmark</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>All-cause mortality at 1 year and 3 years</p>
|
|
<p>Cardiac mortality at 1 year and 3 years</p>
|
|
<p>Target lesion revascularisation at 1 year and 3 years</p>
|
|
<p>Target vessel revascularisation at 1 year and 3 years</p>
|
|
<p>Myocardial infarction at 1 year and 3 years</p>
|
|
<p>Minimal lumen diameter (in-lesion zone and in-stent zone) at 8 months</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in Cochrane Review (STEMI patients)</td></tr><tr><td headers="hd_h_niceng185er6.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Laarman 2006<a class="bibr" href="#niceng185er6.ref67" rid="niceng185er6.ref67"><sup>67</sup></a>: PASSION trial</p>
|
|
<p>Dirksen 2008<a class="bibr" href="#niceng185er6.ref36" rid="niceng185er6.ref36"><sup>36</sup></a></p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Intervention (n=310):</p>
|
|
<p>Drug-eluting stents: paclitaxel-eluting stents</p>
|
|
<p>Comparison (n=309):</p>
|
|
<p>Bare metal stents (type of bare metal stent used was unspecified in the study)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>n=619</p>
|
|
<p>People who had an acute myocardial infarction with ST-segment elevation (>20 minutes of chest pain and ST-segment elevation</p>
|
|
<p>Age (mean): 61 years</p>
|
|
<p>Gender (male to female ratio): 470:149</p>
|
|
<p>Ethnicity: Not reported</p>
|
|
<p>Netherlands</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>All-cause mortality at 1 year and 2 years</p>
|
|
<p>Cardiac mortality at 1 year and 2 years</p>
|
|
<p>Target lesion revascularisation at 1 year and 2 years</p>
|
|
<p>Myocardial infarction (re-current) at 1 year and 2 years</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in Cochrane Review (STEMI patients)</td></tr><tr><td headers="hd_h_niceng185er6.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Menichelli 2007<a class="bibr" href="#niceng185er6.ref76" rid="niceng185er6.ref76"><sup>76</sup></a>: SESAMI trial</p>
|
|
<p>Violini 2010<a class="bibr" href="#niceng185er6.ref131" rid="niceng185er6.ref131"><sup>131</sup></a></p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Intervention (n=160):</p>
|
|
<p>Drug-eluting stents: sirolimus-eluting stents</p>
|
|
<p>Comparison (n=160):</p>
|
|
<p>Bare metal stents (type of bare metal stent used was unspecified in the study)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>n=320</p>
|
|
<p>People who had symptoms of acute MI for ≥30 minutes but ≤12 hours, and had ≥1 mm ST-segment elevation</p>
|
|
<p>Age (median): 62.5 years</p>
|
|
<p>Gender (male to female ratio): 128:32</p>
|
|
<p>Ethnicity: Not reported</p>
|
|
<p>Italy</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>All-cause mortality at 1 year and 3 years</p>
|
|
<p>Target lesion revascularisation at 1 year and 3 years</p>
|
|
<p>Target vessel revascularisation at 1 year and 3 years</p>
|
|
<p>Myocardial infarction (re-infarction) at 1 year and 3 years</p>
|
|
<p>Stent thrombosis (definite) at 1 year and 3 years</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in Cochrane Review (STEMI patients)</td></tr><tr><td headers="hd_h_niceng185er6.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Raber 2012<a class="bibr" href="#niceng185er6.ref90" rid="niceng185er6.ref90"><sup>90</sup></a>: COMFORTABLE trial</p>
|
|
<p>Magro 2014<a class="bibr" href="#niceng185er6.ref73" rid="niceng185er6.ref73"><sup>73</sup></a></p>
|
|
<p>Raber 2016<a class="bibr" href="#niceng185er6.ref88" rid="niceng185er6.ref88"><sup>88</sup></a></p>
|
|
<p>Raber 2014<a class="bibr" href="#niceng185er6.ref91" rid="niceng185er6.ref91"><sup>91</sup></a>, Raber 2012<a class="bibr" href="#niceng185er6.ref89" rid="niceng185er6.ref89"><sup>89</sup></a></p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Intervention (n=578):</p>
|
|
<p>Drug-eluting stents: eluting biolimus from a biodegradable polylactic acid polymer</p>
|
|
<p>Comparison (n=583):</p>
|
|
<p>Bare metal stents (type of bare metal stent used was unspecified in the study)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>n=1161</p>
|
|
<p>People with symptom onset within 24 hours and ST segment elevation</p>
|
|
<p>Age (mean): 60.6 years</p>
|
|
<p>Gender (male to female ratio): 918:243</p>
|
|
<p>Ethnicity: Not reported</p>
|
|
<p>Multinational (11 centres across: Denmark, Israel, Netherlands, Serbia, Switzerland, United Kingdom)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>All-cause mortality at 1 year and 2 years</p>
|
|
<p>Cardiac mortality at 1 year and 2 years</p>
|
|
<p>Target lesion revascularisation at 1 year and 2 years</p>
|
|
<p>Target vessel revascularisation at 2 years</p>
|
|
<p>Stent thrombosis (definite and probable) at 1 year and 2 years</p>
|
|
<p>Minimal lumen diameter (in stent, in segment) at 12 months</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in Cochrane Review (STEMI patients)</td></tr><tr><td headers="hd_h_niceng185er6.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Remkes 2016<a class="bibr" href="#niceng185er6.ref94" rid="niceng185er6.ref94"><sup>94</sup></a>: ELISA 3 trial</td><td headers="hd_h_niceng185er6.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Intervention (n=234):</p>
|
|
<p>Drug-eluting stents: everolimus-eluting stents</p>
|
|
<p>Comparison (n=240):</p>
|
|
<p>Bare metal stents (type of bare metal stent used was unspecified in the study)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>n=474</p>
|
|
<p>People with NSTEMI hospitalised with ischaemic chest pain or dyspnoea at rest, with the last episode occurring 24 hours or less</p>
|
|
<p>Age (mean): 65.27 years</p>
|
|
<p>Gender (male to female ratio): 351:123</p>
|
|
<p>Ethnicity: Not reported</p>
|
|
<p>Netherlands</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Target vessel revascularisation at 2 years</p>
|
|
<p>Minimal lumen diameter at 9 months</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in Cochrane Review (STEMI patients)</td></tr><tr><td headers="hd_h_niceng185er6.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ribamar Costa 2012<a class="bibr" href="#niceng185er6.ref95" rid="niceng185er6.ref95"><sup>95</sup></a></td><td headers="hd_h_niceng185er6.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Intervention (n=20):</p>
|
|
<p>Drug-eluting stent (unspecified), study reports Cypher Select.</p>
|
|
<p>Comparison (n=20):</p>
|
|
<p>Bare metal stents (type of bare metal stent used was unspecified in the study)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>n=40</p>
|
|
<p>People with ST-segment elevation myocardial infarction (MI) treated in the very early phase (primary or rescue percutaneous coronary intervention [PCI]), restenotic lesions, lesions located at grafts and at the left main stem</p>
|
|
<p>Age (mean): 56.3 years</p>
|
|
<p>Gender (male to female ratio): 28:12</p>
|
|
<p>Ethnicity: Not reported</p>
|
|
<p>Brazil</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>All-cause mortality at 1 year</p>
|
|
<p>Myocardial infarction at 1 year</p>
|
|
<p>Stent thrombosis at 1 year</p>
|
|
<p>Minimal lumen diameter (proximal edge and distal edge) at 1 year</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in Cochrane Review (STEMI patients)</td></tr><tr><td headers="hd_h_niceng185er6.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ribichini 2011<a class="bibr" href="#niceng185er6.ref96" rid="niceng185er6.ref96"><sup>96</sup></a>: CEREA-DES trial</td><td headers="hd_h_niceng185er6.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Intervention (n=125):</p>
|
|
<p>Drug-eluting stents: paclitaxel-eluting stents or the sirolimus-eluting stents</p>
|
|
<p>Comparison (n=125):</p>
|
|
<p>Bare metal stents (type of bare metal stent used was unspecified in the study)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>n=250</p>
|
|
<p>People showing significant coronary artery disease (either single or multi-vessel involvement), with signs or symptoms of myocardial ischemia, amenable for PCI</p>
|
|
<p>Unstable angina: 30.8%</p>
|
|
<p>NSTEMI: 26.8%</p>
|
|
<p>Age (mean): 63.99 years</p>
|
|
<p>Gender (male to female ratio): 210:40</p>
|
|
<p>Ethnicity: Not reported</p>
|
|
<p>Italy</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>All-cause mortality at 1 year</p>
|
|
<p>Cardiac mortality at 1 year</p>
|
|
<p>Myocardial infarction (non–Q-wave and Q-wave) at 1 year</p>
|
|
<p>Target lesion revascularisation at 1 year</p>
|
|
<p>Target vessel revascularisation at 1 year</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_niceng185er6.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Rodriguez 2011<a class="bibr" href="#niceng185er6.ref100" rid="niceng185er6.ref100"><sup>100</sup></a>: EUCATAX trial</td><td headers="hd_h_niceng185er6.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Intervention (n=211):</p>
|
|
<p>Drug-eluting stents: paclitaxel-eluting stents coated with a biodegradable polymer and glycocalyx</p>
|
|
<p>Comparison (n=211):</p>
|
|
<p>Bare metal stents (type of bare metal stent used was unspecified in the study)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>n=422</p>
|
|
<p>People with a de novo stenosis in a major coronary artery</p>
|
|
<p>Unstable angina: 63.3%</p>
|
|
<p>Age (mean): 64.3 years</p>
|
|
<p>Gender (male to female ratio): 343:79</p>
|
|
<p>Ethnicity: Not reported</p>
|
|
<p>Argentina</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>All-cause mortality at 1 year</p>
|
|
<p>Cardiac mortality at 1 year</p>
|
|
<p>Myocardial infarction (acute) at 1 year</p>
|
|
<p>Target vessel revascularisation at 1 year</p>
|
|
<p>Target vessel failure at 1 year</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_niceng185er6.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Sabate 2012<a class="bibr" href="#niceng185er6.ref104" rid="niceng185er6.ref104"><sup>104</sup></a></p>
|
|
<p>EXAMINATION trial</p>
|
|
<p>Sabate 2011<a class="bibr" href="#niceng185er6.ref103" rid="niceng185er6.ref103"><sup>103</sup></a></p>
|
|
<p>Sabate, 2014<a class="bibr" href="#niceng185er6.ref102" rid="niceng185er6.ref102"><sup>102</sup></a> (2 year results)</p>
|
|
<p>Brugaletta 2012<a class="bibr" href="#niceng185er6.ref22" rid="niceng185er6.ref22"><sup>22</sup></a>:</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Intervention (n=751):</p>
|
|
<p>Drug-eluting stents: everolimus-eluting stents</p>
|
|
<p>Comparison (n=747):</p>
|
|
<p>Bare metal stents – cobalt chromium balloon expandable bare metal stent</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>n=1498</p>
|
|
<p>People with STEMI within the first 48 hours after symptom onset, requiring emergent percutaneous coronary intervention</p>
|
|
<p>Age (mean): 61.2 years</p>
|
|
<p>Gender (male to female ratio): 1244:254</p>
|
|
<p>Ethnicity: Not reported</p>
|
|
<p>Spain, Italy, Netherlands</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>All-cause mortality at 1 year and 2 years</p>
|
|
<p>Cardiac mortality at 1 year and 2 years</p>
|
|
<p>Target lesion revascularisation at 1 year and 2 years</p>
|
|
<p>Target vessel revascularisation at 1 year and 2 years</p>
|
|
<p>Myocardial infarction at 1 year and 2 years</p>
|
|
<p>Stent thrombosis (definite/definite and probable) at 1 year and 2 years</p>
|
|
<p>Major bleeding at 1 year and 2 years</p>
|
|
<p>Minor bleeding at 1 year and 2 years</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in Cochrane Review (STEMI patients)</td></tr><tr><td headers="hd_h_niceng185er6.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Sanchez 2010<a class="bibr" href="#niceng185er6.ref105" rid="niceng185er6.ref105"><sup>105</sup></a>: GRACIA-3 trial</td><td headers="hd_h_niceng185er6.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Intervention (n=217):</p>
|
|
<p>Drug-eluting stents: paclitaxel-eluting stent with or without tirofiban.</p>
|
|
<p>Comparison (n=216):</p>
|
|
<p>Bare metal stents (type of bare metal stent used was unspecified in the study) - with or without tirofiban.</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>n=433</p>
|
|
<p>People with symptom onset within 12 hours, chest pain lasting more than 20 minutes and ST-segment elevation.</p>
|
|
<p>Age (mean): 61 years</p>
|
|
<p>Gender (male to female ratio): 358/75</p>
|
|
<p>Ethnicity: Not reported</p>
|
|
<p>Spain</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Cardiac mortality at 1 year</p>
|
|
<p>Myocardial infarction at 1 year</p>
|
|
<p>Stent thrombosis (definite and probable) at 1 year</p>
|
|
<p>Minor bleeding at 1 year</p>
|
|
<p>Minimal lumen diameter at 1 year</p>
|
|
<p>Major bleeding at 1 year</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in Cochrane Review (STEMI patients)</td></tr><tr><td headers="hd_h_niceng185er6.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Spaulding 2006<a class="bibr" href="#niceng185er6.ref109" rid="niceng185er6.ref109"><sup>109</sup></a>: TYPHOON 2006 trial</td><td headers="hd_h_niceng185er6.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Intervention (n=356):</p>
|
|
<p>Drug-eluting stents: sirolimus-eluting stent</p>
|
|
<p>Comparison (n=359):</p>
|
|
<p>Bare metal stents (type of bare metal stent used was unspecified in the study)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>n=715</p>
|
|
<p>People with symptoms which began less than 12 hours before catheterization and if the electrocardiogram showed ST segment elevation</p>
|
|
<p>Age (mean): 59.3 years</p>
|
|
<p>Gender (male to female ratio): 558:157</p>
|
|
<p>Ethnicity: Not reported</p>
|
|
<p>Multinational (Australia, Czech Republic, Denmark, France, Germany, Hungary, Israel, Italy, Latvia, Netherlands, Poland, Portugal, Spain, Switzerland, United Kingdom)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>All-cause mortality at 1 year</p>
|
|
<p>Cardiac mortality at 1 year</p>
|
|
<p>Target vessel failure at 1 year</p>
|
|
<p>Myocardial infarction (re-current) at 1 year</p>
|
|
<p>Stent thrombosis at 1 years</p>
|
|
<p>Minimal lumen diameter (in stent and in lesion) at 8 months</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in Cochrane Review (STEMI patients)</td></tr><tr><td headers="hd_h_niceng185er6.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Steinwender 2008<a class="bibr" href="#niceng185er6.ref111" rid="niceng185er6.ref111"><sup>111</sup></a></td><td headers="hd_h_niceng185er6.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Intervention (n=8):</p>
|
|
<p>Drug-eluting stents: sirolimus-eluting stents</p>
|
|
<p>Comparison (n=8):</p>
|
|
<p>Bare metal stents (type of bare metal stent used was unspecified in the study)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>n=16</p>
|
|
<p>People with a first ST-elevation anterior myocardial infarction</p>
|
|
<p>Age (mean): 55.5 years</p>
|
|
<p>Gender (male to female ratio):12:4</p>
|
|
<p>Ethnicity: Not reported</p>
|
|
<p>Austria</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>All-cause mortality at 6 months</p>
|
|
<p>Minimal lumen diameter at 6 months</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in Cochrane Review (STEMI patients)</td></tr><tr><td headers="hd_h_niceng185er6.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Stone 2009<a class="bibr" href="#niceng185er6.ref112" rid="niceng185er6.ref112"><sup>112</sup></a>: HORIZONS-AMI trial</p>
|
|
<p>Mehran 2008<a class="bibr" href="#niceng185er6.ref75" rid="niceng185er6.ref75"><sup>75</sup></a></p>
|
|
<p>Stone 2010<a class="bibr" href="#niceng185er6.ref113" rid="niceng185er6.ref113"><sup>113</sup></a></p>
|
|
<p>Stone 2011<a class="bibr" href="#niceng185er6.ref114" rid="niceng185er6.ref114"><sup>114</sup></a></p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Intervention (n=2257):</p>
|
|
<p>Drug-eluting stents: paclitaxel-eluting stents</p>
|
|
<p>Comparison (n=749):</p>
|
|
<p>Bare metal stents (type of bare metal stent used was unspecified in the study)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>n=3006</p>
|
|
<p>People presenting with ST-segment elevation myocardial infarction</p>
|
|
<p>Age (mean): 59.6 years</p>
|
|
<p>Gender (male to female ratio):</p>
|
|
<p>Ethnicity: Not reported</p>
|
|
<p>Multinational (Argentina, Austria, Germany, Israel, Italy, Netherlands, Norway, Poland, Spain, United Kingdom, USA)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>All-cause mortality at 1 year and 3 years</p>
|
|
<p>Cardiac mortality at 1 year and 3 years</p>
|
|
<p>Target lesion revascularisation at 1 year and 3 years</p>
|
|
<p>Target vessel revascularisation (ischemia-driven) at 1 year and 3 years</p>
|
|
<p>Stent thrombosis at 1 year and 3 years</p>
|
|
<p>Major bleeding (including CABG) at 3 years</p>
|
|
<p>Minimal lumen diameter at 1 year</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in Cochrane Review (STEMI patients)</td></tr><tr><td headers="hd_h_niceng185er6.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Strozzi 2007<a class="bibr" href="#niceng185er6.ref116" rid="niceng185er6.ref116"><sup>116</sup></a></td><td headers="hd_h_niceng185er6.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Intervention (n=39):</p>
|
|
<p>Drug-eluting stents: sirolimus-eluting stents</p>
|
|
<p>Comparison (n=40):</p>
|
|
<p>Bare metal stents (type of bare metal stent used was unspecified in the study)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>n=119</p>
|
|
<p>People with a diagnosis of acute coronary syndrome included acute myocardial infarction with ST elevation, prolonged angina for more than 20 minutes, or recurrent episodes at rest with indicators of cardiac ischemia or injury</p>
|
|
<p>Age (mean): 57.8 years</p>
|
|
<p>Gender (male to female ratio): 95:24</p>
|
|
<p>Ethnicity: Not reported</p>
|
|
<p>Croatia</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>All-cause mortality at 6 months</p>
|
|
<p>Target lesion revascularisation at 6 months</p>
|
|
<p>Myocardial infarction at 6 months</p>
|
|
<p>Minimal lumen diameter at 6 months</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in Cochrane Review (STEMI patients)</td></tr><tr><td headers="hd_h_niceng185er6.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Valgimigli 2008<a class="bibr" href="#niceng185er6.ref122" rid="niceng185er6.ref122"><sup>122</sup></a>: MULTISTRATEGY trial</p>
|
|
<p>Valgimigli 2013<a class="bibr" href="#niceng185er6.ref121" rid="niceng185er6.ref121"><sup>121</sup></a></p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Intervention (n=372):</p>
|
|
<p>Drug-eluting stents: sirolimus-eluting stents</p>
|
|
<p>Comparison (n=372):</p>
|
|
<p>Bare metal stents (type of bare metal stent used was unspecified in the study)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>n=744</p>
|
|
<p>People with chest pain for longer than 30 minutes with an electrocardiographic ST-segment elevation</p>
|
|
<p>Age (mean): 63.9 years</p>
|
|
<p>Gender (male to female ratio): 565:179</p>
|
|
<p>Ethnicity: Not reported</p>
|
|
<p>Multinational (16 centres in: Italy, Argentina and Spain)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>All-cause mortality at 8 months and 3 years</p>
|
|
<p>Cardiac mortality at 3 years</p>
|
|
<p>Target vessel revascularisation at 8 months and 3 years</p>
|
|
<p>Myocardial infarction at 8 months</p>
|
|
<p>Stent thrombosis (definite and/or probable) at 3 years</p>
|
|
<p>Major bleeding at 30 days</p>
|
|
<p>Minor bleeding at 30 days</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in Cochrane Review (STEMI patients)</td></tr><tr><td headers="hd_h_niceng185er6.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Valgimigli 2014<a class="bibr" href="#niceng185er6.ref126" rid="niceng185er6.ref126"><sup>126</sup></a>: PRODIGY trial</p>
|
|
<p>Valgimigli 2010<a class="bibr" href="#niceng185er6.ref123" rid="niceng185er6.ref123"><sup>123</sup></a></p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Intervention 1 (n=1508):</p>
|
|
<p>Drug-eluting stents: everolimus-eluting stents, paclitaxel-eluting stents or zotarolimus eluting stents</p>
|
|
<p>Intervention 2 (n=505):</p>
|
|
<p>Drug-eluting stents: paclitaxel-eluting stents</p>
|
|
<p>Intervention 3 (n=502):</p>
|
|
<p>Drug-eluting stents: zotarolimus-eluting stents</p>
|
|
<p>Comparison (n=505):</p>
|
|
<p>Third-generation thin-strut bare metal stents(metal not specified in the study)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>n=2013</p>
|
|
<p>People with chronic stable coronary artery disease or acute coronary syndromes, including non–ST-segment elevation myocardial infarction (MI) and ST-segment elevation MI</p>
|
|
<p>ACS: 73%</p>
|
|
<p>NSTEMI:22.5%</p>
|
|
<p>STEMI:32.3%</p>
|
|
<p>Unstable angina:18.5%</p>
|
|
<p>Age (mean): 68.5 years</p>
|
|
<p>Gender (male to female ratio): 1538:465</p>
|
|
<p>Ethnicity: Not reported</p>
|
|
<p>Italy</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Target lesion revascularisation at 2 years</p>
|
|
<p>Target vessel revascularisation at 2 years</p>
|
|
<p>Stent thrombosis (definite or probable) at 2 years</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in Cochrane Review (STEMI patients)</td></tr><tr><td headers="hd_h_niceng185er6.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Valgimigli 2015<a class="bibr" href="#niceng185er6.ref125" rid="niceng185er6.ref125"><sup>125</sup></a>: ZEUS trial</p>
|
|
<p>Valgimigli 2013<a class="bibr" href="#niceng185er6.ref124" rid="niceng185er6.ref124"><sup>124</sup></a></p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Intervention (n=802):</p>
|
|
<p>Drug-eluting stents: zotarolimus-eluting stents</p>
|
|
<p>Comparison (n=804):</p>
|
|
<p>Bare metal stents (type of bare metal stent used was unspecified in the study)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>n=1606</p>
|
|
<p>People who underwent elective, urgent, or emergent percutaneous coronary intervention with intended stent implantation 63.3% ACS, 16% unstable angina, 27.5% NSTEMI, 19% STEMI</p>
|
|
<p>Age (median): 71.8 years</p>
|
|
<p>Gender (male to female ratio): 1133:473</p>
|
|
<p>Ethnicity: Not reported</p>
|
|
<p>Multinational (Netherlands, Italy, Greece, Hungary, Ireland, Switzerland, Portugal, Belgium)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>All-cause mortality at 1 year</p>
|
|
<p>Cardiac mortality at 1 year</p>
|
|
<p>Target vessel revascularisation at 1 year</p>
|
|
<p>Target lesion revascularisation at 1 year</p>
|
|
<p>Myocardial infarction at 1 year</p>
|
|
<p>Stent thrombosis (definite and possible) at 1 year</p>
|
|
<p>Bleeding at 1 year</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in Cochrane Review (STEMI patients)</td></tr><tr><td headers="hd_h_niceng185er6.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>van der Hoeven 2008<a class="bibr" href="#niceng185er6.ref128" rid="niceng185er6.ref128"><sup>128</sup></a>: MISSION trial</p>
|
|
<p>Atary 2010<a class="bibr" href="#niceng185er6.ref7" rid="niceng185er6.ref7"><sup>7</sup></a> Boden 2011<a class="bibr" href="#niceng185er6.ref13" rid="niceng185er6.ref13"><sup>13</sup></a></p>
|
|
<p>Boden 2012<a class="bibr" href="#niceng185er6.ref14" rid="niceng185er6.ref14"><sup>14</sup></a></p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Intervention (n=158):</p>
|
|
<p>Drug-eluting stents: sirolimus-eluting stents</p>
|
|
<p>Comparison (n=152):</p>
|
|
<p>Bare metal stents (type of bare metal stent used was unspecified in the study)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>n=310</p>
|
|
<p>People with STEMI symptoms which started 9 hours before primary percutaneous coronary intervention</p>
|
|
<p>Age (mean): 59.2 years</p>
|
|
<p>Gender (male to female ratio): 241:69</p>
|
|
<p>Ethnicity: Not reported</p>
|
|
<p>Netherlands</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>All-cause mortality (cardiac and non-cardiac) at 1 year and 3 years</p>
|
|
<p>Cardiac mortality at 1 year and 3 years</p>
|
|
<p>Target vessel failure at 1 years and 3 years</p>
|
|
<p>Myocardial infarction (re-current MI spontaneous and procedure related) at 1 year and 3 years</p>
|
|
<p>Stent thrombosis (definite) at 3 years</p>
|
|
<p>Minimal lumen diameter (in-stent and in-segment) at 1 year</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in Cochrane Review (STEMI patients)</td></tr><tr><td headers="hd_h_niceng185er6.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Wijnbergen 2012<a class="bibr" href="#niceng185er6.ref133" rid="niceng185er6.ref133"><sup>133</sup></a>: DEBATER trial</td><td headers="hd_h_niceng185er6.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Intervention (n=441):</p>
|
|
<p>Drug-eluting stents: sirolimus-eluting stent</p>
|
|
<p>Comparison (n=466):</p>
|
|
<p>Bare metal stent (type of bare metal stent used was unspecified in the study – choice of the bare metal stent was left to the discretion of the operator)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>n=907</p>
|
|
<p>People with STEMI, who resented within 12 hours of onset of symptoms</p>
|
|
<p>Age (mean): 61 years</p>
|
|
<p>Gender (male to female ratio): 668:202</p>
|
|
<p>Ethnicity: Not reported</p>
|
|
<p>Netherlands</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>All-cause mortality at 1 year</p>
|
|
<p>Target vessel revascularisation at 1 year</p>
|
|
<p>Stent thrombosis (definite and probable) at 1 year</p>
|
|
<p>Bleeding at 1 year</p>
|
|
</td><td headers="hd_h_niceng185er6.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Included in Cochrane Review (STEMI patients)</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng185er6tab4"><div id="niceng185er6.tab4" class="table"><h3><span class="label">Table 4</span><span class="title">Clinical evidence summary: Drug eluting stents (DES) versus bare metal stents (BMS)</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565358/table/niceng185er6.tab4/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er6.tab4_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng185er6.tab4_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_niceng185er6.tab4_1_1_1_1" style="text-align:left;vertical-align:bottom;">Outcomes</th><th id="hd_h_niceng185er6.tab4_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_niceng185er6.tab4_1_1_1_2" style="text-align:left;vertical-align:bottom;">No of Participants (studies) Follow up</th><th id="hd_h_niceng185er6.tab4_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_niceng185er6.tab4_1_1_1_3" style="text-align:left;vertical-align:bottom;">Quality of the evidence (GRADE)</th><th id="hd_h_niceng185er6.tab4_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng185er6.tab4_1_1_1_4" style="text-align:left;vertical-align:bottom;">Relative effect (95% CI)</th><th id="hd_h_niceng185er6.tab4_1_1_1_5" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">Anticipated absolute effects</th></tr><tr><th headers="hd_h_niceng185er6.tab4_1_1_1_5" id="hd_h_niceng185er6.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk with BMS</th><th headers="hd_h_niceng185er6.tab4_1_1_1_5" id="hd_h_niceng185er6.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Risk difference with DES (95% CI)</th></tr></thead><tbody><tr><td headers="hd_h_niceng185er6.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">All-cause mortality</td><td headers="hd_h_niceng185er6.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>14049</p>
|
|
<p>(22 studies)</p>
|
|
<p>up to 1 year</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup><sup>,</sup><sup>3</sup></p>
|
|
<p>due to risk of bias, imprecision</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N/A<sup>5</sup></td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">49 per 1000</td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2 fewer per 1000</p>
|
|
<p>(from 9 fewer to 5 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er6.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">All-cause mortality</td><td headers="hd_h_niceng185er6.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>12999</p>
|
|
<p>(12 studies)</p>
|
|
<p>1-3 years</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, imprecision</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.87</p>
|
|
<p>(0.75 to 1.01)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">57 per 1000</td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>7 fewer per 1000</p>
|
|
<p>(from 14 fewer to 1 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er6.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cardiac mortality</td><td headers="hd_h_niceng185er6.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>12117</p>
|
|
<p>(14 studies)</p>
|
|
<p>up to 1 year</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊕⊝</p>
|
|
<p>MODERATE<sup>1</sup></p>
|
|
<p>due to risk of bias</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.98</p>
|
|
<p>(0.82 to 1.17)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">39 per 1000</td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1 fewer per 1000</p>
|
|
<p>(from 7 fewer to 7 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er6.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cardiac mortality</td><td headers="hd_h_niceng185er6.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>12416</p>
|
|
<p>(10 studies)</p>
|
|
<p>1-3 years</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, imprecision</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.85</p>
|
|
<p>(0.70 to 1.03)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">37 per 1000</td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>6 fewer per 1000</p>
|
|
<p>(from 11 fewer to 1 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er6.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Target vessel failure</td><td headers="hd_h_niceng185er6.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2041</p>
|
|
<p>(4 studies)</p>
|
|
<p>up to 1 year</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊝⊝⊝</p>
|
|
<p>VERY LOW<sup>1</sup><sup>,</sup><sup>2</sup><sup>,</sup><sup>4</sup></p>
|
|
<p>due to risk of bias, inconsistency, imprecision</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.62</p>
|
|
<p>(0.44 to 0.88)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">164 per 1000</td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>62 fewer per 1000</p>
|
|
<p>(from 20 fewer to 92 fewer)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er6.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Target vessel failure</td><td headers="hd_h_niceng185er6.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>703</p>
|
|
<p>(3 studies)</p>
|
|
<p>1-3 years</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊕⊝</p>
|
|
<p>MODERATE<sup>1</sup></p>
|
|
<p>due to risk of bias</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.55</p>
|
|
<p>(0.41 to 0.74)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">259 per 1000</td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>117 fewer per 1000</p>
|
|
<p>(from 67 fewer to 153 fewer)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er6.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Target vessel revascularisation</td><td headers="hd_h_niceng185er6.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>12858</p>
|
|
<p>(18 studies)</p>
|
|
<p>up to 1 year</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊕⊝</p>
|
|
<p>MODERATE<sup>1</sup></p>
|
|
<p>due to risk of bias</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.52</p>
|
|
<p>(0.46 to 0.59)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">100 per 1000</td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>48 fewer per 1000</p>
|
|
<p>(from 41 fewer to 54 fewer)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er6.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Target vessel revascularisation</td><td headers="hd_h_niceng185er6.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>15141</p>
|
|
<p>(13 studies)</p>
|
|
<p>1-3 years</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊕⊝</p>
|
|
<p>MODERATE<sup>1</sup></p>
|
|
<p>due to risk of bias</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.52</p>
|
|
<p>(0.47 to 0.57)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">129 per 1000</td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>62 fewer per 1000</p>
|
|
<p>(from 55 fewer to 68 fewer)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er6.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Stent thrombosis - definite or probable</td><td headers="hd_h_niceng185er6.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>11405</p>
|
|
<p>(12 studies)</p>
|
|
<p>up to 1 year</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, imprecision</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.71</p>
|
|
<p>(0.57 to 0.89)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">34 per 1000</td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>10 fewer per 1000</p>
|
|
<p>(from 4 fewer to 15 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er6.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Stent thrombosis - definite or probable</td><td headers="hd_h_niceng185er6.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>14390</p>
|
|
<p>(12 studies)</p>
|
|
<p>1-3 years</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, imprecision</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.80</p>
|
|
<p>(0.64 to 0.99)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">28 per 1000</td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>6 fewer per 1000</p>
|
|
<p>(from 0 fewer to 10 fewer)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er6.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Myocardial infarction</td><td headers="hd_h_niceng185er6.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>10780</p>
|
|
<p>(20 studies)</p>
|
|
<p>up to 1 year</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>⊕⊕⊕⊝</p>
|
|
<p>MODERATE<sup>1</sup></p>
|
|
<p>due to risk of bias</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">N/A<sup>5</sup></td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">46 per 1000</td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>18 fewer per 1000</p>
|
|
<p>(from 12 fewer to 23 fewer)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er6.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Myocardial infarction</td><td headers="hd_h_niceng185er6.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>9456</p>
|
|
<p>(10 studies)</p>
|
|
<p>1-3 years</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, imprecision</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.66</p>
|
|
<p>(0.53 to 0.83)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">41 per 1000</td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>14 fewer per 1000</p>
|
|
<p>(from 7 fewer to 19 fewer)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er6.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Bleeding - Unspecified</td><td headers="hd_h_niceng185er6.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1467</p>
|
|
<p>(2 studies)</p>
|
|
<p>up to 1 year</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊝⊝⊝</p>
|
|
<p>VERY LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, imprecision</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.73</p>
|
|
<p>(0.41 to 1.31)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">35 per 1000</td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>9 fewer per 1000</p>
|
|
<p>(from 20 fewer to 11 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er6.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Bleeding - Major</td><td headers="hd_h_niceng185er6.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>7395</p>
|
|
<p>(6 studies)</p>
|
|
<p>up to 1 year</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, imprecision</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.79</p>
|
|
<p>(0.56 to 1.11)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20 per 1000</td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>4 fewer per 1000</p>
|
|
<p>(from 9 fewer to 2 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er6.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Bleeding - Minor</td><td headers="hd_h_niceng185er6.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>6595</p>
|
|
<p>(5 studies)</p>
|
|
<p>up to 1 year</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, imprecision</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.84</p>
|
|
<p>(0.63 to 1.12)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">32 per 1000</td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>5 fewer per 1000</p>
|
|
<p>(from 12 fewer to 4 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er6.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Bleeding - Major</td><td headers="hd_h_niceng185er6.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>5104</p>
|
|
<p>(2 studies)</p>
|
|
<p>1-3 years</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊝⊝⊝</p>
|
|
<p>VERY LOW<sup>1</sup><sup>,</sup><sup>2</sup><sup>,</sup><sup>4</sup></p>
|
|
<p>due to risk of bias, inconsistency, imprecision</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.99</p>
|
|
<p>(0.63 to 1.57)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">54 per 1000</td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1 fewer per 1000</p>
|
|
<p>(from 20 fewer to 31 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er6.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Bleeding - Minor</td><td headers="hd_h_niceng185er6.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2314</p>
|
|
<p>(1 study)</p>
|
|
<p>1-3 years</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊝⊝⊝</p>
|
|
<p>VERY LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, imprecision</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>RR 0.91</p>
|
|
<p>(0.47 to 1.78)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17 per 1000</td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2 fewer per 1000</p>
|
|
<p>(from 9 fewer to 13 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er6.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Minimal luminal diameter - In-segment</td><td headers="hd_h_niceng185er6.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>346</p>
|
|
<p>(2 studies)</p>
|
|
<p>up to 1 year</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊕⊝</p>
|
|
<p>MODERATE<sup>1</sup></p>
|
|
<p>due to risk of bias</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>The mean minimal luminal diameter - in-segment in the control groups was</p>
|
|
<p>1.745 mm</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>The mean minimal luminal diameter - in-segment in the intervention groups was</p>
|
|
<p>0.53 higher</p>
|
|
<p>(0.4 to 0.65 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er6.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Minimal luminal diameter - In-stent</td><td headers="hd_h_niceng185er6.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>1103</p>
|
|
<p>(5 studies)</p>
|
|
<p>up to 1 year</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊕⊝</p>
|
|
<p>MODERATE<sup>1</sup></p>
|
|
<p>due to risk of bias</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>The mean minimal luminal diameter - in-stent in the control groups was</p>
|
|
<p>1.75 mm</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>The mean minimal luminal diameter - in-stent in the intervention groups was</p>
|
|
<p>0.68 higher</p>
|
|
<p>(0.60 to 0.77 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er6.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Minimal luminal diameter - In-lesion</td><td headers="hd_h_niceng185er6.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>695</p>
|
|
<p>(2 studies)</p>
|
|
<p>up to 1 year</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, imprecision</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>The mean minimal luminal diameter - in-lesion in the control groups was</p>
|
|
<p>1.84 mm</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>The mean minimal luminal diameter - in-lesion in the intervention groups was</p>
|
|
<p>0.43 higher</p>
|
|
<p>(0.32 to 0.53 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er6.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Minimal luminal diameter - Proximal edge</td><td headers="hd_h_niceng185er6.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>37</p>
|
|
<p>(1 study)</p>
|
|
<p>up to 1 year</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊕⊝⊝</p>
|
|
<p>LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, imprecision</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>The mean minimal luminal diameter - proximal edge in the control groups was</p>
|
|
<p>2.86 mm</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>The mean minimal luminal diameter - proximal edge in the intervention groups was</p>
|
|
<p>0.12 lower</p>
|
|
<p>(0.45 lower to 0.21 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er6.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Minimal luminal diameter - Distal edge</td><td headers="hd_h_niceng185er6.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>40</p>
|
|
<p>(1 study)</p>
|
|
<p>up to 1 year</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊝⊝⊝</p>
|
|
<p>VERY LOW<sup>1</sup><sup>,</sup><sup>2</sup></p>
|
|
<p>due to risk of bias, imprecision</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>The mean minimal luminal diameter - distal edge in the control groups was</p>
|
|
<p>2.85 mm</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>The mean minimal luminal diameter - distal edge in the intervention groups was</p>
|
|
<p>0.05 lower</p>
|
|
<p>(0.39 lower to 0.29 higher)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er6.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Minimal luminal diameter - Unspecified</td><td headers="hd_h_niceng185er6.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>5273</p>
|
|
<p>(7 studies)</p>
|
|
<p>up to 1 year</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>⊕⊝⊝⊝</p>
|
|
<p>VERY LOW<sup>1</sup><sup>,</sup><sup>2</sup><sup>,</sup><sup>4</sup></p>
|
|
<p>due to risk of bias, inconsistency, imprecision</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>The mean minimal luminal diameter - unspecified in the control groups was</p>
|
|
<p>2.25 mm</p>
|
|
</td><td headers="hd_h_niceng185er6.tab4_1_1_1_5 hd_h_niceng185er6.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>The mean minimal luminal diameter - unspecified in the intervention groups was</p>
|
|
<p>0.18 higher</p>
|
|
<p>(0.05 to 0.32 higher)</p>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng185er6.tab4_1"><p class="no_margin">Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="niceng185er6.tab4_2"><p class="no_margin">Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="niceng185er6.tab4_3"><p class="no_margin">Imprecision was assessed by calculating the optimal information size and graded as follows: <80% - very serious imprecision, 80-90%- serious imprecision, >90%– no imprecision</p></div></dd></dl><dl class="bkr_refwrap"><dt>4</dt><dd><div id="niceng185er6.tab4_4"><p class="no_margin">Downgraded by 1 or 2 increments because heterogeneity, I2= > 50%, p= > 0.04, unexplained by subgroup analysis</p></div></dd></dl><dl class="bkr_refwrap"><dt>5</dt><dd><div id="niceng185er6.tab4_5"><p class="no_margin">No relative effect due to 0 events. Risk difference calculated in Review Manager</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng185er6tab5"><div id="niceng185er6.tab5" class="table"><h3><span class="label">Table 5</span><span class="title">Health economic evidence profile: drug-eluting stents versus bare metal stents</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565358/table/niceng185er6.tab5/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er6.tab5_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng185er6.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study</th><th id="hd_h_niceng185er6.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Applicability</th><th id="hd_h_niceng185er6.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Limitations</th><th id="hd_h_niceng185er6.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Other comments</th><th id="hd_h_niceng185er6.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Incremental cost</th><th id="hd_h_niceng185er6.tab5_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Incremental effects</th><th id="hd_h_niceng185er6.tab5_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Cost effectiveness</th><th id="hd_h_niceng185er6.tab5_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Uncertainty</th></tr></thead><tbody><tr><td headers="hd_h_niceng185er6.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Canoui-Poitrine 2009<a class="bibr" href="#niceng185er6.ref24" rid="niceng185er6.ref24"><sup>24</sup></a></p>
|
|
<p>(France)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Partially applicable<sup>(a)</sup></td><td headers="hd_h_niceng185er6.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Potentially serious limitations<sup>(b)</sup></td><td headers="hd_h_niceng185er6.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Within-trial analysis of French subgroup of the TYPHOON RCT with probabilistic analysis. QALYs estimated by attributing a QALY loss to all adverse events that occurred during follow-up.<sup>(c)</sup></div></li><li class="half_rhythm"><div>Cost-utility analysis (QALYs) / cost-effectiveness analysis (TVR avoided)</div></li><li class="half_rhythm"><div>Population: people presenting with STEMI less than 12 hours after the onset of chest pain, undergoing PCI.</div></li><li class="half_rhythm"><div>Comparators:
|
|
<ol><li class="half_rhythm"><div>Bare metal stents</div></li><li class="half_rhythm"><div>Drug eluting stents (sirolimus)</div></li></ol></div></li><li class="half_rhythm"><div>Follow-up: 1 year</div></li></ul></td><td headers="hd_h_niceng185er6.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£911<sup>(d)</sup></td><td headers="hd_h_niceng185er6.tab5_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>−0.0006 QALYs</p>
|
|
<p>−15.6% TVR</p>
|
|
</td><td headers="hd_h_niceng185er6.tab5_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>BMS dominates DES (lower cost and higher QALYs)</p>
|
|
<p>£5,842 per repeat TVR avoided</p>
|
|
</td><td headers="hd_h_niceng185er6.tab5_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>No probabilistic analysis for QALY analysis.</p>
|
|
<p>54.9% of ICERs estimated remain under the threshold of £7,980 per repeat TVR avoided.</p>
|
|
<p>One person in the DES arm had a heart transplant which considerably increased costs of the DES arm. Removing this incident resulted in an ICER of £4,635 per TVR avoided.</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er6.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Hill 2007<a class="bibr" href="#niceng185er6.ref48" rid="niceng185er6.ref48"><sup>48</sup></a></p>
|
|
<p>(UK)</p>
|
|
<p>
|
|
<i>ERG analysis for NICE TA152</i>
|
|
</p>
|
|
</td><td headers="hd_h_niceng185er6.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Partially applicable<sup>(e)</sup></td><td headers="hd_h_niceng185er6.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Potentially serious limitations<sup>(f)</sup></td><td headers="hd_h_niceng185er6.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Decision analytic model based around differences in repeat revascularisation within 12 months. QALY differences arise due to lower QOL weights being attributed to those that have a repeat revascularisation. Mortality and long-term morbidity assumed to be unaffected.</div></li><li class="half_rhythm"><div>Cost-utility analysis (QALYs)</div></li><li class="half_rhythm"><div>Population: people with coronary artery disease revascularised in NHS hospitals - non-elective index PCI results presented here (assumed to equate to ACS)</div></li><li class="half_rhythm"><div>Comparators:
|
|
<ol><li class="half_rhythm"><div>Bare metal stents</div></li><li class="half_rhythm"><div>Drug eluting stents (Taxus, Cypher)</div></li></ol></div></li><li class="half_rhythm"><div>Time horizon: 1 year</div></li></ul></td><td headers="hd_h_niceng185er6.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<i>Narrow effectiveness</i>
|
|
<sup>
|
|
(g)
|
|
</sup>
|
|
</p>
|
|
<p>Taxus = £852<sup>(h)</sup></p>
|
|
<p>Cypher = £919<sup>(h)</sup></p>
|
|
<p>
|
|
<i>Broad effectiveness</i>
|
|
<sup>
|
|
(g)
|
|
</sup>
|
|
</p>
|
|
<p>Taxus = £795<sup>(h)</sup></p>
|
|
<p>Cypher = £861<sup>(h)</sup></p>
|
|
</td><td headers="hd_h_niceng185er6.tab5_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<i>Narrow effectiveness</i>
|
|
<sup>
|
|
(g)
|
|
</sup>
|
|
</p>
|
|
<p>0.002444 QALYs</p>
|
|
<p>
|
|
<i>Broad effectiveness</i>
|
|
<sup>
|
|
(g)
|
|
</sup>
|
|
</p>
|
|
<p>0.003251 QALYs</p>
|
|
</td><td headers="hd_h_niceng185er6.tab5_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<i>Narrow effectiveness</i>
|
|
<sup>
|
|
(g)
|
|
</sup>
|
|
</p>
|
|
<p>Taxus = £348,700</p>
|
|
<p>Cypher = £376,100</p>
|
|
<p>
|
|
<i>Broad effectiveness</i>
|
|
<sup>
|
|
(g)
|
|
</sup>
|
|
</p>
|
|
<p>Taxus = £244,400</p>
|
|
<p>Cypher = £264,800</p>
|
|
</td><td headers="hd_h_niceng185er6.tab5_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>No probabilistic analysis.</p>
|
|
<p>A wide range of sensitivity analyses around baseline risks, relative risks, costs, utilities and other inputs were undertaken. The ICERs ranged from £185,300 to £702,200 per QALY gained. Additional results are presented after this table.</p>
|
|
<p>A scenario exploring the absolute risk and difference in the costs of BMS and DES was undertaken. This showed that for nonelective patients with an absolute risk of 18% or more and a price difference of £300 the ICER ranged from DES being dominant to £24,000. This led to the previous recommendation in NICE TA152. A breakdown of these results is demonstrated in <a class="figpopup" href="/books/NBK565358/table/niceng185er6.tab7/?report=objectonly" target="object" rid-figpopup="figniceng185er6tab7" rid-ob="figobniceng185er6tab7">Table 7</a>.</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er6.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Schur 2018<a class="bibr" href="#niceng185er6.ref106" rid="niceng185er6.ref106"><sup>106</sup></a></p>
|
|
<p>(Spain)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Partially applicable<sup>(i)</sup></td><td headers="hd_h_niceng185er6.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Potentially serious limitations<sup>(j)</sup></td><td headers="hd_h_niceng185er6.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Within-trial analysis of the EXAMINATION RCT 5 year data with modelled extrapolation and probabilistic analysis; incorporates mortality, MI, stent thrombosis and revascularisation.</div></li><li class="half_rhythm"><div>Cost-utility analysis (QALYs)</div></li><li class="half_rhythm"><div>Population: STEMI within the first 48 hours requiring emergent PCI (with vessel sizes of 2.25 to 4.00mm); 85% PPCI.</div></li><li class="half_rhythm"><div>Comparators:
|
|
<ol><li class="half_rhythm"><div>Bare metal stents</div></li><li class="half_rhythm"><div>Drug eluting stents (everolimus)</div></li></ol></div></li><li class="half_rhythm"><div>Time horizon: lifetime (with treatment effect duration 5 years)</div></li></ul></td><td headers="hd_h_niceng185er6.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£455<sup>(k)</sup></td><td headers="hd_h_niceng185er6.tab5_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.10 QALYs</td><td headers="hd_h_niceng185er6.tab5_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£4,180 per QALY gained</td><td headers="hd_h_niceng185er6.tab5_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>86.9% of simulations were below a threshold of £26,467 per QALY gained.</p>
|
|
<p>ICERs in sensitivity analyses ranged from ~£3000 to ~£8000 per QALY gained.</p>
|
|
<p>Analyses varying the different in stent costs found that if this was £116 there was no difference in lifetime costs.</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er6.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Wisloff 2013<a class="bibr" href="#niceng185er6.ref135" rid="niceng185er6.ref135"><sup>135</sup></a></p>
|
|
<p>(Norway)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Partially applicable<sup>(l)</sup></td><td headers="hd_h_niceng185er6.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Potentially serious limitations<sup>(m)</sup></td><td headers="hd_h_niceng185er6.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Decision analytic model with treatment effects obtained from a published network meta-analysis, this included mortality, myocardial infarction and revascularisation.</div></li><li class="half_rhythm"><div>Cost-effectiveness analysis (life years)</div></li><li class="half_rhythm"><div>Population: people with STEMI, NSTEMI, unstable or stable angina undergoing PCI with stent</div></li><li class="half_rhythm"><div>Comparators:
|
|
<ol><li class="half_rhythm"><div>Bare metal stents</div></li><li class="half_rhythm"><div>Drug-eluting stents (sirolimus)</div></li><li class="half_rhythm"><div>Drug-eluting stents (paclitaxel)</div></li></ol></div></li><li class="half_rhythm"><div>Time horizon: lifetime (with treatment effect for 5 years)</div></li></ul></td><td headers="hd_h_niceng185er6.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2−1: -£1,473<sup>(n)</sup></p>
|
|
<p>3-1: -£223<sup>(n)</sup></p>
|
|
<p>3−2: £1,250<sup>(n)</sup></p>
|
|
</td><td headers="hd_h_niceng185er6.tab5_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>2−1: 0.003 life years</p>
|
|
<p>3-1: 0.151 life years</p>
|
|
<p>3−2: 0.148 life years</p>
|
|
</td><td headers="hd_h_niceng185er6.tab5_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>DES dominates (lower costs and higher life years) BMS</p>
|
|
<p>3 vs 2: £9,553 per life year gained</p>
|
|
</td><td headers="hd_h_niceng185er6.tab5_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>With a cost effectiveness threshold of <£8,571per life year gained SES had highest probability of being cost-effective. With a cost effectiveness threshold of >£8,571per life year gained PES had the highest probability of being cost-effective.</p>
|
|
<p>An analysis was conducted assuming lifetime treatment effectiveness of DES demonstrated that PES was the most cost-effective option.</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er6.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Zbinden 2017<a class="bibr" href="#niceng185er6.ref137" rid="niceng185er6.ref137"><sup>137</sup></a></p>
|
|
<p>(Switzerland)</p>
|
|
</td><td headers="hd_h_niceng185er6.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Partially applicable<sup>(o)</sup></td><td headers="hd_h_niceng185er6.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Potentially serious limitations<sup>(p)</sup></td><td headers="hd_h_niceng185er6.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Within-trial analysis of a subgroup of BASKET-PROVE RCT with probabilistic analysis</div></li><li class="half_rhythm"><div>Cost-utility analysis (QALYs) based on within-trial analysis of EQ-5D data; also cost-effectiveness analysis (target lesion revascularisations avoided)</div></li><li class="half_rhythm"><div>Population: people with stable CAD or ACS undergoing PCI with at least one stent with a diameter ≥3mm and ≤15 mm lesion</div></li><li class="half_rhythm"><div>Comparators:
|
|
<ol><li class="half_rhythm"><div>Bare metal stents</div></li><li class="half_rhythm"><div>Drug eluting stents (Cypher, Xience)</div></li></ol></div></li><li class="half_rhythm"><div>Follow-up: 2 years</div></li></ul></td><td headers="hd_h_niceng185er6.tab5_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£75<sup>(q)</sup></td><td headers="hd_h_niceng185er6.tab5_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>0.005 QALYs</p>
|
|
<p>0.083 TLRs avoided</p>
|
|
</td><td headers="hd_h_niceng185er6.tab5_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>£15,105 per QALY gained</p>
|
|
<p>£1,986 per TLR avoided</p>
|
|
</td><td headers="hd_h_niceng185er6.tab5_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>QALY analysis</b>
|
|
</p>
|
|
<p>Probability DES cost effective (£26,486 threshold): 52.0%</p>
|
|
<p>
|
|
<b>TLR avoided analysis</b>
|
|
</p>
|
|
<p>Probability DES cost effective (£5,297 threshold): 88.2%</p>
|
|
<p>No deterministic sensitivity analysis.</p>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Abbreviations: BMS = bare-metal stent; DES = drug-eluting stent; ERG = evidence review group; ICER = incremental cost-effectiveness ratio; PCI = percutaneous coronary intervention; PES = paclitaxel-eluting stent; QALY = quality-adjusted life years; RCT = randomised controlled trial; SES = sirolimus-eluting stent; STEMI = ST segment elevation myocardial infarction; TLR = target lesion revascularisation; TVR = target vessel revascularisation</p></div></dd></dl><dl class="bkr_refwrap"><dt>(a)</dt><dd><div id="niceng185er6.tab5_1"><p class="no_margin">2007 French healthcare perspective may not reflect current UK context. Some methods used to derive quality of life weights are not in line with NICE reference case and where EQ5D has been used it is unclear if with the UK tariff.</p></div></dd></dl><dl class="bkr_refwrap"><dt>(b)</dt><dd><div id="niceng185er6.tab5_2"><p class="no_margin">Within-trial analysis based on a French subgroup of a single trial (TYPHOON RCT) and so does not reflect full body of available evidence for this area and may not reflect real world UK context.. Time horizon of 1 year may not fully capture differences in costs and health outcomes as NGC review suggests effects continue beyond 1 year. It is unclear what is driving lower QALYs in the DES group as most outcomes favour DES; the only outcomes that are numerically worse in the DES group are ‘Other cardiac events’ which authors’ state includes things such as such as hospitalizations for chest pain without proof of ischaemia, acute pulmonary oedema or heart failure and stroke where 1 event occurred with DES and 0 with BMS. Utility scores are reported for the following events suggesting they were incorporated: angioplasty, CABG, MI, congestive heart failure, severe chest pain, stroke, implantable cardioverter defibrillator, carotid thromboendarterectomy, infrainguinal surgery, insulin-dependent diabetes mellitus, medulloblastoma tumour – non-metastatic, stomach ulcer, hip fracture, catheter ablation in patients with ventricular tachycardia.</p></div></dd></dl><dl class="bkr_refwrap"><dt>(c)</dt><dd><div id="niceng185er6.tab5_3"><p class="no_margin">Utility scores are reported for angioplasty, CABG, MI, congestive heart failure, severe chest pain, stroke, implantable cardioverter defibrillator, carotid thromboendarterectomy, infrainguinal surgery, insulin dependent diabetes mellitus, medulloblastoma tumour – non-metastatic, stomach ulcer, hip fracture, catheter ablation in patients with ventricular tachycardia.</p></div></dd></dl><dl class="bkr_refwrap"><dt>(d)</dt><dd><div id="niceng185er6.tab5_4"><p class="no_margin">2007 French Euros converted to UK pounds.<a class="bibr" href="#niceng185er6.ref83" rid="niceng185er6.ref83"><sup>83</sup></a> Cost components included: index admission costs (stent costs, procedure cost, drug costs, ICU cost, ward costs, rehabilitation) and follow-up including medication and all repeat hospitalisation costs. (Cost of stents included in analysis (mean, median): BMS = £544, £439; DES = £1,587, £1,237).</p></div></dd></dl><dl class="bkr_refwrap"><dt>(e)</dt><dd><div id="niceng185er6.tab5_5"><p class="no_margin">Resource use from 2000-2002 and 2004/05 UK unit costs may not reflect current UK practice. The analysis does not include the variety of drug-eluting stents currently available in the NHS as it only focuses on two types of stents (CYPHER and TAXUS) which dominated the market at the time.</p></div></dd></dl><dl class="bkr_refwrap"><dt>(f)</dt><dd><div id="niceng185er6.tab5_6"><p class="no_margin">Analysis based on 7 RCTS (TAXUS I, TAXUS II, TAXUS IV, E-SIRIUS, RAVEL, SIRIUS and Pache) and so does not reflect full body of available evidence for this area and also includes studies stable patients that have been excluded from the clinical review for this guideline. Time horizon of 1 year may not fully capture differences in costs and health outcomes as NGC review suggests effects continue beyond 1 year and there may be benefits other than revascularisation that are not captured in the analysis..</p></div></dd></dl><dl class="bkr_refwrap"><dt>(g)</dt><dd><div id="niceng185er6.tab5_7"><p class="no_margin">Different relative risks were applied based on ‘broad’ and ‘narrow’ estimates. ‘Broad’ estimates are based on cases involved any TLR/TVR irrespective of any other lesions/vessels revascularised (0.369) and ‘narrow’ estimates are based on cases involving TLR/TVR only (0.492).</p></div></dd></dl><dl class="bkr_refwrap"><dt>(h)</dt><dd><div id="niceng185er6.tab5_8"><p class="no_margin">Cost components: stent costs, cost of angiography, follow-up appointments and repeat revascularisation cost. Stent costs: BMS = £291.95; DES effective list price Taxus = £997.50, Cypher = £1044.75; DES actual cost Taxus = £855.43, Cypher = £983.51.</p></div></dd></dl><dl class="bkr_refwrap"><dt>(i)</dt><dd><div id="niceng185er6.tab5_9"><p class="no_margin">Spanish healthcare perspective and international resource use may not reflect current UK context. STEMI only. Discounting at 3% and use of Spanish EQ5D tariff not fully in line with NICE reference case.</p></div></dd></dl><dl class="bkr_refwrap"><dt>(j)</dt><dd><div id="niceng185er6.tab5_10"><p class="no_margin">Within-trial analysis of a single RCT and so does not reflect full body of available evidence for this area. Baseline risks based on multinational RCT (Spain, Italy, Netherlands) and so may not be reflective of real world UK risk; although authors note that “The EXAMINATION trial had broad inclusion and few exclusion criteria to ensure an all-comers population of adult STEMI patients which is representative of routine clinical practice”.</p></div></dd></dl><dl class="bkr_refwrap"><dt>(k)</dt><dd><div id="niceng185er6.tab5_11"><p class="no_margin">2016 Spanish Euros converted to UK pounds.<a class="bibr" href="#niceng185er6.ref83" rid="niceng185er6.ref83"><sup>83</sup></a> Cost components included: type and number of stents; clinical events up to 5 years: MIs, stent thrombosis events, revascularisation procedures (PCI and CABG); annual CV outpatient treatment and drug costs during first 5 years (when clinical events accounted for explicitly); long-term annual CV treatment costs after year 5; 12 months antiplatelet therapy after revascularisation events. Cost of stents: BMS = £466; DES = £897.</p></div></dd></dl><dl class="bkr_refwrap"><dt>(l)</dt><dd><div id="niceng185er6.tab5_12"><p class="no_margin">2008 Norwegian healthcare perspective may not reflect current UK context. Analysis includes patients with stable coronary artery disease as well as ACS. 4% discount rate and measure of effect (life years) not in line with NICE reference case methods.</p></div></dd></dl><dl class="bkr_refwrap"><dt>(m)</dt><dd><div id="niceng185er6.tab5_13"><p class="no_margin">Baseline risks are based on the overall CAD population in Scandinavia and so may differ from a UK ACS population. Treatment effects were based on both ACS and stable patients and so studies excluded from our review have been incorporated; additional studies have also been identified by the review undertaken for this guideline. The price of stents used in the model was not official prices and were obtained through personal communication with a cardiologist.</p></div></dd></dl><dl class="bkr_refwrap"><dt>(n)</dt><dd><div id="niceng185er6.tab5_14"><p class="no_margin">2008 Norwegian Kroner converted to UK pounds.<a class="bibr" href="#niceng185er6.ref83" rid="niceng185er6.ref83"><sup>83</sup></a> Cost components included: stent costs, costs of procedures and cost of medication. Cost of stents: BMS = £107; SES = £515; PES = £419.</p></div></dd></dl><dl class="bkr_refwrap"><dt>(o)</dt><dd><div id="niceng185er6.tab5_15"><p class="no_margin">2013 Swiss healthcare payer perspective and international resource use from 2007-2008 may not reflect the current UK context. Analysis includes patients with stable coronary artery disease as well as ACS (proportion not reported for analysis subgroups but for overall BASKET-PROVE RCT was 64% ACS). QALYs were derived using EQ-5D German population utility value set instead of the UK population value set.</p></div></dd></dl><dl class="bkr_refwrap"><dt>(p)</dt><dd><div id="niceng185er6.tab5_16"><p class="no_margin">Within-trial analysis of subgroup of one RCT (BASKET-PROVE subgroup with stents >3mm and <15mm lesion length) and so does not reflect full body of available evidence for this area. Analysis was conducted on a retrospective subgroup. Incremental cost data is not numerically reported. Time horizon of 2 years may not fully capture differences in costs and health outcomes as NGC review suggests effects on revascularisations for ACS overall maintained at 1-3 year time point and approach to modelling may not fully capture benefits to patients e.g. if QALY losses are generally short-term following revascularisation. Unclear if survival incorporated when calculating QALYs per patient.</p></div></dd></dl><dl class="bkr_refwrap"><dt>(q)</dt><dd><div id="niceng185er6.tab5_17"><p class="no_margin">Incremental cost data not reported numerically, but was calculated using reported incremental QALYs and ICER. 2013 Swiss Francs converted to UK pounds.<a class="bibr" href="#niceng185er6.ref83" rid="niceng185er6.ref83"><sup>83</sup></a> Cost components: stent costs, inpatient and outpatient procedures, only included costs of follow-up if it involved revascularisation. Cost of stents: BMS = £610; DES = £761.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng185er6tab6"><div id="niceng185er6.tab6" class="table"><h3><span class="label">Table 6</span><span class="title">Hill 2007 cost-effectiveness results for non-elective PCI patients</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565358/table/niceng185er6.tab6/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er6.tab6_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng185er6.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Prices</th><th id="hd_h_niceng185er6.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Effectiveness</th><th id="hd_h_niceng185er6.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Brand</th><th id="hd_h_niceng185er6.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incremental cost</th><th id="hd_h_niceng185er6.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incremental QALYs</th><th id="hd_h_niceng185er6.tab6_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ICER</th></tr></thead><tbody><tr><th headers="hd_h_niceng185er6.tab6_1_1_1_1" id="hd_b_niceng185er6.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Overall</th><th headers="hd_h_niceng185er6.tab6_1_1_1_2" id="hd_b_niceng185er6.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></th><th headers="hd_h_niceng185er6.tab6_1_1_1_3" id="hd_b_niceng185er6.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></th><th headers="hd_h_niceng185er6.tab6_1_1_1_4" id="hd_b_niceng185er6.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></th><th headers="hd_h_niceng185er6.tab6_1_1_1_5" id="hd_b_niceng185er6.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></th><th headers="hd_h_niceng185er6.tab6_1_1_1_6" id="hd_b_niceng185er6.tab6_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></th></tr><tr><td headers="hd_h_niceng185er6.tab6_1_1_1_1 hd_b_niceng185er6.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Effective list</td><td headers="hd_h_niceng185er6.tab6_1_1_1_2 hd_b_niceng185er6.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Narrow</td><td headers="hd_h_niceng185er6.tab6_1_1_1_3 hd_b_niceng185er6.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Taxus</td><td headers="hd_h_niceng185er6.tab6_1_1_1_4 hd_b_niceng185er6.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£852</td><td headers="hd_h_niceng185er6.tab6_1_1_1_5 hd_b_niceng185er6.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.002444</td><td headers="hd_h_niceng185er6.tab6_1_1_1_6 hd_b_niceng185er6.tab6_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£348,700</td></tr><tr><td headers="hd_h_niceng185er6.tab6_1_1_1_1 hd_b_niceng185er6.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab6_1_1_1_2 hd_b_niceng185er6.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab6_1_1_1_3 hd_b_niceng185er6.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cypher</td><td headers="hd_h_niceng185er6.tab6_1_1_1_4 hd_b_niceng185er6.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£919</td><td headers="hd_h_niceng185er6.tab6_1_1_1_5 hd_b_niceng185er6.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.002444</td><td headers="hd_h_niceng185er6.tab6_1_1_1_6 hd_b_niceng185er6.tab6_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£376,100</td></tr><tr><td headers="hd_h_niceng185er6.tab6_1_1_1_1 hd_b_niceng185er6.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab6_1_1_1_2 hd_b_niceng185er6.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Broad</td><td headers="hd_h_niceng185er6.tab6_1_1_1_3 hd_b_niceng185er6.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Taxus</td><td headers="hd_h_niceng185er6.tab6_1_1_1_4 hd_b_niceng185er6.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£795</td><td headers="hd_h_niceng185er6.tab6_1_1_1_5 hd_b_niceng185er6.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.003251</td><td headers="hd_h_niceng185er6.tab6_1_1_1_6 hd_b_niceng185er6.tab6_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£244,400</td></tr><tr><td headers="hd_h_niceng185er6.tab6_1_1_1_1 hd_b_niceng185er6.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab6_1_1_1_2 hd_b_niceng185er6.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab6_1_1_1_3 hd_b_niceng185er6.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cypher</td><td headers="hd_h_niceng185er6.tab6_1_1_1_4 hd_b_niceng185er6.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£861</td><td headers="hd_h_niceng185er6.tab6_1_1_1_5 hd_b_niceng185er6.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.003251</td><td headers="hd_h_niceng185er6.tab6_1_1_1_6 hd_b_niceng185er6.tab6_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£264,800</td></tr><tr><td headers="hd_h_niceng185er6.tab6_1_1_1_1 hd_b_niceng185er6.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Actual</td><td headers="hd_h_niceng185er6.tab6_1_1_1_2 hd_b_niceng185er6.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Narrow</td><td headers="hd_h_niceng185er6.tab6_1_1_1_3 hd_b_niceng185er6.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Taxus</td><td headers="hd_h_niceng185er6.tab6_1_1_1_4 hd_b_niceng185er6.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£651</td><td headers="hd_h_niceng185er6.tab6_1_1_1_5 hd_b_niceng185er6.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.002444</td><td headers="hd_h_niceng185er6.tab6_1_1_1_6 hd_b_niceng185er6.tab6_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£266,200</td></tr><tr><td headers="hd_h_niceng185er6.tab6_1_1_1_1 hd_b_niceng185er6.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab6_1_1_1_2 hd_b_niceng185er6.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab6_1_1_1_3 hd_b_niceng185er6.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cypher</td><td headers="hd_h_niceng185er6.tab6_1_1_1_4 hd_b_niceng185er6.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£832</td><td headers="hd_h_niceng185er6.tab6_1_1_1_5 hd_b_niceng185er6.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.002444</td><td headers="hd_h_niceng185er6.tab6_1_1_1_6 hd_b_niceng185er6.tab6_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£340,500</td></tr><tr><td headers="hd_h_niceng185er6.tab6_1_1_1_1 hd_b_niceng185er6.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab6_1_1_1_2 hd_b_niceng185er6.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Broad</td><td headers="hd_h_niceng185er6.tab6_1_1_1_3 hd_b_niceng185er6.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Taxus</td><td headers="hd_h_niceng185er6.tab6_1_1_1_4 hd_b_niceng185er6.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£595</td><td headers="hd_h_niceng185er6.tab6_1_1_1_5 hd_b_niceng185er6.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.003251</td><td headers="hd_h_niceng185er6.tab6_1_1_1_6 hd_b_niceng185er6.tab6_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£182,900</td></tr><tr><td headers="hd_h_niceng185er6.tab6_1_1_1_1 hd_b_niceng185er6.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab6_1_1_1_2 hd_b_niceng185er6.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab6_1_1_1_3 hd_b_niceng185er6.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cypher</td><td headers="hd_h_niceng185er6.tab6_1_1_1_4 hd_b_niceng185er6.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£775</td><td headers="hd_h_niceng185er6.tab6_1_1_1_5 hd_b_niceng185er6.tab6_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.003251</td><td headers="hd_h_niceng185er6.tab6_1_1_1_6 hd_b_niceng185er6.tab6_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£238,300</td></tr><tr><th headers="hd_h_niceng185er6.tab6_1_1_1_1 hd_h_niceng185er6.tab6_1_1_1_2 hd_h_niceng185er6.tab6_1_1_1_3 hd_h_niceng185er6.tab6_1_1_1_4 hd_h_niceng185er6.tab6_1_1_1_5 hd_h_niceng185er6.tab6_1_1_1_6" id="hd_b_niceng185er6.tab6_1_1_10_1" colspan="6" rowspan="1" style="text-align:left;vertical-align:top;">No risk factors</th></tr><tr><td headers="hd_h_niceng185er6.tab6_1_1_1_1 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Effective list</td><td headers="hd_h_niceng185er6.tab6_1_1_1_2 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Narrow</td><td headers="hd_h_niceng185er6.tab6_1_1_1_3 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Taxus</td><td headers="hd_h_niceng185er6.tab6_1_1_1_4 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£844</td><td headers="hd_h_niceng185er6.tab6_1_1_1_5 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.002155</td><td headers="hd_h_niceng185er6.tab6_1_1_1_6 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£391,600</td></tr><tr><td headers="hd_h_niceng185er6.tab6_1_1_1_1 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab6_1_1_1_2 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab6_1_1_1_3 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cypher</td><td headers="hd_h_niceng185er6.tab6_1_1_1_4 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£909</td><td headers="hd_h_niceng185er6.tab6_1_1_1_5 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.002155</td><td headers="hd_h_niceng185er6.tab6_1_1_1_6 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£421,900</td></tr><tr><td headers="hd_h_niceng185er6.tab6_1_1_1_1 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab6_1_1_1_2 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Broad</td><td headers="hd_h_niceng185er6.tab6_1_1_1_3 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Taxus</td><td headers="hd_h_niceng185er6.tab6_1_1_1_4 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£793</td><td headers="hd_h_niceng185er6.tab6_1_1_1_5 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.002867</td><td headers="hd_h_niceng185er6.tab6_1_1_1_6 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£276,600</td></tr><tr><td headers="hd_h_niceng185er6.tab6_1_1_1_1 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab6_1_1_1_2 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab6_1_1_1_3 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cypher</td><td headers="hd_h_niceng185er6.tab6_1_1_1_4 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£858</td><td headers="hd_h_niceng185er6.tab6_1_1_1_5 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.002867</td><td headers="hd_h_niceng185er6.tab6_1_1_1_6 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£299,200</td></tr><tr><td headers="hd_h_niceng185er6.tab6_1_1_1_1 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Actual</td><td headers="hd_h_niceng185er6.tab6_1_1_1_2 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Narrow</td><td headers="hd_h_niceng185er6.tab6_1_1_1_3 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Taxus</td><td headers="hd_h_niceng185er6.tab6_1_1_1_4 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£648</td><td headers="hd_h_niceng185er6.tab6_1_1_1_5 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.002155</td><td headers="hd_h_niceng185er6.tab6_1_1_1_6 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£300,500</td></tr><tr><td headers="hd_h_niceng185er6.tab6_1_1_1_1 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab6_1_1_1_2 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab6_1_1_1_3 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cypher</td><td headers="hd_h_niceng185er6.tab6_1_1_1_4 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£825</td><td headers="hd_h_niceng185er6.tab6_1_1_1_5 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.002155</td><td headers="hd_h_niceng185er6.tab6_1_1_1_6 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£382,600</td></tr><tr><td headers="hd_h_niceng185er6.tab6_1_1_1_1 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab6_1_1_1_2 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Broad</td><td headers="hd_h_niceng185er6.tab6_1_1_1_3 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Taxus</td><td headers="hd_h_niceng185er6.tab6_1_1_1_4 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£598</td><td headers="hd_h_niceng185er6.tab6_1_1_1_5 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.002867</td><td headers="hd_h_niceng185er6.tab6_1_1_1_6 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£208,700</td></tr><tr><td headers="hd_h_niceng185er6.tab6_1_1_1_1 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab6_1_1_1_2 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab6_1_1_1_3 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cypher</td><td headers="hd_h_niceng185er6.tab6_1_1_1_4 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£774</td><td headers="hd_h_niceng185er6.tab6_1_1_1_5 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.002867</td><td headers="hd_h_niceng185er6.tab6_1_1_1_6 hd_b_niceng185er6.tab6_1_1_10_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£269,900</td></tr><tr><th headers="hd_h_niceng185er6.tab6_1_1_1_1" id="hd_b_niceng185er6.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 risk factor</th><th headers="hd_h_niceng185er6.tab6_1_1_1_2" id="hd_b_niceng185er6.tab6_1_1_19_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></th><th headers="hd_h_niceng185er6.tab6_1_1_1_3" id="hd_b_niceng185er6.tab6_1_1_19_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></th><th headers="hd_h_niceng185er6.tab6_1_1_1_4" id="hd_b_niceng185er6.tab6_1_1_19_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></th><th headers="hd_h_niceng185er6.tab6_1_1_1_5" id="hd_b_niceng185er6.tab6_1_1_19_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></th><th headers="hd_h_niceng185er6.tab6_1_1_1_6" id="hd_b_niceng185er6.tab6_1_1_19_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></th></tr><tr><td headers="hd_h_niceng185er6.tab6_1_1_1_1 hd_b_niceng185er6.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Effective list</td><td headers="hd_h_niceng185er6.tab6_1_1_1_2 hd_b_niceng185er6.tab6_1_1_19_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Narrow</td><td headers="hd_h_niceng185er6.tab6_1_1_1_3 hd_b_niceng185er6.tab6_1_1_19_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Taxus</td><td headers="hd_h_niceng185er6.tab6_1_1_1_4 hd_b_niceng185er6.tab6_1_1_19_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£947</td><td headers="hd_h_niceng185er6.tab6_1_1_1_5 hd_b_niceng185er6.tab6_1_1_19_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.005332</td><td headers="hd_h_niceng185er6.tab6_1_1_1_6 hd_b_niceng185er6.tab6_1_1_19_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£177,500</td></tr><tr><td headers="hd_h_niceng185er6.tab6_1_1_1_1 hd_b_niceng185er6.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab6_1_1_1_2 hd_b_niceng185er6.tab6_1_1_19_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab6_1_1_1_3 hd_b_niceng185er6.tab6_1_1_19_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cypher</td><td headers="hd_h_niceng185er6.tab6_1_1_1_4 hd_b_niceng185er6.tab6_1_1_19_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,032</td><td headers="hd_h_niceng185er6.tab6_1_1_1_5 hd_b_niceng185er6.tab6_1_1_19_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.005332</td><td headers="hd_h_niceng185er6.tab6_1_1_1_6 hd_b_niceng185er6.tab6_1_1_19_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£193,500</td></tr><tr><td headers="hd_h_niceng185er6.tab6_1_1_1_1 hd_b_niceng185er6.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab6_1_1_1_2 hd_b_niceng185er6.tab6_1_1_19_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Broad</td><td headers="hd_h_niceng185er6.tab6_1_1_1_3 hd_b_niceng185er6.tab6_1_1_19_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Taxus</td><td headers="hd_h_niceng185er6.tab6_1_1_1_4 hd_b_niceng185er6.tab6_1_1_19_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£821</td><td headers="hd_h_niceng185er6.tab6_1_1_1_5 hd_b_niceng185er6.tab6_1_1_19_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.007095</td><td headers="hd_h_niceng185er6.tab6_1_1_1_6 hd_b_niceng185er6.tab6_1_1_19_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£115,700</td></tr><tr><td headers="hd_h_niceng185er6.tab6_1_1_1_1 hd_b_niceng185er6.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab6_1_1_1_2 hd_b_niceng185er6.tab6_1_1_19_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab6_1_1_1_3 hd_b_niceng185er6.tab6_1_1_19_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cypher</td><td headers="hd_h_niceng185er6.tab6_1_1_1_4 hd_b_niceng185er6.tab6_1_1_19_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£905</td><td headers="hd_h_niceng185er6.tab6_1_1_1_5 hd_b_niceng185er6.tab6_1_1_19_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.007095</td><td headers="hd_h_niceng185er6.tab6_1_1_1_6 hd_b_niceng185er6.tab6_1_1_19_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£127,600</td></tr><tr><td headers="hd_h_niceng185er6.tab6_1_1_1_1 hd_b_niceng185er6.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Actual</td><td headers="hd_h_niceng185er6.tab6_1_1_1_2 hd_b_niceng185er6.tab6_1_1_19_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Narrow</td><td headers="hd_h_niceng185er6.tab6_1_1_1_3 hd_b_niceng185er6.tab6_1_1_19_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Taxus</td><td headers="hd_h_niceng185er6.tab6_1_1_1_4 hd_b_niceng185er6.tab6_1_1_19_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£691</td><td headers="hd_h_niceng185er6.tab6_1_1_1_5 hd_b_niceng185er6.tab6_1_1_19_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.005332</td><td headers="hd_h_niceng185er6.tab6_1_1_1_6 hd_b_niceng185er6.tab6_1_1_19_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£129,500</td></tr><tr><td headers="hd_h_niceng185er6.tab6_1_1_1_1 hd_b_niceng185er6.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab6_1_1_1_2 hd_b_niceng185er6.tab6_1_1_19_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab6_1_1_1_3 hd_b_niceng185er6.tab6_1_1_19_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cypher</td><td headers="hd_h_niceng185er6.tab6_1_1_1_4 hd_b_niceng185er6.tab6_1_1_19_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£921</td><td headers="hd_h_niceng185er6.tab6_1_1_1_5 hd_b_niceng185er6.tab6_1_1_19_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.005332</td><td headers="hd_h_niceng185er6.tab6_1_1_1_6 hd_b_niceng185er6.tab6_1_1_19_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£172,800</td></tr><tr><td headers="hd_h_niceng185er6.tab6_1_1_1_1 hd_b_niceng185er6.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab6_1_1_1_2 hd_b_niceng185er6.tab6_1_1_19_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Broad</td><td headers="hd_h_niceng185er6.tab6_1_1_1_3 hd_b_niceng185er6.tab6_1_1_19_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Taxus</td><td headers="hd_h_niceng185er6.tab6_1_1_1_4 hd_b_niceng185er6.tab6_1_1_19_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£569</td><td headers="hd_h_niceng185er6.tab6_1_1_1_5 hd_b_niceng185er6.tab6_1_1_19_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.007095</td><td headers="hd_h_niceng185er6.tab6_1_1_1_6 hd_b_niceng185er6.tab6_1_1_19_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£80,200</td></tr><tr><td headers="hd_h_niceng185er6.tab6_1_1_1_1 hd_b_niceng185er6.tab6_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab6_1_1_1_2 hd_b_niceng185er6.tab6_1_1_19_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab6_1_1_1_3 hd_b_niceng185er6.tab6_1_1_19_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cypher</td><td headers="hd_h_niceng185er6.tab6_1_1_1_4 hd_b_niceng185er6.tab6_1_1_19_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£796</td><td headers="hd_h_niceng185er6.tab6_1_1_1_5 hd_b_niceng185er6.tab6_1_1_19_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.007095</td><td headers="hd_h_niceng185er6.tab6_1_1_1_6 hd_b_niceng185er6.tab6_1_1_19_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£112,200</td></tr><tr><th headers="hd_h_niceng185er6.tab6_1_1_1_1 hd_h_niceng185er6.tab6_1_1_1_2 hd_h_niceng185er6.tab6_1_1_1_3 hd_h_niceng185er6.tab6_1_1_1_4 hd_h_niceng185er6.tab6_1_1_1_5 hd_h_niceng185er6.tab6_1_1_1_6" id="hd_b_niceng185er6.tab6_1_1_28_1" colspan="6" rowspan="1" style="text-align:left;vertical-align:top;">2 risk factors</th></tr><tr><td headers="hd_h_niceng185er6.tab6_1_1_1_1 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Effective list</td><td headers="hd_h_niceng185er6.tab6_1_1_1_2 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Narrow</td><td headers="hd_h_niceng185er6.tab6_1_1_1_3 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Taxus</td><td headers="hd_h_niceng185er6.tab6_1_1_1_4 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£627</td><td headers="hd_h_niceng185er6.tab6_1_1_1_5 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.009716</td><td headers="hd_h_niceng185er6.tab6_1_1_1_6 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£64.600</td></tr><tr><td headers="hd_h_niceng185er6.tab6_1_1_1_1 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab6_1_1_1_2 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab6_1_1_1_3 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cypher</td><td headers="hd_h_niceng185er6.tab6_1_1_1_4 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£709</td><td headers="hd_h_niceng185er6.tab6_1_1_1_5 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.009716</td><td headers="hd_h_niceng185er6.tab6_1_1_1_6 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£73,000</td></tr><tr><td headers="hd_h_niceng185er6.tab6_1_1_1_1 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab6_1_1_1_2 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Broad</td><td headers="hd_h_niceng185er6.tab6_1_1_1_3 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Taxus</td><td headers="hd_h_niceng185er6.tab6_1_1_1_4 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£399</td><td headers="hd_h_niceng185er6.tab6_1_1_1_5 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.012928</td><td headers="hd_h_niceng185er6.tab6_1_1_1_6 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£30,800</td></tr><tr><td headers="hd_h_niceng185er6.tab6_1_1_1_1 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab6_1_1_1_2 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab6_1_1_1_3 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cypher</td><td headers="hd_h_niceng185er6.tab6_1_1_1_4 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£478</td><td headers="hd_h_niceng185er6.tab6_1_1_1_5 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.012928</td><td headers="hd_h_niceng185er6.tab6_1_1_1_6 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£37,000</td></tr><tr><td headers="hd_h_niceng185er6.tab6_1_1_1_1 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Actual</td><td headers="hd_h_niceng185er6.tab6_1_1_1_2 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Narrow</td><td headers="hd_h_niceng185er6.tab6_1_1_1_3 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Taxus</td><td headers="hd_h_niceng185er6.tab6_1_1_1_4 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£382</td><td headers="hd_h_niceng185er6.tab6_1_1_1_5 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.009716</td><td headers="hd_h_niceng185er6.tab6_1_1_1_6 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£39,300</td></tr><tr><td headers="hd_h_niceng185er6.tab6_1_1_1_1 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab6_1_1_1_2 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab6_1_1_1_3 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cypher</td><td headers="hd_h_niceng185er6.tab6_1_1_1_4 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£603</td><td headers="hd_h_niceng185er6.tab6_1_1_1_5 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.009716</td><td headers="hd_h_niceng185er6.tab6_1_1_1_6 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£62,100</td></tr><tr><td headers="hd_h_niceng185er6.tab6_1_1_1_1 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab6_1_1_1_2 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Broad</td><td headers="hd_h_niceng185er6.tab6_1_1_1_3 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Taxus</td><td headers="hd_h_niceng185er6.tab6_1_1_1_4 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£160</td><td headers="hd_h_niceng185er6.tab6_1_1_1_5 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.012928</td><td headers="hd_h_niceng185er6.tab6_1_1_1_6 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>£12,400</b>
|
|
</td></tr><tr><td headers="hd_h_niceng185er6.tab6_1_1_1_1 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab6_1_1_1_2 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab6_1_1_1_3 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cypher</td><td headers="hd_h_niceng185er6.tab6_1_1_1_4 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£375</td><td headers="hd_h_niceng185er6.tab6_1_1_1_5 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.012928</td><td headers="hd_h_niceng185er6.tab6_1_1_1_6 hd_b_niceng185er6.tab6_1_1_28_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£29,000</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>(a)</dt><dd><div id="niceng185er6.tab6_1"><p class="no_margin">ICERs in bold indicate where drug-eluting stents are cost-effective at a threshold of £20,000.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng185er6tab7"><div id="niceng185er6.tab7" class="table"><h3><span class="label">Table 7</span><span class="title">Hill 2007 cost–effectiveness results for all non-elective patients (using mean number of stents implanted, 1.46 stents) by absolute risk of TVR and level of price premium for DES</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565358/table/niceng185er6.tab7/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er6.tab7_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng185er6.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Absolute risk (%)</th><th id="hd_h_niceng185er6.tab7_1_1_1_2" colspan="8" rowspan="1" style="text-align:left;vertical-align:bottom;">Incremental cost per QALY by levels of price premium</th></tr></thead><tbody><tr><td headers="hd_h_niceng185er6.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>£100</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>£200</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>£300</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>£400</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>£500</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>£600</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>£700</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>£800</b>
|
|
</td></tr><tr><td headers="hd_h_niceng185er6.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>£18,000</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£87,400</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£156,800</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£226,100</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£295,500</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£364,900</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£434,200</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£503,600</td></tr><tr><td headers="hd_h_niceng185er6.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>£2,100</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£57,500</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£112,800</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£168,200</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£223,600</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£279,000</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£334,300</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£389,700</td></tr><tr><td headers="hd_h_niceng185er6.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£37,400</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£83,400</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£129,400</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£175,400</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£221,400</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£267,400</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£313,400</td></tr><tr><td headers="hd_h_niceng185er6.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10.04</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£37,100</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£83,000</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£128,800</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£174,700</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£220,500</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£266,400</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£312,200</td></tr><tr><td headers="hd_h_niceng185er6.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£23,000</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£62,300</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£101,600</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£140,800</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£180,100</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£219,400</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£258,600</td></tr><tr><td headers="hd_h_niceng185er6.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>£12,200</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£46,400</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£80,700</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£114,900</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£149,100</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£183,300</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£217,500</td></tr><tr><td headers="hd_h_niceng185er6.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>£3,800</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£34,100</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£64,300</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£94,600</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£124,900</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£155,200</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£185,400</td></tr><tr><td headers="hd_h_niceng185er6.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£24,200</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£51,300</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£78,400</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£105,500</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£132,600</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£159,700</td></tr><tr><td headers="hd_h_niceng185er6.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>£16,100</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£40,600</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£65,100</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£89,600</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£114,200</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£138,700</td></tr><tr><td headers="hd_h_niceng185er6.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">22</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>£9,300</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£31,700</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£54,000</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£76,400</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£98,800</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£121,100</td></tr><tr><td headers="hd_h_niceng185er6.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>£3,500</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£24,100</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£44,600</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£65,200</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£85,700</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£106,300</td></tr><tr><td headers="hd_h_niceng185er6.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>£17,600</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£36,600</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£55,600</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£74,500</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£93,500</td></tr><tr><td headers="hd_h_niceng185er6.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">28</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>£12,000</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£29,600</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£47,200</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£64,800</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£82,400</td></tr><tr><td headers="hd_h_niceng185er6.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>£7,100</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£23,500</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£39,900</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£56,300</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£72,800</td></tr><tr><td headers="hd_h_niceng185er6.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">32</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>£2,700</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>£18,100</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£33,500</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£48,800</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£64,200</td></tr><tr><td headers="hd_h_niceng185er6.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">34</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>£13,300</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£27,700</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£42,200</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£56,600</td></tr><tr><td headers="hd_h_niceng185er6.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">36</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>£9,000</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£22,600</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£36,200</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£49,800</td></tr><tr><td headers="hd_h_niceng185er6.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">38</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>£5,100</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>£18,000</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£30,800</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£43,700</td></tr><tr><td headers="hd_h_niceng185er6.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>£1,600</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>£13,800</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£26,000</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£38,100</td></tr><tr><td headers="hd_h_niceng185er6.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">42</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>-£1,600</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>£10,000</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£21,500</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£33,100</td></tr><tr><td headers="hd_h_niceng185er6.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">44</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>-£4,500</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>£6,500</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>£17,500</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£28,500</td></tr><tr><td headers="hd_h_niceng185er6.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">46</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>DES dominant</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>-£7,100</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>£3,300</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>£13,800</b>
|
|
</td><td headers="hd_h_niceng185er6.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£24,300</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>(b)</dt><dd><div id="niceng185er6.tab7_1"><p class="no_margin">ICERs in bold indicate where drug-eluting stents are cost-effective at a threshold of £20,000</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng185er6tab8"><div id="niceng185er6.tab8" class="table"><h3><span class="label">Table 8</span><span class="title">Stent costs used in studies</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565358/table/niceng185er6.tab8/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er6.tab8_lrgtbl__"><table><thead><tr><th id="hd_h_niceng185er6.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Study</th><th id="hd_h_niceng185er6.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">BMS cost</th><th id="hd_h_niceng185er6.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DES cost</th><th id="hd_h_niceng185er6.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Difference</th></tr></thead><tbody><tr><td headers="hd_h_niceng185er6.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Canoui-Poitrine 2009<a class="bibr" href="#niceng185er6.ref24" rid="niceng185er6.ref24"><sup>24</sup></a> (France)</td><td headers="hd_h_niceng185er6.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£439</td><td headers="hd_h_niceng185er6.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£1,237</td><td headers="hd_h_niceng185er6.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£798</td></tr><tr><td headers="hd_h_niceng185er6.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hill 2007<a class="bibr" href="#niceng185er6.ref48" rid="niceng185er6.ref48"><sup>48</sup></a> (UK)</td><td headers="hd_h_niceng185er6.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£292</td><td headers="hd_h_niceng185er6.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Taxus = £997, Cypher = £1,045</td><td headers="hd_h_niceng185er6.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£705 (Taxus), £753 (Cypher)</td></tr><tr><td headers="hd_h_niceng185er6.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Schur 2018<a class="bibr" href="#niceng185er6.ref106" rid="niceng185er6.ref106"><sup>106</sup></a> (Spain)</td><td headers="hd_h_niceng185er6.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£466</td><td headers="hd_h_niceng185er6.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£897</td><td headers="hd_h_niceng185er6.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£431</td></tr><tr><td headers="hd_h_niceng185er6.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Wisloff 2013<a class="bibr" href="#niceng185er6.ref135" rid="niceng185er6.ref135"><sup>135</sup></a> (Norway)</td><td headers="hd_h_niceng185er6.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£107</td><td headers="hd_h_niceng185er6.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SES = £515, PES = £419</td><td headers="hd_h_niceng185er6.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£408 (SES), £312 (PES)</td></tr><tr><td headers="hd_h_niceng185er6.tab8_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Zbinden 2017<a class="bibr" href="#niceng185er6.ref137" rid="niceng185er6.ref137"><sup>137</sup></a> (Switzerland)</td><td headers="hd_h_niceng185er6.tab8_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£610</td><td headers="hd_h_niceng185er6.tab8_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£761</td><td headers="hd_h_niceng185er6.tab8_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£151</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng185er6tab9"><div id="niceng185er6.tab9" class="table"><h3><span class="label">Table 9</span><span class="title">Comparison of NGC meta-analysis results and treatment effects in economic studies</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565358/table/niceng185er6.tab9/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er6.tab9_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng185er6.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></th><th id="hd_h_niceng185er6.tab9_1_1_1_2" colspan="4" rowspan="1" style="text-align:left;vertical-align:middle;">NGC meta-analysis</th><th id="hd_h_niceng185er6.tab9_1_1_1_3" colspan="2" rowspan="1" style="text-align:center;vertical-align:bottom;">Canoui-Poitrine 2009 (Typhoon trial - French subgroup)<sup>(a)</sup></th><th id="hd_h_niceng185er6.tab9_1_1_1_4" colspan="4" rowspan="1" style="text-align:center;vertical-align:bottom;">Schur 2018 (Examination trial)<sup>(b)</sup></th><th id="hd_h_niceng185er6.tab9_1_1_1_5" colspan="2" rowspan="1" style="text-align:center;vertical-align:bottom;">Zbinden 2017 (Basket prove trial)<sup>(c)</sup></th><th id="hd_h_niceng185er6.tab9_1_1_1_6" colspan="2" rowspan="1" style="text-align:center;vertical-align:bottom;">Hill 2007 (model)<sup>(d)</sup></th><th id="hd_h_niceng185er6.tab9_1_1_1_7" colspan="4" rowspan="1" style="text-align:center;vertical-align:bottom;">Wisloff 2013 (model)<sup>(e)</sup></th></tr><tr><th headers="hd_h_niceng185er6.tab9_1_1_1_1" id="hd_h_niceng185er6.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;"></th><th headers="hd_h_niceng185er6.tab9_1_1_1_2" id="hd_h_niceng185er6.tab9_1_1_2_2" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;"></= 12 months</th><th headers="hd_h_niceng185er6.tab9_1_1_1_2" id="hd_h_niceng185er6.tab9_1_1_2_3" colspan="2" rowspan="1" style="text-align:left;vertical-align:bottom;">1-3 years</th><th headers="hd_h_niceng185er6.tab9_1_1_1_3" id="hd_h_niceng185er6.tab9_1_1_2_4" colspan="2" rowspan="1" style="text-align:center;vertical-align:bottom;">1yr</th><th headers="hd_h_niceng185er6.tab9_1_1_1_4" id="hd_h_niceng185er6.tab9_1_1_2_5" colspan="2" rowspan="1" style="text-align:center;vertical-align:bottom;">2 year</th><th headers="hd_h_niceng185er6.tab9_1_1_1_4" id="hd_h_niceng185er6.tab9_1_1_2_6" colspan="2" rowspan="1" style="text-align:center;vertical-align:bottom;">5 year</th><th headers="hd_h_niceng185er6.tab9_1_1_1_5" id="hd_h_niceng185er6.tab9_1_1_2_7" colspan="2" rowspan="1" style="text-align:center;vertical-align:bottom;">1-3 yrs</th><th headers="hd_h_niceng185er6.tab9_1_1_1_6" id="hd_h_niceng185er6.tab9_1_1_2_8" colspan="2" rowspan="1" style="text-align:center;vertical-align:bottom;">1 year</th><th headers="hd_h_niceng185er6.tab9_1_1_1_7" id="hd_h_niceng185er6.tab9_1_1_2_9" colspan="2" rowspan="1" style="text-align:center;vertical-align:bottom;">6 month probabilities</th><th headers="hd_h_niceng185er6.tab9_1_1_1_7" id="hd_h_niceng185er6.tab9_1_1_2_10" colspan="2" rowspan="1" style="text-align:center;vertical-align:bottom;">Applied for 5 years</th></tr><tr><th headers="hd_h_niceng185er6.tab9_1_1_1_1 hd_h_niceng185er6.tab9_1_1_2_1" id="hd_h_niceng185er6.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;"></th><th headers="hd_h_niceng185er6.tab9_1_1_1_2 hd_h_niceng185er6.tab9_1_1_2_2" id="hd_h_niceng185er6.tab9_1_1_3_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">BMS</th><th headers="hd_h_niceng185er6.tab9_1_1_1_2 hd_h_niceng185er6.tab9_1_1_2_2" id="hd_h_niceng185er6.tab9_1_1_3_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">RR DES</th><th headers="hd_h_niceng185er6.tab9_1_1_1_2 hd_h_niceng185er6.tab9_1_1_2_3" id="hd_h_niceng185er6.tab9_1_1_3_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">BMS</th><th headers="hd_h_niceng185er6.tab9_1_1_1_2 hd_h_niceng185er6.tab9_1_1_2_3" id="hd_h_niceng185er6.tab9_1_1_3_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">RR DES</th><th headers="hd_h_niceng185er6.tab9_1_1_1_3 hd_h_niceng185er6.tab9_1_1_2_4" id="hd_h_niceng185er6.tab9_1_1_3_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">BR BMS</th><th headers="hd_h_niceng185er6.tab9_1_1_1_3 hd_h_niceng185er6.tab9_1_1_2_4" id="hd_h_niceng185er6.tab9_1_1_3_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">RR DES</th><th headers="hd_h_niceng185er6.tab9_1_1_1_4 hd_h_niceng185er6.tab9_1_1_2_5" id="hd_h_niceng185er6.tab9_1_1_3_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">BR BMS</th><th headers="hd_h_niceng185er6.tab9_1_1_1_4 hd_h_niceng185er6.tab9_1_1_2_5" id="hd_h_niceng185er6.tab9_1_1_3_9" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">RR DES</th><th headers="hd_h_niceng185er6.tab9_1_1_1_4 hd_h_niceng185er6.tab9_1_1_2_6" id="hd_h_niceng185er6.tab9_1_1_3_10" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">BR BMS</th><th headers="hd_h_niceng185er6.tab9_1_1_1_4 hd_h_niceng185er6.tab9_1_1_2_6" id="hd_h_niceng185er6.tab9_1_1_3_11" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">HR DES</th><th headers="hd_h_niceng185er6.tab9_1_1_1_5 hd_h_niceng185er6.tab9_1_1_2_7" id="hd_h_niceng185er6.tab9_1_1_3_12" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">BR BMS</th><th headers="hd_h_niceng185er6.tab9_1_1_1_5 hd_h_niceng185er6.tab9_1_1_2_7" id="hd_h_niceng185er6.tab9_1_1_3_13" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">RR DES</th><th headers="hd_h_niceng185er6.tab9_1_1_1_6 hd_h_niceng185er6.tab9_1_1_2_8" id="hd_h_niceng185er6.tab9_1_1_3_14" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">BR BMS</th><th headers="hd_h_niceng185er6.tab9_1_1_1_6 hd_h_niceng185er6.tab9_1_1_2_8" id="hd_h_niceng185er6.tab9_1_1_3_15" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">RR DES</th><th headers="hd_h_niceng185er6.tab9_1_1_1_7 hd_h_niceng185er6.tab9_1_1_2_9" id="hd_h_niceng185er6.tab9_1_1_3_16" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">BR BMS first 6 months</th><th headers="hd_h_niceng185er6.tab9_1_1_1_7 hd_h_niceng185er6.tab9_1_1_2_9" id="hd_h_niceng185er6.tab9_1_1_3_17" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">BR BMS after 6 months</th><th headers="hd_h_niceng185er6.tab9_1_1_1_7 hd_h_niceng185er6.tab9_1_1_2_10" id="hd_h_niceng185er6.tab9_1_1_3_18" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">RR PES</th><th headers="hd_h_niceng185er6.tab9_1_1_1_7 hd_h_niceng185er6.tab9_1_1_2_10" id="hd_h_niceng185er6.tab9_1_1_3_19" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">RR SES</th></tr></thead><tbody><tr><th headers="hd_h_niceng185er6.tab9_1_1_1_1 hd_h_niceng185er6.tab9_1_1_2_1 hd_h_niceng185er6.tab9_1_1_3_1" id="hd_b_niceng185er6.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">All-cause mortality</th><td headers="hd_h_niceng185er6.tab9_1_1_1_2 hd_h_niceng185er6.tab9_1_1_2_2 hd_h_niceng185er6.tab9_1_1_3_2 hd_b_niceng185er6.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">5%</td><td headers="hd_h_niceng185er6.tab9_1_1_1_2 hd_h_niceng185er6.tab9_1_1_2_2 hd_h_niceng185er6.tab9_1_1_3_3 hd_b_niceng185er6.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">0.95</td><td headers="hd_h_niceng185er6.tab9_1_1_1_2 hd_h_niceng185er6.tab9_1_1_2_3 hd_h_niceng185er6.tab9_1_1_3_4 hd_b_niceng185er6.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">6%</td><td headers="hd_h_niceng185er6.tab9_1_1_1_2 hd_h_niceng185er6.tab9_1_1_2_3 hd_h_niceng185er6.tab9_1_1_3_5 hd_b_niceng185er6.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">0.87</td><td headers="hd_h_niceng185er6.tab9_1_1_1_3 hd_h_niceng185er6.tab9_1_1_2_4 hd_h_niceng185er6.tab9_1_1_3_6 hd_b_niceng185er6.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">4%</td><td headers="hd_h_niceng185er6.tab9_1_1_1_3 hd_h_niceng185er6.tab9_1_1_2_4 hd_h_niceng185er6.tab9_1_1_3_7 hd_b_niceng185er6.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">0.69</td><td headers="hd_h_niceng185er6.tab9_1_1_1_4 hd_h_niceng185er6.tab9_1_1_2_5 hd_h_niceng185er6.tab9_1_1_3_8 hd_b_niceng185er6.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">5%</td><td headers="hd_h_niceng185er6.tab9_1_1_1_4 hd_h_niceng185er6.tab9_1_1_2_5 hd_h_niceng185er6.tab9_1_1_3_9 hd_b_niceng185er6.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">0.86</td><td headers="hd_h_niceng185er6.tab9_1_1_1_4 hd_h_niceng185er6.tab9_1_1_2_6 hd_h_niceng185er6.tab9_1_1_3_10 hd_b_niceng185er6.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">12%</td><td headers="hd_h_niceng185er6.tab9_1_1_1_4 hd_h_niceng185er6.tab9_1_1_2_6 hd_h_niceng185er6.tab9_1_1_3_11 hd_b_niceng185er6.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">0.72</td><td headers="hd_h_niceng185er6.tab9_1_1_1_5 hd_h_niceng185er6.tab9_1_1_2_7 hd_h_niceng185er6.tab9_1_1_3_12 hd_b_niceng185er6.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">4%</td><td headers="hd_h_niceng185er6.tab9_1_1_1_5 hd_h_niceng185er6.tab9_1_1_2_7 hd_h_niceng185er6.tab9_1_1_3_13 hd_b_niceng185er6.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">0.77</td><td headers="hd_h_niceng185er6.tab9_1_1_1_6 hd_h_niceng185er6.tab9_1_1_2_8 hd_h_niceng185er6.tab9_1_1_3_14 hd_b_niceng185er6.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;"></td><td headers="hd_h_niceng185er6.tab9_1_1_1_6 hd_h_niceng185er6.tab9_1_1_2_8 hd_h_niceng185er6.tab9_1_1_3_15 hd_b_niceng185er6.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;"></td><td headers="hd_h_niceng185er6.tab9_1_1_1_7 hd_h_niceng185er6.tab9_1_1_2_9 hd_h_niceng185er6.tab9_1_1_3_16 hd_b_niceng185er6.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">uncle ar</td><td headers="hd_h_niceng185er6.tab9_1_1_1_7 hd_h_niceng185er6.tab9_1_1_2_9 hd_h_niceng185er6.tab9_1_1_3_17 hd_b_niceng185er6.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">1%</td><td headers="hd_h_niceng185er6.tab9_1_1_1_7 hd_h_niceng185er6.tab9_1_1_2_10 hd_h_niceng185er6.tab9_1_1_3_18 hd_b_niceng185er6.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">0.89</td><td headers="hd_h_niceng185er6.tab9_1_1_1_7 hd_h_niceng185er6.tab9_1_1_2_10 hd_h_niceng185er6.tab9_1_1_3_19 hd_b_niceng185er6.tab9_1_1_1_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">
|
|
<p>1.0</p>
|
|
<p>5</p>
|
|
</td></tr><tr><th headers="hd_h_niceng185er6.tab9_1_1_1_1 hd_h_niceng185er6.tab9_1_1_2_1 hd_h_niceng185er6.tab9_1_1_3_1" id="hd_b_niceng185er6.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">TVR</th><td headers="hd_h_niceng185er6.tab9_1_1_1_2 hd_h_niceng185er6.tab9_1_1_2_2 hd_h_niceng185er6.tab9_1_1_3_2 hd_b_niceng185er6.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">10%</td><td headers="hd_h_niceng185er6.tab9_1_1_1_2 hd_h_niceng185er6.tab9_1_1_2_2 hd_h_niceng185er6.tab9_1_1_3_3 hd_b_niceng185er6.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">0.51</td><td headers="hd_h_niceng185er6.tab9_1_1_1_2 hd_h_niceng185er6.tab9_1_1_2_3 hd_h_niceng185er6.tab9_1_1_3_4 hd_b_niceng185er6.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">13%</td><td headers="hd_h_niceng185er6.tab9_1_1_1_2 hd_h_niceng185er6.tab9_1_1_2_3 hd_h_niceng185er6.tab9_1_1_3_5 hd_b_niceng185er6.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">0.52</td><td headers="hd_h_niceng185er6.tab9_1_1_1_3 hd_h_niceng185er6.tab9_1_1_2_4 hd_h_niceng185er6.tab9_1_1_3_6 hd_b_niceng185er6.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">22%</td><td headers="hd_h_niceng185er6.tab9_1_1_1_3 hd_h_niceng185er6.tab9_1_1_2_4 hd_h_niceng185er6.tab9_1_1_3_7 hd_b_niceng185er6.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">0.30</td><td headers="hd_h_niceng185er6.tab9_1_1_1_4 hd_h_niceng185er6.tab9_1_1_2_5 hd_h_niceng185er6.tab9_1_1_3_8 hd_b_niceng185er6.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">8%</td><td headers="hd_h_niceng185er6.tab9_1_1_1_4 hd_h_niceng185er6.tab9_1_1_2_5 hd_h_niceng185er6.tab9_1_1_3_9 hd_b_niceng185er6.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">0.61</td><td headers="hd_h_niceng185er6.tab9_1_1_1_4 hd_h_niceng185er6.tab9_1_1_2_6 hd_h_niceng185er6.tab9_1_1_3_10 hd_b_niceng185er6.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">10%</td><td headers="hd_h_niceng185er6.tab9_1_1_1_4 hd_h_niceng185er6.tab9_1_1_2_6 hd_h_niceng185er6.tab9_1_1_3_11 hd_b_niceng185er6.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">0.62</td><td headers="hd_h_niceng185er6.tab9_1_1_1_5 hd_h_niceng185er6.tab9_1_1_2_7 hd_h_niceng185er6.tab9_1_1_3_12 hd_b_niceng185er6.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">10%</td><td headers="hd_h_niceng185er6.tab9_1_1_1_5 hd_h_niceng185er6.tab9_1_1_2_7 hd_h_niceng185er6.tab9_1_1_3_13 hd_b_niceng185er6.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">0.39</td><td headers="hd_h_niceng185er6.tab9_1_1_1_6 hd_h_niceng185er6.tab9_1_1_2_8 hd_h_niceng185er6.tab9_1_1_3_14 hd_b_niceng185er6.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;"></td><td headers="hd_h_niceng185er6.tab9_1_1_1_6 hd_h_niceng185er6.tab9_1_1_2_8 hd_h_niceng185er6.tab9_1_1_3_15 hd_b_niceng185er6.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">0.43</td><td headers="hd_h_niceng185er6.tab9_1_1_1_7 hd_h_niceng185er6.tab9_1_1_2_9 hd_h_niceng185er6.tab9_1_1_3_16 hd_b_niceng185er6.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;"></td><td headers="hd_h_niceng185er6.tab9_1_1_1_7 hd_h_niceng185er6.tab9_1_1_2_9 hd_h_niceng185er6.tab9_1_1_3_17 hd_b_niceng185er6.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;"></td><td headers="hd_h_niceng185er6.tab9_1_1_1_7 hd_h_niceng185er6.tab9_1_1_2_10 hd_h_niceng185er6.tab9_1_1_3_18 hd_b_niceng185er6.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;"></td><td headers="hd_h_niceng185er6.tab9_1_1_1_7 hd_h_niceng185er6.tab9_1_1_2_10 hd_h_niceng185er6.tab9_1_1_3_19 hd_b_niceng185er6.tab9_1_1_2_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;"></td></tr><tr><th headers="hd_h_niceng185er6.tab9_1_1_1_1 hd_h_niceng185er6.tab9_1_1_2_1 hd_h_niceng185er6.tab9_1_1_3_1" id="hd_b_niceng185er6.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Stent thrombosis</th><td headers="hd_h_niceng185er6.tab9_1_1_1_2 hd_h_niceng185er6.tab9_1_1_2_2 hd_h_niceng185er6.tab9_1_1_3_2 hd_b_niceng185er6.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">3%</td><td headers="hd_h_niceng185er6.tab9_1_1_1_2 hd_h_niceng185er6.tab9_1_1_2_2 hd_h_niceng185er6.tab9_1_1_3_3 hd_b_niceng185er6.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">0.71</td><td headers="hd_h_niceng185er6.tab9_1_1_1_2 hd_h_niceng185er6.tab9_1_1_2_3 hd_h_niceng185er6.tab9_1_1_3_4 hd_b_niceng185er6.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">3%</td><td headers="hd_h_niceng185er6.tab9_1_1_1_2 hd_h_niceng185er6.tab9_1_1_2_3 hd_h_niceng185er6.tab9_1_1_3_5 hd_b_niceng185er6.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">0.81</td><td headers="hd_h_niceng185er6.tab9_1_1_1_3 hd_h_niceng185er6.tab9_1_1_2_4 hd_h_niceng185er6.tab9_1_1_3_6 hd_b_niceng185er6.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">5%</td><td headers="hd_h_niceng185er6.tab9_1_1_1_3 hd_h_niceng185er6.tab9_1_1_2_4 hd_h_niceng185er6.tab9_1_1_3_7 hd_b_niceng185er6.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">0.90</td><td headers="hd_h_niceng185er6.tab9_1_1_1_4 hd_h_niceng185er6.tab9_1_1_2_5 hd_h_niceng185er6.tab9_1_1_3_8 hd_b_niceng185er6.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">3%</td><td headers="hd_h_niceng185er6.tab9_1_1_1_4 hd_h_niceng185er6.tab9_1_1_2_5 hd_h_niceng185er6.tab9_1_1_3_9 hd_b_niceng185er6.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">0.47</td><td headers="hd_h_niceng185er6.tab9_1_1_1_4 hd_h_niceng185er6.tab9_1_1_2_6 hd_h_niceng185er6.tab9_1_1_3_10 hd_b_niceng185er6.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">3%</td><td headers="hd_h_niceng185er6.tab9_1_1_1_4 hd_h_niceng185er6.tab9_1_1_2_6 hd_h_niceng185er6.tab9_1_1_3_11 hd_b_niceng185er6.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">0.64</td><td headers="hd_h_niceng185er6.tab9_1_1_1_5 hd_h_niceng185er6.tab9_1_1_2_7 hd_h_niceng185er6.tab9_1_1_3_12 hd_b_niceng185er6.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">1%</td><td headers="hd_h_niceng185er6.tab9_1_1_1_5 hd_h_niceng185er6.tab9_1_1_2_7 hd_h_niceng185er6.tab9_1_1_3_13 hd_b_niceng185er6.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">0.60</td><td headers="hd_h_niceng185er6.tab9_1_1_1_6 hd_h_niceng185er6.tab9_1_1_2_8 hd_h_niceng185er6.tab9_1_1_3_14 hd_b_niceng185er6.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;"></td><td headers="hd_h_niceng185er6.tab9_1_1_1_6 hd_h_niceng185er6.tab9_1_1_2_8 hd_h_niceng185er6.tab9_1_1_3_15 hd_b_niceng185er6.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;"></td><td headers="hd_h_niceng185er6.tab9_1_1_1_7 hd_h_niceng185er6.tab9_1_1_2_9 hd_h_niceng185er6.tab9_1_1_3_16 hd_b_niceng185er6.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;"></td><td headers="hd_h_niceng185er6.tab9_1_1_1_7 hd_h_niceng185er6.tab9_1_1_2_9 hd_h_niceng185er6.tab9_1_1_3_17 hd_b_niceng185er6.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;"></td><td headers="hd_h_niceng185er6.tab9_1_1_1_7 hd_h_niceng185er6.tab9_1_1_2_10 hd_h_niceng185er6.tab9_1_1_3_18 hd_b_niceng185er6.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;"></td><td headers="hd_h_niceng185er6.tab9_1_1_1_7 hd_h_niceng185er6.tab9_1_1_2_10 hd_h_niceng185er6.tab9_1_1_3_19 hd_b_niceng185er6.tab9_1_1_3_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;"></td></tr><tr><th headers="hd_h_niceng185er6.tab9_1_1_1_1 hd_h_niceng185er6.tab9_1_1_2_1 hd_h_niceng185er6.tab9_1_1_3_1" id="hd_b_niceng185er6.tab9_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">MI</th><td headers="hd_h_niceng185er6.tab9_1_1_1_2 hd_h_niceng185er6.tab9_1_1_2_2 hd_h_niceng185er6.tab9_1_1_3_2 hd_b_niceng185er6.tab9_1_1_4_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">5%</td><td headers="hd_h_niceng185er6.tab9_1_1_1_2 hd_h_niceng185er6.tab9_1_1_2_2 hd_h_niceng185er6.tab9_1_1_3_3 hd_b_niceng185er6.tab9_1_1_4_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">0.60</td><td headers="hd_h_niceng185er6.tab9_1_1_1_2 hd_h_niceng185er6.tab9_1_1_2_3 hd_h_niceng185er6.tab9_1_1_3_4 hd_b_niceng185er6.tab9_1_1_4_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">4%</td><td headers="hd_h_niceng185er6.tab9_1_1_1_2 hd_h_niceng185er6.tab9_1_1_2_3 hd_h_niceng185er6.tab9_1_1_3_5 hd_b_niceng185er6.tab9_1_1_4_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">0.66</td><td headers="hd_h_niceng185er6.tab9_1_1_1_3 hd_h_niceng185er6.tab9_1_1_2_4 hd_h_niceng185er6.tab9_1_1_3_6 hd_b_niceng185er6.tab9_1_1_4_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">2%</td><td headers="hd_h_niceng185er6.tab9_1_1_1_3 hd_h_niceng185er6.tab9_1_1_2_4 hd_h_niceng185er6.tab9_1_1_3_7 hd_b_niceng185er6.tab9_1_1_4_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">1.03</td><td headers="hd_h_niceng185er6.tab9_1_1_1_4 hd_h_niceng185er6.tab9_1_1_2_5 hd_h_niceng185er6.tab9_1_1_3_8 hd_b_niceng185er6.tab9_1_1_4_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">2%</td><td headers="hd_h_niceng185er6.tab9_1_1_1_4 hd_h_niceng185er6.tab9_1_1_2_5 hd_h_niceng185er6.tab9_1_1_3_9 hd_b_niceng185er6.tab9_1_1_4_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">0.77</td><td headers="hd_h_niceng185er6.tab9_1_1_1_4 hd_h_niceng185er6.tab9_1_1_2_6 hd_h_niceng185er6.tab9_1_1_3_10 hd_b_niceng185er6.tab9_1_1_4_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">4%</td><td headers="hd_h_niceng185er6.tab9_1_1_1_4 hd_h_niceng185er6.tab9_1_1_2_6 hd_h_niceng185er6.tab9_1_1_3_11 hd_b_niceng185er6.tab9_1_1_4_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">1.27</td><td headers="hd_h_niceng185er6.tab9_1_1_1_5 hd_h_niceng185er6.tab9_1_1_2_7 hd_h_niceng185er6.tab9_1_1_3_12 hd_b_niceng185er6.tab9_1_1_4_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">3%</td><td headers="hd_h_niceng185er6.tab9_1_1_1_5 hd_h_niceng185er6.tab9_1_1_2_7 hd_h_niceng185er6.tab9_1_1_3_13 hd_b_niceng185er6.tab9_1_1_4_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">0.49</td><td headers="hd_h_niceng185er6.tab9_1_1_1_6 hd_h_niceng185er6.tab9_1_1_2_8 hd_h_niceng185er6.tab9_1_1_3_14 hd_b_niceng185er6.tab9_1_1_4_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;"></td><td headers="hd_h_niceng185er6.tab9_1_1_1_6 hd_h_niceng185er6.tab9_1_1_2_8 hd_h_niceng185er6.tab9_1_1_3_15 hd_b_niceng185er6.tab9_1_1_4_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;"></td><td headers="hd_h_niceng185er6.tab9_1_1_1_7 hd_h_niceng185er6.tab9_1_1_2_9 hd_h_niceng185er6.tab9_1_1_3_16 hd_b_niceng185er6.tab9_1_1_4_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">6%</td><td headers="hd_h_niceng185er6.tab9_1_1_1_7 hd_h_niceng185er6.tab9_1_1_2_9 hd_h_niceng185er6.tab9_1_1_3_17 hd_b_niceng185er6.tab9_1_1_4_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">2%</td><td headers="hd_h_niceng185er6.tab9_1_1_1_7 hd_h_niceng185er6.tab9_1_1_2_10 hd_h_niceng185er6.tab9_1_1_3_18 hd_b_niceng185er6.tab9_1_1_4_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">1.05</td><td headers="hd_h_niceng185er6.tab9_1_1_1_7 hd_h_niceng185er6.tab9_1_1_2_10 hd_h_niceng185er6.tab9_1_1_3_19 hd_b_niceng185er6.tab9_1_1_4_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">
|
|
<p>0.8</p>
|
|
<p>1</p>
|
|
</td></tr><tr><th headers="hd_h_niceng185er6.tab9_1_1_1_1 hd_h_niceng185er6.tab9_1_1_2_1 hd_h_niceng185er6.tab9_1_1_3_1" id="hd_b_niceng185er6.tab9_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">All revasc</th><td headers="hd_h_niceng185er6.tab9_1_1_1_2 hd_h_niceng185er6.tab9_1_1_2_2 hd_h_niceng185er6.tab9_1_1_3_2 hd_b_niceng185er6.tab9_1_1_5_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;"></td><td headers="hd_h_niceng185er6.tab9_1_1_1_2 hd_h_niceng185er6.tab9_1_1_2_2 hd_h_niceng185er6.tab9_1_1_3_3 hd_b_niceng185er6.tab9_1_1_5_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;"></td><td headers="hd_h_niceng185er6.tab9_1_1_1_2 hd_h_niceng185er6.tab9_1_1_2_3 hd_h_niceng185er6.tab9_1_1_3_4 hd_b_niceng185er6.tab9_1_1_5_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;"></td><td headers="hd_h_niceng185er6.tab9_1_1_1_2 hd_h_niceng185er6.tab9_1_1_2_3 hd_h_niceng185er6.tab9_1_1_3_5 hd_b_niceng185er6.tab9_1_1_5_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;"></td><td headers="hd_h_niceng185er6.tab9_1_1_1_3 hd_h_niceng185er6.tab9_1_1_2_4 hd_h_niceng185er6.tab9_1_1_3_6 hd_b_niceng185er6.tab9_1_1_5_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">29%</td><td headers="hd_h_niceng185er6.tab9_1_1_1_3 hd_h_niceng185er6.tab9_1_1_2_4 hd_h_niceng185er6.tab9_1_1_3_7 hd_b_niceng185er6.tab9_1_1_5_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">0.39</td><td headers="hd_h_niceng185er6.tab9_1_1_1_4 hd_h_niceng185er6.tab9_1_1_2_5 hd_h_niceng185er6.tab9_1_1_3_8 hd_b_niceng185er6.tab9_1_1_5_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;"></td><td headers="hd_h_niceng185er6.tab9_1_1_1_4 hd_h_niceng185er6.tab9_1_1_2_5 hd_h_niceng185er6.tab9_1_1_3_9 hd_b_niceng185er6.tab9_1_1_5_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;"></td><td headers="hd_h_niceng185er6.tab9_1_1_1_4 hd_h_niceng185er6.tab9_1_1_2_6 hd_h_niceng185er6.tab9_1_1_3_10 hd_b_niceng185er6.tab9_1_1_5_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">16%</td><td headers="hd_h_niceng185er6.tab9_1_1_1_4 hd_h_niceng185er6.tab9_1_1_2_6 hd_h_niceng185er6.tab9_1_1_3_11 hd_b_niceng185er6.tab9_1_1_5_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">0.77</td><td headers="hd_h_niceng185er6.tab9_1_1_1_5 hd_h_niceng185er6.tab9_1_1_2_7 hd_h_niceng185er6.tab9_1_1_3_12 hd_b_niceng185er6.tab9_1_1_5_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;"></td><td headers="hd_h_niceng185er6.tab9_1_1_1_5 hd_h_niceng185er6.tab9_1_1_2_7 hd_h_niceng185er6.tab9_1_1_3_13 hd_b_niceng185er6.tab9_1_1_5_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;"></td><td headers="hd_h_niceng185er6.tab9_1_1_1_6 hd_h_niceng185er6.tab9_1_1_2_8 hd_h_niceng185er6.tab9_1_1_3_14 hd_b_niceng185er6.tab9_1_1_5_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">
|
|
<p>7%</p>
|
|
<p>11%</p>
|
|
</td><td headers="hd_h_niceng185er6.tab9_1_1_1_6 hd_h_niceng185er6.tab9_1_1_2_8 hd_h_niceng185er6.tab9_1_1_3_15 hd_b_niceng185er6.tab9_1_1_5_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">
|
|
<p>0.59</p>
|
|
<p>0.45</p>
|
|
</td><td headers="hd_h_niceng185er6.tab9_1_1_1_7 hd_h_niceng185er6.tab9_1_1_2_9 hd_h_niceng185er6.tab9_1_1_3_16 hd_b_niceng185er6.tab9_1_1_5_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">2%</td><td headers="hd_h_niceng185er6.tab9_1_1_1_7 hd_h_niceng185er6.tab9_1_1_2_9 hd_h_niceng185er6.tab9_1_1_3_17 hd_b_niceng185er6.tab9_1_1_5_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">2%</td><td headers="hd_h_niceng185er6.tab9_1_1_1_7 hd_h_niceng185er6.tab9_1_1_2_10 hd_h_niceng185er6.tab9_1_1_3_18 hd_b_niceng185er6.tab9_1_1_5_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">0.46</td><td headers="hd_h_niceng185er6.tab9_1_1_1_7 hd_h_niceng185er6.tab9_1_1_2_10 hd_h_niceng185er6.tab9_1_1_3_19 hd_b_niceng185er6.tab9_1_1_5_1" rowspan="1" colspan="1" style="text-align:right;vertical-align:bottom;">
|
|
<p>0.2</p>
|
|
<p>9</p>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>(a)</dt><dd><div id="niceng185er6.tab9_1"><p class="no_margin">Economic analysis was a within-trial analysis; data here is as reported in paper for the French subgroup of the Typhoon RCT used for the economic analysis</p></div></dd></dl><dl class="bkr_refwrap"><dt>(b)</dt><dd><div id="niceng185er6.tab9_2"><p class="no_margin">Economic analysis was a within-trial analysis; 2 year data here is as reported in NGC met- analysis (to facilitate comparison with estimate from same timepoint); 5 year data is as reported in economic paper</p></div></dd></dl><dl class="bkr_refwrap"><dt>(c)</dt><dd><div id="niceng185er6.tab9_3"><p class="no_margin">Economic analysis was a within-trial analysis of a subgroup of the Basket Prove RCT with >15mm lesion (a people in Basket prove had stent >3mm diameter); data for these outcomes was not reported for the subgroup and the results for the overall population are presented here.</p></div></dd></dl><dl class="bkr_refwrap"><dt>(d)</dt><dd><div id="niceng185er6.tab9_4"><p class="no_margin">Economic analysis was a model. The all revascularisation data is what is reported as the model inputs; the TVR RR was used to estimate the all revasc effect by combining with real world data about repeat revascularisations. The first figures were what were calculated for the basecase initially; the second figures were the agreed best estimates following TA committee discussion.</p></div></dd></dl><dl class="bkr_refwrap"><dt>(e)</dt><dd><div id="niceng185er6.tab9_5"><p class="no_margin">Economic analysis was a model; data here is as reported in the paper</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng185er6tab10"><div id="niceng185er6.tab10" class="table"><h3><span class="label">Table 10</span><span class="title">UK unit costs of coronary stents: local costs and equivalent NHS supply chain costs</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565358/table/niceng185er6.tab10/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er6.tab10_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng185er6.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;"></th><th id="hd_h_niceng185er6.tab10_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Using local costs</th><th id="hd_h_niceng185er6.tab10_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Using NHS supply chain costs 1<sup>(a)</sup></th><th id="hd_h_niceng185er6.tab10_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Using NHS supply chain costs 2<sup>(b)</sup></th></tr></thead><tbody><tr><th headers="hd_h_niceng185er6.tab10_1_1_1_1" id="hd_b_niceng185er6.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Average DES cost (weighted by stent type usage)</th><td headers="hd_h_niceng185er6.tab10_1_1_1_2 hd_b_niceng185er6.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£250<sup>(c)</sup></td><td headers="hd_h_niceng185er6.tab10_1_1_1_3 hd_b_niceng185er6.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£348</td><td headers="hd_h_niceng185er6.tab10_1_1_1_4 hd_b_niceng185er6.tab10_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£380</td></tr><tr><th headers="hd_h_niceng185er6.tab10_1_1_1_1" id="hd_b_niceng185er6.tab10_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Typical BMS cost<sup>(d)</sup></th><td headers="hd_h_niceng185er6.tab10_1_1_1_2 hd_b_niceng185er6.tab10_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£75</td><td headers="hd_h_niceng185er6.tab10_1_1_1_3 hd_b_niceng185er6.tab10_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£87</td><td headers="hd_h_niceng185er6.tab10_1_1_1_4 hd_b_niceng185er6.tab10_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£87</td></tr><tr><th headers="hd_h_niceng185er6.tab10_1_1_1_1" id="hd_b_niceng185er6.tab10_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Difference</th><td headers="hd_h_niceng185er6.tab10_1_1_1_2 hd_b_niceng185er6.tab10_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£175</td><td headers="hd_h_niceng185er6.tab10_1_1_1_3 hd_b_niceng185er6.tab10_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£261</td><td headers="hd_h_niceng185er6.tab10_1_1_1_4 hd_b_niceng185er6.tab10_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">£293</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">Source: Stent type usage from BCIS audit for 1st April 2017 to 31st March 2018 on people undergoing PCI for</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">ACS; local stent costs provided by committee members; NHS Supply Chain 2018<a class="bibr" href="#niceng185er6.ref82" rid="niceng185er6.ref82"><sup>82</sup></a></p></div></dd></dl><dl class="bkr_refwrap"><dt>(a)</dt><dd><div id="niceng185er6.tab10_1"><p class="no_margin">Where there were two costs listed for one stent in the NHS Supply Chain Catalogue, this estimate uses the lower cost that was listed.</p></div></dd></dl><dl class="bkr_refwrap"><dt>(b)</dt><dd><div id="niceng185er6.tab10_2"><p class="no_margin">Where there were two costs listed for one stent in the NHS Supply Chain Catalogue, this estimate uses the higher cost that was listed.</p></div></dd></dl><dl class="bkr_refwrap"><dt>(c)</dt><dd><div id="niceng185er6.tab10_3"><p class="no_margin">Two types of drug-eluting stents did not have local costs available therefore the cost listed in the NHS supply chain catalogue was used. These two types of stents had low usage and it is not thought to impact estimates significantly.</p></div></dd></dl><dl class="bkr_refwrap"><dt>(d)</dt><dd><div id="niceng185er6.tab10_4"><p class="no_margin">Audit data does not report a breakdown of bare metal stent use as their use is low. Therefore, the cost of bare metal stents was based on the cost of the Integrity bare metal stent which was the last available BMS at one of the committee member’s local hospital. Please note that this was the cheapest BMS listed on the NHS Supply Chain catalogue and therefore estimates are considered conservative towards drug-eluting stents.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng185er6appatab1"><div id="niceng185er6.appa.tab1" class="table"><h3><span class="label">Table 11</span><span class="title">Review protocol: Clinical and cost-effectiveness of drug-eluting stents</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565358/table/niceng185er6.appa.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er6.appa.tab1_lrgtbl__"><table><thead><tr><th id="hd_h_niceng185er6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">ID</th><th id="hd_h_niceng185er6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Field</th><th id="hd_h_niceng185er6.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Content</th></tr></thead><tbody><tr><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">I</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Review question</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5.1 What is the clinical and cost effectiveness of drug-eluting stents in adults with acute coronary syndromes, including those with unstable angina or NSTEMI undergoing percutaneous coronary intervention and those with STEMI undergoing primary percutaneous coronary intervention?</td></tr><tr><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">II</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Type of review question</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Intervention</p>
|
|
<p>A review of health economic evidence related to the same review question was conducted in parallel with this review. For details see the health economic review protocol for this NICE guideline.</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">III</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Objective of the review</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>To determine the comparative effectiveness of bare metal stents and drug eluting stents.</p>
|
|
<p>Rationale for including this question:</p>
|
|
<p>CG167 does not make any recommendations on the use of PPCI using drug-eluting stents in patients with STEMI. It refers to the general recommendation in <a href="https://www.nice.org.uk/guidance/ta152/chapter/4-Evidence-and-interpretation#clinical-effectiveness" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">TA 152</a> (see section XIV below).</p>
|
|
<p>New evidence on the efficacy and safety of drug eluting stents has been identified and warrants a review as it may provide enough evidence to make a recommendation. It would also be useful to extrapolate this question to the UA/NSTEMI population</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IV</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Eligibility criteria – population / disease / condition / issue / domain</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Patients with UA/NSTEMI and those with STEMI intended for treatment with a stent</p>
|
|
<p>Include PCI for various indications only if reports populations separately</p>
|
|
<p>Populations:</p>
|
|
<p>Can include global ACS population and can include papers specifically looking at NSTEMI and STEMI, - pathophysiology is the same and the long term mechanistic results shouldn’t be different. Main benefit is a reduction in repeat revascularisation</p>
|
|
<p>For studies including stable and unstable disease, include only if majority is ACS - >50% -</p>
|
|
<p>For studies that have stable and ACS and have reported ACS separately use ACS data only</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">V</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Eligibility criteria – intervention(s) / exposure(s) / prognostic factor(s)</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Drug eluting stents including:
|
|
<ul><li class="half_rhythm"><div>Sirolimus</div></li><li class="half_rhythm"><div>Everolimus</div></li><li class="half_rhythm"><div>Paclitaxel</div></li><li class="half_rhythm"><div>Rapamycin</div></li><li class="half_rhythm"><div>Paclitaxel & Cilostazol</div></li><li class="half_rhythm"><div>Ridaforolimus</div></li><li class="half_rhythm"><div>Novolimus</div></li><li class="half_rhythm"><div>Zotarolimus</div></li></ul>
|
|
Include stents with or without bioabsorbable poylmers</p>
|
|
<p>Not comparing DES to DES and BMS to BMS</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VI</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Eligibility criteria – comparator(s) / control or reference (gold) standard</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Bare metal stents including:
|
|
<ul><li class="half_rhythm"><div>Cobalt Chronium</div></li><li class="half_rhythm"><div>Platinium Chronium</div></li><li class="half_rhythm"><div>Stainless Steel</div></li></ul></td></tr><tr><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VII</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcomes and prioritisation</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>
|
|
<b>CRITICAL</b>
|
|
</p>
|
|
<p>Time points: early ≤1 and later >1-3 year
|
|
<ul><li class="half_rhythm"><div>All-cause mortality</div></li><li class="half_rhythm"><div>Cardiac mortality</div></li><li class="half_rhythm"><div>TVF- target vessel failure</div></li><li class="half_rhythm"><div>TLR and TVR – target lesion and target vessel revascularisation</div></li><li class="half_rhythm"><div>Stent thrombosis(definite and/or probable) (record if assessed using optical coherence tomography (OCT), Intravascular ultrasound (IVUS) or angio)</div></li><li class="half_rhythm"><div>Myocardial infarction</div></li><li class="half_rhythm"><div>Health-related quality of life including EQ5D and SF-36. All data for the stated quality of life measures will be collected. Only overall scores will be reported for meta-analysis and GRADE.</div></li></ul>
|
|
<b>IMPORTANT</b>
|
|
<ul><li class="half_rhythm"><div>Bleeding- Where possible, bleeding outcomes will be categorised into:
|
|
<ul class="circle"><li class="half_rhythm"><div>Major bleeding (including BARC 3-5 and as reported by author)</div></li><li class="half_rhythm"><div>Minor bleeding (including BARC 2, TIMI and as reported by author).</div></li></ul></div></li><li class="half_rhythm"><div>The following hierarchy of bleeding scales will be used:
|
|
<ul class="circle"><li class="half_rhythm"><div>BARC</div></li><li class="half_rhythm"><div>Author’s definition</div></li><li class="half_rhythm"><div>TIMI</div></li><li class="half_rhythm"><div>GUSTO</div></li></ul></div></li><li class="half_rhythm"><div>MLD - Minimal lumen diameter (measuring how much restenosis there is)- surrogate marker for TLR and TVR</div></li></ul></p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">VIII</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Eligibility criteria – study design</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Randomised Controlled Trials (RCT)</div></li><li class="half_rhythm"><div>Systematic Reviews (SR) of RCTs</div></li></ul></td></tr><tr><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">IX</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other inclusion exclusion criteria</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Exclude endothelial progenitor cell (EPC) capture</div></li><li class="half_rhythm"><div>Bioabsorbable scaffolds – these are not stents – include DES with bioabsorbable polymer but exclude any that are re-absorbed</div></li></ul></td></tr><tr><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">X</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Proposed sensitivity / subgroup analysis, or metaregression</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">If there is heterogeneity (P-value is <0.1 or I<sup>2</sup> is >50%), the following subgroups will be investigated:
|
|
<ul><li class="half_rhythm"><div>diameter and number of stents if possible (length and width)-> = 3mm width and length 15</div></li><li class="half_rhythm"><div>STEMI and NSTEMI</div></li><li class="half_rhythm"><div>duration of antiplatelet therapy</div></li><li class="half_rhythm"><div>differential usage of antiplatelet therapy</div></li><li class="half_rhythm"><div>renal disease/renal insufficiency</div></li><li class="half_rhythm"><div>older patients (>75)</div></li><li class="half_rhythm"><div>Diabetes</div></li><li class="half_rhythm"><div>Mixed Stable and ACS</div></li><li class="half_rhythm"><div>restenosis</div></li></ul>
|
|
A statement will be included about subgroup analyses that have been conducted. However, only those analyses that explain heterogeneity will be reported.</td></tr><tr><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XI</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Selection process – duplicate screening / selection / analysis</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Studies will be sifted by title and abstract. Potentially relevant publications obtained in full text and assessed against the inclusion criteria specified in this protocol. A sample of a minimum of 10% of the abstract lists will be double-sifted by a senior research fellow and any discrepancies discussed and rectified.</td></tr><tr><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XII</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Data management (software)</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>EndNote will be used for reference management, sifting, citations and bibliographies.</div></li><li class="half_rhythm"><div>EviBASE will be used for data extraction and quality assessment for clinical studies.</div></li><li class="half_rhythm"><div>MS Excel will be used for data extraction and critical appraisal for health economic studies.</div></li><li class="half_rhythm"><div>Pairwise meta-analyses will be performed using Cochrane Review Manager (RevMan5).</div></li><li class="half_rhythm"><div>GRADEpro will be used to assess the quality of evidence for each outcome.</div></li></ul></td></tr><tr><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XIII</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Information sources – databases and dates</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Clinical search databases to be used: Medline, Embase, Cochrane Library</p>
|
|
<p>Language: Restrict to English only</p>
|
|
<p>Supplementary search techniques: backward citation searching</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XIV</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Identify if an update</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>This question is an update of TA 152</p>
|
|
<p>Recommendation in TA 152 states the following:</p>
|
|
<p>Drug-eluting stents are recommended for use in percutaneous coronary intervention for the treatment of coronary artery disease, within their instructions for use, only if:
|
|
<ul><li class="half_rhythm"><div>the target artery to be treated has less than a 3-mm calibre or the lesion is longer than 15 mm, and</div></li><li class="half_rhythm"><div>the price difference between drug-eluting stents and bare-metal stents is no more than £300.</div></li></ul></p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XV</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Author contacts</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<a href="http://ACS@nice.org.uk" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">ACS@nice<wbr style="display:inline-block"></wbr>​.org.uk</a>
|
|
</td></tr><tr><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XVI</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Highlight if amendment to previous protocol</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details please see section 4.5 of <a href="https://www.nice.org.uk/article/pmg20/chapter/4-Developing-review-questions-and-planning-the-evidence-review#planning-the-evidence-review" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a>.</td></tr><tr><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XVII</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Search strategy – for one database</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details please see <a href="#niceng185er6.appb">appendix B</a></td></tr><tr><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XVIII</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Data collection process – forms / duplicate</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">A standardised evidence table format will be used, and published as appendix/ces [X] of the evidence report.</td></tr><tr><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XIX</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Data items – define all variables to be collected</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details please see evidence tables in <a href="#niceng185er6.appd">Appendix D</a> (clinical evidence tables) or <a href="#niceng185er6.apph">H</a> (health economic evidence tables).</td></tr><tr><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XX</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Methods for assessing bias at outcome / study level</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Standard study checklists were used to critically appraise individual studies. For details please see section 6.2 of <a href="https://www.nice.org.uk/article/pmg20/chapter/6-Reviewing-research-evidence#assessing-the-quality-of-the-evidence" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a></p>
|
|
<p>The risk of bias across all available evidence was evaluated for each outcome using an adaptation of the ‘Grading of Recommendations Assessment, Development and Evaluation (GRADE) toolbox’ developed by the international GRADE working group <a href="http://www.gradeworkinggroup.org/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">http://www<wbr style="display:inline-block"></wbr>​.gradeworkinggroup.org/</a></p>
|
|
<p>[Please document any deviations/alternative approach when GRADE isn’t used or if a modified GRADE approach has been used for non-intervention or non-comparative studies.]</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XXI</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Criteria for quantitative synthesis</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details please see section 6.4 of <a href="https://www.nice.org.uk/article/pmg20/chapter/6-Reviewing-research-evidence#assessing-the-quality-of-the-evidence" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a>.</td></tr><tr><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XXII</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Methods for quantitative analysis – combining studies and exploring (in)consistency</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details please see the separate <a href="/books/NBK565358/bin/niceng185er6_bm3.pdf">Methods</a> report for this guideline.</td></tr><tr><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XXIII</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Meta-bias assessment – publication bias, selective reporting bias</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>For details please see section 6.2 of <a href="https://www.nice.org.uk/article/pmg20/chapter/6-Reviewing-research-evidence#assessing-the-quality-of-the-evidence" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a>.</p>
|
|
<p>[Consider exploring publication bias for review questions where it may be more common, such as pharmacological questions, certain disease areas, etc. Describe any steps taken to mitigate publication bias, such as examining trial registries.]</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XXIV</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Confidence in cumulative evidence</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details please see sections 6.4 and 9.1 of <a href="https://www.nice.org.uk/article/pmg20/chapter/1-Introduction-and-overview" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a>.</td></tr><tr><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XXV</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Rationale / context – what is known</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">For details please see the introduction to the evidence review.</td></tr><tr><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XXVI</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Describe contributions of authors and guarantor</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>A multidisciplinary committee [<a href="http://www.nice.org.uk/guidance/ng185/history" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">www<wbr style="display:inline-block"></wbr>​.nice.org.uk/guidance/ng185/history</a>] developed the evidence review. The committee was convened by the National Guideline Centre (NGC) and chaired by Margaret Lally in line with section 3 of <a href="https://www.nice.org.uk/article/pmg20/chapter/1%20Introduction%20and%20overview" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a>.</p>
|
|
<p>Staff from NGC undertook systematic literature searches, appraised the evidence, conducted meta-analysis and cost-effectiveness analysis where appropriate, and drafted the evidence review in collaboration with the committee. For details please see <a href="https://www.nice.org.uk/article/pmg20/chapter/1-Introduction-and-overview" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a>.</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XXVII</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Sources of funding / support</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NGC is funded by NICE and hosted by the Royal College of Physicians.</td></tr><tr><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XXVIII</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Name of sponsor</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NGC is funded by NICE and hosted by the Royal College of Physicians.</td></tr><tr><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XXIX</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Roles of sponsor</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NICE funds NGC to develop guidelines for those working in the NHS, public health and social care in England.</td></tr><tr><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">XXX</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PROSPERO registration number</td><td headers="hd_h_niceng185er6.appa.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Not registered</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng185er6appatab2"><div id="niceng185er6.appa.tab2" class="table"><h3><span class="label">Table 12</span><span class="title">Health economic review protocol</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565358/table/niceng185er6.appa.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er6.appa.tab2_lrgtbl__"><table><thead><tr><th id="hd_h_niceng185er6.appa.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Review question</th><th id="hd_h_niceng185er6.appa.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">All questions – health economic evidence</th></tr></thead><tbody><tr><td headers="hd_h_niceng185er6.appa.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Objectives</b>
|
|
</td><td headers="hd_h_niceng185er6.appa.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">To identify health economic studies relevant to any of the review questions.</td></tr><tr><td headers="hd_h_niceng185er6.appa.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Search criteria</b>
|
|
</td><td headers="hd_h_niceng185er6.appa.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Populations, interventions and comparators must be as specified in the clinical review protocol above.</div></li><li class="half_rhythm"><div>Studies must be of a relevant health economic study design (cost–utility analysis, cost-effectiveness analysis, cost–benefit analysis, cost–consequences analysis, comparative cost analysis).</div></li><li class="half_rhythm"><div>Studies must not be a letter, editorial or commentary, or a review of health economic evaluations. (Recent reviews will be ordered although not reviewed. The bibliographies will be checked for relevant studies, which will then be ordered.)</div></li><li class="half_rhythm"><div>Unpublished reports will not be considered unless submitted as part of a call for evidence.</div></li><li class="half_rhythm"><div>Studies must be in English.</div></li></ul></td></tr><tr><td headers="hd_h_niceng185er6.appa.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Search strategy</b>
|
|
</td><td headers="hd_h_niceng185er6.appa.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">A health economic study search will be undertaken using population-specific terms and a health economic study filter – see <a href="#niceng185er6.appb">appendix B</a> below.</td></tr><tr><td headers="hd_h_niceng185er6.appa.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<b>Review strategy</b>
|
|
</td><td headers="hd_h_niceng185er6.appa.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Studies not meeting any of the search criteria above will be excluded. Studies published before 2003, abstract-only studies and studies from non-OECD countries or the USA will also be excluded.</p>
|
|
<p>Studies published after 2003 that were included in the previous guidelines will be reassessed for inclusion and may be included or selectively excluded based on their relevance to the questions covered in this update and whether more applicable evidence is also identified.</p>
|
|
<p>Each remaining study will be assessed for applicability and methodological limitations using the NICE economic evaluation checklist which can be found in appendix H of Developing NICE guidelines: the manual (2014).<a class="bibr" href="#niceng185er6.ref80" rid="niceng185er6.ref80"><sup>80</sup></a></p>
|
|
<p><b>Inclusion and exclusion criteria</b>
|
|
<ul><li class="half_rhythm"><div>If a study is rated as both ‘Directly applicable’ and with ‘Minor limitations’ then it will be included in the guideline. A health economic evidence table will be completed and it will be included in the health economic evidence profile.</div></li><li class="half_rhythm"><div>If a study is rated as either ‘Not applicable’ or with ‘Very serious limitations’ then it will usually be excluded from the guideline. If it is excluded then a health economic evidence table will not be completed and it will not be included in the health economic evidence profile.</div></li><li class="half_rhythm"><div>If a study is rated as ‘Partially applicable’, with ‘Potentially serious limitations’ or both then there is discretion over whether it should be included.</div></li></ul>
|
|
<b>Where there is discretion</b></p>
|
|
<p>The health economist will make a decision based on the relative applicability and quality of the available evidence for that question, in discussion with the guideline committee if required. The ultimate aim is to include health economic studies that are helpful for decision-making in the context of the guideline and the current NHS setting. If several studies are considered of sufficiently high applicability and methodological quality that they could all be included, then the health economist, in discussion with the committee if required, may decide to include only the most applicable studies and to selectively exclude the remaining studies. All studies excluded on the basis of applicability or methodological limitations will be listed with explanation in the excluded health economic studies appendix below.</p>
|
|
<p>The health economist will be guided by the following hierarchies.</p>
|
|
<p><i>Setting:</i>
|
|
<ul><li class="half_rhythm"><div>UK NHS (most applicable).</div></li><li class="half_rhythm"><div>OECD countries with predominantly public health insurance systems (for example, France, Germany, Sweden).</div></li><li class="half_rhythm"><div>OECD countries with predominantly private health insurance systems (for example, Switzerland).</div></li><li class="half_rhythm"><div>Studies set in non-OECD countries or in the USA will be excluded before being assessed for applicability and methodological limitations.</div></li></ul>
|
|
<i>Health economic study type:</i>
|
|
<ul><li class="half_rhythm"><div>Cost–utility analysis (most applicable).</div></li><li class="half_rhythm"><div>Other type of full economic evaluation (cost–benefit analysis, cost-effectiveness analysis, cost–consequences analysis).</div></li><li class="half_rhythm"><div>Comparative cost analysis.</div></li><li class="half_rhythm"><div>Non-comparative cost analyses including cost-of-illness studies will be excluded before being assessed for applicability and methodological limitations.</div></li></ul>
|
|
<i>Year of analysis:</i>
|
|
<ul><li class="half_rhythm"><div>The more recent the study, the more applicable it will be.</div></li><li class="half_rhythm"><div>Studies published in 2003 or later (including any such studies included in the previous guideline(s)) but that depend on unit costs and resource data entirely or predominantly from before 2003 will be rated as ‘Not applicable’.</div></li><li class="half_rhythm"><div>Studies published before 2003 (including any such studies included in the previous guidelines) will be excluded before being assessed for applicability and methodological limitations.</div></li></ul>
|
|
<i>Quality and relevance of effectiveness data used in the health economic analysis:</i>
|
|
<ul><li class="half_rhythm"><div>The more closely the clinical effectiveness data used in the health economic analysis match with the outcomes of the studies included in the clinical review the more useful the analysis will be for decision-making in the guideline.</div></li><li class="half_rhythm"><div>The following will be rated as ‘Very serious limitations’ and excluded: economic analyses undertaken as part of clinical studies that are excluded from the clinical review; economic models where relative treatment effects are based entirely on studies that are excluded from the clinical review.</div></li></ul></p>
|
|
</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng185er6appbtab1"><div id="niceng185er6.appb.tab1" class="table"><h3><span class="label">Table 13</span><span class="title">Database date parameters and filters used</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565358/table/niceng185er6.appb.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er6.appb.tab1_lrgtbl__"><table><thead><tr><th id="hd_h_niceng185er6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Database</th><th id="hd_h_niceng185er6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Dates searched</th><th id="hd_h_niceng185er6.appb.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Search filter used</th></tr></thead><tbody><tr><td headers="hd_h_niceng185er6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Medline (OVID)</td><td headers="hd_h_niceng185er6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1946 – 24 June 2019</td><td headers="hd_h_niceng185er6.appb.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Exclusions</p>
|
|
<p>Randomised controlled trials</p>
|
|
<p>Systematic review studies</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Embase (OVID)</td><td headers="hd_h_niceng185er6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1974 – 24 June 2019</td><td headers="hd_h_niceng185er6.appb.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Exclusions</p>
|
|
<p>Randomised controlled trials</p>
|
|
<p>Systematic review studies</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er6.appb.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">The Cochrane Library (Wiley)</td><td headers="hd_h_niceng185er6.appb.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Cochrane Reviews to 2019 Issue 6 of 12</p>
|
|
<p>CENTRAL to 2019 Issue 6 of 12</p>
|
|
</td><td headers="hd_h_niceng185er6.appb.tab1_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng185er6appbtab2"><div id="niceng185er6.appb.tab2" class="table"><h3><span class="title">Medline (Ovid) search terms</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565358/table/niceng185er6.appb.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er6.appb.tab2_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Acute Coronary Syndrome/ or Angina Pectoris/ or Angina, Unstable/ or Coronary Thrombosis/ or exp Myocardial Infarction/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Heart Arrest/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(acute coronary adj2 syndrome*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((myocardial or heart) adj infarct*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(heart adj (attack* or event*)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((heart or cardiac) adj arrest*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(coronary adj2 thrombos*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(stemi or st-segment or st segment or st-elevation or st elevation).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">“non-ST-segment elevation”.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(non-STEMI or NSTEMI or nonSTEMI).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">“Q wave myocardial infarction”.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">“non Q wave MI”.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(NSTE-ACS or STE-ACS).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(subendocardial adj3 infarct*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((unstable or variant) adj2 angina*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(unstable adj2 coronary).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/1-16</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">letter/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">19.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">editorial/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">news/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">21.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp historical article/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">22.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Anecdotes as Topic/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">comment/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">case report/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">25.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(letter or comment*).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/18-25</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomized controlled trial/ or random*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">28.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26 not 27</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">29.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">animals/ not humans/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Animals, Laboratory/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">31.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Animal Experimentation/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">32.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Models, Animal/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">33.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Rodentia/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">34.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(rat or rats or mouse or mice).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">35.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/28-34</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">36.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17 not 35</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">37.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">limit 36 to English language</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">38.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomized controlled trial.pt.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">39.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">controlled clinical trial.pt.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomi#ed.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">41.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">placebo.ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">42.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomly.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">43.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Clinical Trials as topic.sh.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">44.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">trial.ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">45.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/38-44</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">46.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Meta-Analysis/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">47.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Meta-Analysis as Topic/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">48.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(meta analy* or metanaly* or metaanaly* or meta regression).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">49.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((systematic* or evidence*) adj3 (review* or overview*)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">50.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">51.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(search strategy or search criteria or systematic search or study selection or data extraction).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">52.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(search* adj4 literature).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">53.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">54.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">cochrane.jw.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">55.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">56.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/46-55</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">57.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Percutaneous Coronary Intervention/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">58.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Percutaneous coronary intervention*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">59.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(PPCI or PCI).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">60.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Percutaneous Transluminal Coronary Angioplasty.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">61.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PTCA.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">62.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Angioplasty, Balloon, Coronary/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">63.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Angioplasty/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">64.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(Balloon adj3 coronary).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">65.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((primary or coronary or transluminal or balloon) adj3 angioplasty).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">66.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Coronary artery dilat*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">67.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/57-66</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">68.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp *Stents/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">69.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">drug eluting stent*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">70.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(eluting adj3 stent*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">71.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((paclitaxel or sirolimus or everolimus or biolimus or ridaforolimus or zotarolimus or novolimus) adj3 stent*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">72.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/68-71</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">73.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">37 and 67 and 72</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">74.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">73 and (45 or 56)</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng185er6appbtab3"><div id="niceng185er6.appb.tab3" class="table"><h3><span class="title">Embase (Ovid) search terms</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565358/table/niceng185er6.appb.tab3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er6.appb.tab3_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">acute coronary syndrome/ or angina pectoris/ or unstable angina pectoris/ or coronary artery thrombosis/ or exp heart infarction/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">heart arrest/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(acute coronary adj2 syndrome*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((myocardial or heart) adj infarct*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(heart adj (attack* or event*)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((heart or cardiac) adj arrest*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(coronary adj2 thrombos*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(stemi or st-segment or st segment or st-elevation or st elevation).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">“non-ST-segment elevation”.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(non-STEMI or NSTEMI or nonSTEMI).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">“Q wave myocardial infarction”.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">“non Q wave MI”.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(NSTE-ACS or STE-ACS).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(subendocardial adj3 infarct*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((unstable or variant) adj2 angina*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(unstable adj2 coronary).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/1-16</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">letter.pt. or letter/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">19.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">note.pt.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">editorial.pt.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">21.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Case report/ or Case study/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">22.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(letter or comment*).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/18-22</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomized controlled trial/ or random*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">25.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23 not 24</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">animal/ not human/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Nonhuman/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">28.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Animal Experiment/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">29.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Experimental animal/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Animal model/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">31.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Rodent/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">32.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(rat or rats or mouse or mice).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">33.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/25-32</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">34.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17 not 33</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">35.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">limit 34 to English language</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">36.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">random*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">37.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">factorial*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">38.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(crossover* or cross over*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">39.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((doubl* or singl*) adj blind*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(assign* or allocat* or volunteer* or placebo*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">41.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">crossover procedure/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">42.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">single blind procedure/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">43.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomized controlled trial/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">44.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">double blind procedure/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">45.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/36-44</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">46.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">systematic review/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">47.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">meta-analysis/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">48.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(meta analy* or metanaly* or metaanaly* or meta regression).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">49.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((systematic or evidence) adj3 (review* or overview*)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">50.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">51.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(search strategy or search criteria or systematic search or study selection or data extraction).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">52.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(search* adj4 literature).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">53.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">54.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((pool* or combined) adj2 (data or trials or studies or results)).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">55.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">cochrane.jw.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">56.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">57.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/46-56</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">58.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">transluminal coronary angioplasty/ or percutaneous coronary intervention/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">59.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Percutaneous coronary intervention*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">60.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(PPCI or PCI).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">61.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Percutaneous Transluminal Coronary Angioplasty.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">62.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PTCA.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">63.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">transluminal coronary angioplasty/ or percutaneous transluminal angioplasty/ or angioplasty/ or percutaneous transluminal angioplasty balloon/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">64.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(Balloon adj3 coronary).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">65.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((primary or coronary or transluminal or balloon) adj3 angioplasty).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">66.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Coronary artery dilat*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">67.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/58-66</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">68.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">*stent/ or exp *cardiovascular stent/ or exp *drug eluting stent/ or exp *metal stent/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">69.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">drug eluting stent*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">70.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(eluting adj3 stent*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">71.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((paclitaxel or sirolimus or everolimus or biolimus or ridaforolimus or zotarolimus or novolimus) adj3 stent*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">72.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/68-71</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">73.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">35 and 67 and 72</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">74.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">73 and (45 or 57)</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng185er6appbtab4"><div id="niceng185er6.appb.tab4" class="table"><h3><span class="title">Cochrane Library (Wiley) search terms</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565358/table/niceng185er6.appb.tab4/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er6.appb.tab4_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#1.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Acute Coronary Syndrome] this term only</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#2.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Angina Pectoris] this term only</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#3.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Angina, Unstable] this term only</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#4.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Coronary Thrombosis] this term only</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#5.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Myocardial Infarction] explode all trees</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#6.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(or #1-#5)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#7.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Heart Arrest] this term only</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#8.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(acute coronary near/2 syndrome*):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#9.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((myocardial or heart) next infarct*):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#10.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(heart next (attack* or event*)):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#11.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((heart or cardiac) next arrest*):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#12.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(coronary near/2 thrombos*):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#13.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(stemi or st-segment or st segment or st-elevation or st elevation):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#14.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">non-ST-segment elevation:ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#15.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(non-STEMI or NSTEMI or nonSTEMI):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#16.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Q wave myocardial infarction:ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#17.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">non Q wave MI:ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#18.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NSTE-ACS:ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#19.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(subendocardial near/3 infarct*):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#20.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((unstable or variant) near/2 angina*):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#21.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(unstable near/2 coronary):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#22.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(or #6-#21)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#23.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Percutaneous Coronary Intervention] explode all trees</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#24.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Percutaneous coronary intervention*:ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#25.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(PPCI or PCI):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#26.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Angioplasty, Balloon, Coronary] explode all trees</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#27.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Percutaneous Transluminal Coronary Angioplasty:ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#28.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PTCA:ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#29.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Angioplasty] explode all trees</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#30.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(Balloon near/3 coronary):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#31.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((primary or coronary or transluminal or balloon) near/3 angioplasty):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#32.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Coronary artery dilat*:ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#33.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(or #23-#32)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#34.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH descriptor: [Stents] explode all trees</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#35.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(drug next eluting next stent*):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#36.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(eluting near/3 stent*):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#37.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((paclitaxel or sirolimus) near/3 stent*):ti,ab</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#38.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(or #34-#37)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#39.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#22 and #33 and #38</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng185er6appbtab5"><div id="niceng185er6.appb.tab5" class="table"><h3><span class="label">Table 14</span><span class="title">Database date parameters and filters used</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565358/table/niceng185er6.appb.tab5/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er6.appb.tab5_lrgtbl__"><table><thead><tr><th id="hd_h_niceng185er6.appb.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Database</th><th id="hd_h_niceng185er6.appb.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Dates searched</th><th id="hd_h_niceng185er6.appb.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Search filter used</th></tr></thead><tbody><tr><td headers="hd_h_niceng185er6.appb.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Medline</td><td headers="hd_h_niceng185er6.appb.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">01 January 2014 – 18 June 2019</td><td headers="hd_h_niceng185er6.appb.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Exclusions</p>
|
|
<p>Health economics studies</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er6.appb.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Embase</td><td headers="hd_h_niceng185er6.appb.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">01 January 2014 – 18 June 2019</td><td headers="hd_h_niceng185er6.appb.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Exclusions</p>
|
|
<p>Health economics studies</p>
|
|
</td></tr><tr><td headers="hd_h_niceng185er6.appb.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Centre for Research and Dissemination (CRD)</td><td headers="hd_h_niceng185er6.appb.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>HTA - 2003 – 31 March 2018</p>
|
|
<p>NHSEED - 2003 to 31 March 2015</p>
|
|
</td><td headers="hd_h_niceng185er6.appb.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng185er6appbtab6"><div id="niceng185er6.appb.tab6" class="table"><h3><span class="title">Medline (Ovid) search terms</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565358/table/niceng185er6.appb.tab6/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er6.appb.tab6_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Acute Coronary Syndrome/ or Angina Pectoris/ or Angina, Unstable/ or Coronary Thrombosis/ or exp Myocardial Infarction/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Heart Arrest/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(acute coronary adj2 syndrome*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((myocardial or heart) adj infarct*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(heart adj (attack* or event*)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((heart or cardiac) adj arrest*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(coronary adj2 thrombos*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(stemi or st-segment or st segment or st-elevation or st elevation).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">“non-ST-segment elevation”.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(non-STEMI or NSTEMI or nonSTEMI).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">“Q wave myocardial infarction”.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">“non Q wave MI”.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NSTE-ACS.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(subendocardial adj3 infarct*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((unstable or variant) adj2 angina*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(unstable adj2 coronary).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/1-16</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">letter/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">19.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">editorial/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">news/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">21.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp historical article/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">22.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Anecdotes as Topic/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">comment/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">case report/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">25.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(letter or comment*).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/18-25</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomized controlled trial/ or random*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">28.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26 not 27</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">29.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">animals/ not humans/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Animals, Laboratory/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">31.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Animal Experimentation/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">32.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Models, Animal/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">33.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Rodentia/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">34.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(rat or rats or mouse or mice).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">35.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/28-34</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">36.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17 not 35</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">37.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">limit 36 to English language</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">38.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Economics/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">39.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Value of life/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp “Costs and Cost Analysis”/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">41.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Economics, Hospital/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">42.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Economics, Medical/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">43.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Economics, Nursing/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">44.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Economics, Pharmaceutical/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">45.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp “Fees and Charges”/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">46.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Budgets/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">47.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">budget*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">48.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">cost*.ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">49.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(economic* or pharmaco?economic*).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">50.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(price* or pricing*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">51.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">52.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(financ* or fee or fees).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">53.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(value adj2 (money or monetary)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">54.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/38-53</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">55.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">37 and 54</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">56.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">*Angiography/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">57.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Angiocardiography/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">58.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Coronary Angiography/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">59.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Angiograph*.ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">60.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Arteriograph*.ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">61.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Angiocardiograph*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">62.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Coronary Angiograph*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">63.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Angiogram*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">64.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cardioangiograph*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">65.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Angiocardiogram.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">66.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Angio Cardiograph*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">67.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Coronary Arteriogra*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">68.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Coronarograph*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">69.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">*Myocardial Revascularization/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">70.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Angioplasty, Balloon, Coronary/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">71.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(Myocardial adj revasculari?ation).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">72.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PCI.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">73.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Percutaneous coronary intervention.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">74.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Percutaneous Transluminal Coronary Angioplasty.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">75.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PTCA.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">76.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Angioplasty/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">77.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Blunt microdissection.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">78.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((laser or patch) adj angioplasty).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">79.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Percutaneous Transluminal Angioplasty.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">80.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Transluminal Coronary Angioplasty.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">81.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(Balloon adj3 coronary).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">82.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(Balloon adj3 angioplasty).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">83.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp STENTS/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">84.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">stent*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">85.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Or/56-84</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">86.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">aspirin/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">87.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(aspirin or acetylsalicylic acid).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">88.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(clopidogrel or plavix).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">89.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(ticagrelor or brilique).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">90.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(prasugrel or efient or effient or prasita).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">91.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Prasugrel Hydrochloride/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">92.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">platelet aggregation inhibitors/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">93.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(Glycoproteins IIb-IIIa or GPIIb-IIIa Receptors or Integrin alpha-IIb beta-3 or Integrin alphaIIbbeta3 or GPIIB IIIA).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">94.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Platelet Glycoprotein GPIIb-IIIa Complex/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">95.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Receptors, Fibrinogen/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">96.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(Abciximab or Reopro or Eptifibatide or Integrelin or Integrilin or Intrifiban or Tirofiban or Aggrastat).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">97.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp adrenergic beta-antagonists/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">98.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(propranolol or angilol or inderal-la or half-inderal or inderal or bedranol or prograne or slo-pro or acebutolol or sectral or atenolol or tenormin or bisoprolol or cardicor or emcor or carvedilol or eucardic or celiprolol or celectol or co-tenidone or tenoret or tenoretic or esmolol or brevibloc or labetalol or trandate or metoprolol or betaloc or lopresor or nadolol or corgard or nebivolol or nebilet or hypoloc or oxprenolol or trasicor or slow-trasicor or pindolol or visken or sotalol or beta-cardone or sotacor or timolol or betim).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">99.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">propranolol/ or acebutolol/ or atenolol/ or bisoprolol/ or celiprolol/ or labetalol/ or metoprolol/ or nadolol/ or nebivolol/ or oxprenolol/ or pindolol/ or sotalol/ or timolol/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">100.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(beta adj3 block*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">101.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(b adj3 block*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">102.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(beta adj2 antagonist*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">103.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Antithrombins/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">104.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Antithrombin*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">105.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(thrombin adj3 inhibitor*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">106.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hirudins/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">107.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hirudin*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">108.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hirulog.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">109.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Bivalirudin.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">110.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Or/86-109</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">111.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">and (85 or 110)</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng185er6appbtab7"><div id="niceng185er6.appb.tab7" class="table"><h3><span class="title">Embase (Ovid) search terms</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565358/table/niceng185er6.appb.tab7/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er6.appb.tab7_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">acute coronary syndrome/ or angina pectoris/ or unstable angina pectoris/ or coronary artery thrombosis/ or exp heart infarction/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">heart arrest/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(acute coronary adj2 syndrome*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((myocardial or heart) adj infarct*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(heart adj (attack* or event*)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((heart or cardiac) adj arrest*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(coronary adj2 thrombos*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(stemi or st-segment or st segment or st-elevation or st elevation).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">9.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">“non-ST-segment elevation”.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(non-STEMI or NSTEMI or nonSTEMI).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">“Q wave myocardial infarction”.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">“non Q wave MI”.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NSTE-ACS.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(subendocardial adj3 infarct*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((unstable or variant) adj2 angina*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(unstable adj2 coronary).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/1-16</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">letter.pt. or letter/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">19.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">note.pt.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">editorial.pt.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">21.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Case report/ or Case study/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">22.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(letter or comment*).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/18-22</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomized controlled trial/ or random*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">25.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">23 not 24</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">animal/ not human/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">27.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Nonhuman/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">28.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Animal Experiment/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">29.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Experimental animal/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">30.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Animal model/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">31.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp Rodent/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">32.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(rat or rats or mouse or mice).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">33.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/25-32</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">34.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17 not 33</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">35.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">limit 34 to English language</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">36.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">health economics/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">37.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp economic evaluation/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">38.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp health care cost/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">39.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp fee/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">40.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">budget/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">41.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">funding/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">42.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">budget*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">43.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">cost*.ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">44.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(economic* or pharmaco?economic*).ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">45.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(price* or pricing*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">46.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">47.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(financ* or fee or fees).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">48.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(value adj2 (money or monetary)).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">49.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">or/36-48</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">50.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">35 and 49</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">51.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">angiography/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">52.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">angiocardiography/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">53.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">coronary angiography/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">54.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Angiograph*.ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">55.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Arteriograph*.ti.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">56.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Angiocardiograph*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">57.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Coronary Angiograph*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">58.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Angiogram*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">59.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cardioangiograph*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">60.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Angiocardiogram.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">61.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Angio Cardiograph*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">62.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Coronary Arteriogra*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">63.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Coronarograph*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">64.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">*heart muscle revascularization/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">65.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">transluminal coronary angioplasty/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">66.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(Myocardial adj revasculari?ation).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">67.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PCI.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">68.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Percutaneous coronary intervention.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">69.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Percutaneous Transluminal Coronary Angioplasty.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">70.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PTCA.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">71.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">*angioplasty/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">72.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Blunt microdissection.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">73.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((laser or patch) adj angioplasty).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">74.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Percutaneous Transluminal Angioplasty.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">75.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Transluminal Coronary Angioplasty.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">76.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(Balloon adj3 coronary).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">77.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(Balloon adj3 angioplasty).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">78.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp STENTS/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">79.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">stent*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">80.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Or/51-79</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">81.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">acetylsalicylic acid/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">82.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(aspirin or acetylsalicylic acid).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">83.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(clopidogrel or plavix).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">84.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(ticagrelor or brilique).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">85.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(prasugrel or efient or effient or prasita).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">86.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">prasugrel/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">87.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">antithrombocytic agent/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">88.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(Glycoproteins IIb-IIIa or GPIIb-IIIa Receptors or Integrin alpha-IIb beta-3 or Integrin alphaIIbbeta3 or GPIIB IIIA).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">89.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp fibrinogen receptor/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">90.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(Abciximab or Reopro or Eptifibatide or Integrelin or Integrilin or Intrifiban or Tirofiban or Aggrastat).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">91.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">abciximab/ or eptifibatide/ or tirofiban/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">92.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">exp beta adrenergic receptor blocking agent/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">93.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(propranolol or angilol or inderal-la or half-inderal or inderal or bedranol or prograne or slo-pro or acebutolol or sectral or atenolol or tenormin or bisoprolol or cardicor or emcor or carvedilol or eucardic or celiprolol or celectol or co-tenidone or tenoret or tenoretic or esmolol or brevibloc or labetalol or trandate or metoprolol or betaloc or lopresor or nadolol or corgard or nebivolol or nebilet or hypoloc or oxprenolol or trasicor or slow-trasicor or pindolol or visken or sotalol or beta-cardone or sotacor or timolol or betim).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">94.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">propranolol/ or acebutolol/ or atenolol/ or bisoprolol/ or bisoprolol fumarate/ or carvedilol/ or celiprolol/ or esmolol/ or labetalol/ or metoprolol/ or nadolol/ or nebivolol/ or oxprenolol/ or pindolol/ or sotalol/ or timolol/ or timolol maleate/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">95.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(beta adj3 block*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">96.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(b adj3 block*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">97.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(beta adj2 antagonist*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">98.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">antithrombin/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">99.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Antithrombin*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">100.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(thrombin adj3 inhibitor*).ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">101.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">hirudin derivative/</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">102.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hirudin*.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">103.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hirulog.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">104.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Bivalirudin.ti,ab.</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">105.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Or/81-104</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">106.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">50 and (80 or 105)</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng185er6appbtab8"><div id="niceng185er6.appb.tab8" class="table"><h3><span class="title">NHS EED and HTA (CRD) search terms</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565358/table/niceng185er6.appb.tab8/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er6.appb.tab8_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#1.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH DESCRIPTOR Acute Coronary Syndrome</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#2.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR angina pectoris)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#3.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR Angina, Unstable)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#4.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR Coronary Thrombosis)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#5.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH DESCRIPTOR Myocardial Infarction EXPLODE ALL TREES</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#6.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#1 OR #2 OR #3 OR #4 OR #5</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#7.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR Heart Arrest)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#8.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((acute coronary adj2 syndrome*))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#9.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(((myocardial or heart) adj infarct*))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#10.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((heart adj (attack* or event*)))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#11.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(((heart or cardiac) adj arrest*))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#12.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((coronary adj2 thrombos*))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#13.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((stemi or st-segment or st segment or st-elevation or st elevation))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#14.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(“non-ST-segment elevation”)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#15.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((non-STEMI or NSTEMI or nonSTEMI))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#16.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(“Q wave myocardial infarction”)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#17.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(“non Q wave MI”)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#18.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(NSTE-ACS)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#19.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(STE-ACS)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#20.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(((subendocardial adj3 infarct*)))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#21.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((((unstable or variant) adj2 angina*)))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#22.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(((unstable adj2 coronary)))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#23.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(#6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#24.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR Angiography)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#25.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR Angiocardiography)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#26.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((MeSH DESCRIPTOR Coronary Angiography))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#27.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((Angiograph*))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#28.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((Arteriograph*))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#29.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((Angiocardiograph*))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#30.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((Coronary Angiograph*))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#31.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((Angiogram*))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#32.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((Cardioangiograph*))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#33.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((Angiocardiogram))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#34.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((Angio Cardiograph*))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#35.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((Coronary Arteriogra*))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#36.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((Coronarograph*))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#37.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR Myocardial Revascularization)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#38.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR Angioplasty, Balloon, Coronary)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#39.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(((Myocardial adj revasculari?ation)))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#40.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((PCI))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#41.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((Percutaneous coronary intervention))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#42.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((Percutaneous Transluminal Coronary Angioplasty))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#43.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((PTCA))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#44.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR Angioplasty EXPLODE ALL TREES)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#45.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((Blunt microdissection))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#46.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((((laser or patch) adj angioplasty)))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#47.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((Percutaneous Transluminal Angioplasty))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#48.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((Transluminal Coronary Angioplasty))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#49.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(((Balloon adj3 coronary)))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#50.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((Balloon adj3 angioplasty))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#51.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR Stents EXPLODE ALL TREES)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#52.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((stent*))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#53.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(#24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#54.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR Aspirin)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#55.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((aspirin or acetylsalicylic acid))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#56.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((clopidogrel or plavix))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#57.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((ticagrelor or brilique))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#58.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((prasugrel or efient or effient or prasita))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#59.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH DESCRIPTOR Prasugrel Hydrochloride</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#60.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH DESCRIPTOR Platelet Aggregation Inhibitors</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#61.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((Glycoproteins IIb-IIIa or GPIIb-IIIa Receptors or Integrin alpha-IIb beta-3 or Integrin alphaIIbbeta3 or GPIIB IIIA))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#62.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH DESCRIPTOR Platelet Glycoprotein GPIIb-IIIa Complex EXPLODE ALL TREES</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#63.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH DESCRIPTOR Receptors, Fibrinogen EXPLODE ALL TREES</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#64.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((Abciximab or Reopro or Eptifibatide or Integrelin or Integrilin or Intrifiban or Tirofiban or Aggrastat))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#65.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH DESCRIPTOR Adrenergic beta-Antagonists EXPLODE ALL TREES</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#66.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((propranolol or angilol or inderal-la or half-inderal or inderal or bedranol or prograne or slo-pro or acebutolol or sectral or atenolol or tenormin or bisoprolol or cardicor or emcor or carvedilol or eucardic or celiprolol or celectol or co-tenidone or tenoret or tenoretic or esmolol or brevibloc or labetalol or trandate or metoprolol or betaloc or lopresor or nadolol or corgard or nebivolol or nebilet or hypoloc or oxprenolol or trasicor or slow-trasicor or pindolol or visken or sotalol or beta-cardone or sotacor or timolol or betim))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#67.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR propranolol)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#68.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR acebutolol)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#69.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR atenolol)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#70.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR bisoprolol)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#71.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR celiprolol)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#72.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR labetalol)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#73.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR metoprolol)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#74.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR nadolol)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#75.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR nebivolol)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#76.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR oxprenolol)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#77.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR pindolol)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#78.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR sotalol)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#79.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(MeSH DESCRIPTOR timolol)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#80.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((beta adj3 block*))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#81.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((b adj3 block*))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#82.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((beta adj2 antagonist*))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#83.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH DESCRIPTOR Antithrombins</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#84.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(Antithrombin*)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#85.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">((thrombin adj3 inhibitor*))</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#86.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MeSH DESCRIPTOR Hirudins</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#87.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(Hirudin*)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#88.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(Hirulog)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#89.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(Bivalirudin)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#90.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#54 OR #55 OR #56 OR #57 OR #58 OR #59 OR #60 OR #61 OR #62 OR #63 OR #64 OR #65 OR #66 OR #67 OR #68 OR #69 OR #70 OR #71 OR #72 OR #73 OR #74 OR #75 OR #76 OR #77 OR #78 OR #79 OR #80 OR #81 OR #82 OR #83 OR #84 OR #85 OR #86 OR #87 OR #88 OR #89</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">#91.</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">(#23 AND (#53 OR #90))</td></tr></tbody></table></div></div></article><article data-type="fig" id="figobniceng185er6appcfig1"><div id="niceng185er6.appc.fig1" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%201.%20Flow%20chart%20of%20clinical%20study%20selection%20for%20the%20review%20of%20drug-eluting%20stents%20in%20adults%20with%20acute%20coronary%20syndromes%2C%20including%20those%20with%20unstable%20angina%20or%20NSTEMI%20undergoing%20percutaneous%20coronary%20intervention%20and%20those%20with%20STEMI%20undergoing%20primary%20percutaneous%20coronary%20intervention.&p=BOOKS&id=565358_niceng185er6appcf1.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565358/bin/niceng185er6appcf1.jpg" alt="Figure 1. Flow chart of clinical study selection for the review of drug-eluting stents in adults with acute coronary syndromes, including those with unstable angina or NSTEMI undergoing percutaneous coronary intervention and those with STEMI undergoing primary percutaneous coronary intervention." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 1</span><span class="title">Flow chart of clinical study selection for the review of drug-eluting stents in adults with acute coronary syndromes, including those with unstable angina or NSTEMI undergoing percutaneous coronary intervention and those with STEMI undergoing primary percutaneous coronary intervention</span></h3></div></article><article data-type="fig" id="figobniceng185er6appefig1"><div id="niceng185er6.appe.fig1" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%202.%20All-cause%20mortality%20(%022641%20year).&p=BOOKS&id=565358_niceng185er6appef1.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565358/bin/niceng185er6appef1.jpg" alt="Figure 2. All-cause mortality (≤1 year)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 2</span><span class="title">All-cause mortality (≤1 year)</span></h3></div></article><article data-type="fig" id="figobniceng185er6appefig2"><div id="niceng185er6.appe.fig2" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%203.%20All-cause%20mortality%20(%3E1-3%20years).&p=BOOKS&id=565358_niceng185er6appef2.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565358/bin/niceng185er6appef2.jpg" alt="Figure 3. All-cause mortality (>1-3 years)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 3</span><span class="title">All-cause mortality (>1-3 years)</span></h3></div></article><article data-type="fig" id="figobniceng185er6appefig3"><div id="niceng185er6.appe.fig3" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%204.%20Cardiac%20mortality%20(%022641%20year).&p=BOOKS&id=565358_niceng185er6appef3.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565358/bin/niceng185er6appef3.jpg" alt="Figure 4. Cardiac mortality (≤1 year)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 4</span><span class="title">Cardiac mortality (≤1 year)</span></h3></div></article><article data-type="fig" id="figobniceng185er6appefig4"><div id="niceng185er6.appe.fig4" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%205.%20Cardiac%20mortality%20(%3E1-3%20years).&p=BOOKS&id=565358_niceng185er6appef4.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565358/bin/niceng185er6appef4.jpg" alt="Figure 5. Cardiac mortality (>1-3 years)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 5</span><span class="title">Cardiac mortality (>1-3 years)</span></h3></div></article><article data-type="fig" id="figobniceng185er6appefig5"><div id="niceng185er6.appe.fig5" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%206.%20Target%20vessel%20failure%20(%022641%20year).&p=BOOKS&id=565358_niceng185er6appef5.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565358/bin/niceng185er6appef5.jpg" alt="Figure 6. Target vessel failure (≤1 year)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 6</span><span class="title">Target vessel failure (≤1 year)</span></h3></div></article><article data-type="fig" id="figobniceng185er6appefig6"><div id="niceng185er6.appe.fig6" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%207.%20Target%20vessel%20failure%20(%3E1-3%20years).&p=BOOKS&id=565358_niceng185er6appef6.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565358/bin/niceng185er6appef6.jpg" alt="Figure 7. Target vessel failure (>1-3 years)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 7</span><span class="title">Target vessel failure (>1-3 years)</span></h3></div></article><article data-type="fig" id="figobniceng185er6appefig7"><div id="niceng185er6.appe.fig7" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%208.%20Target%20vessel%20revascularisation%20(%022641%20year).&p=BOOKS&id=565358_niceng185er6appef7.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565358/bin/niceng185er6appef7.jpg" alt="Figure 8. Target vessel revascularisation (≤1 year)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 8</span><span class="title">Target vessel revascularisation (≤1 year)</span></h3><div class="caption"><p>Di Lorenzo - data is TLR</p><p>Laarman 2006 - data is TLR</p><p>Bonna - data is TLR</p><p>Strozzi - data is TLR</p></div></div></article><article data-type="fig" id="figobniceng185er6appefig8"><div id="niceng185er6.appe.fig8" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%209.%20Target%20vessel%20revascularisation%20(%3E1-3%20years).&p=BOOKS&id=565358_niceng185er6appef8.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565358/bin/niceng185er6appef8.jpg" alt="Figure 9. Target vessel revascularisation (>1-3 years)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 9</span><span class="title">Target vessel revascularisation (>1-3 years)</span></h3><div class="caption"><p>Di Lorenzo - data is TLR</p><p>Laarman 2006 - data is TLR</p></div></div></article><article data-type="fig" id="figobniceng185er6appefig9"><div id="niceng185er6.appe.fig9" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2010.%20Stent%20thrombosis%20%02013%20definite%20or%20probable%20(%022641%20year).&p=BOOKS&id=565358_niceng185er6appef9.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565358/bin/niceng185er6appef9.jpg" alt="Figure 10. Stent thrombosis – definite or probable (≤1 year)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 10</span><span class="title">Stent thrombosis – definite or probable (≤1 year)</span></h3></div></article><article data-type="fig" id="figobniceng185er6appefig10"><div id="niceng185er6.appe.fig10" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2011.%20Stent%20thrombosis%20%02013%20definite%20or%20probable%20(%3E1-3%20years).&p=BOOKS&id=565358_niceng185er6appef10.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565358/bin/niceng185er6appef10.jpg" alt="Figure 11. Stent thrombosis – definite or probable (>1-3 years)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 11</span><span class="title">Stent thrombosis – definite or probable (>1-3 years)</span></h3></div></article><article data-type="fig" id="figobniceng185er6appefig11"><div id="niceng185er6.appe.fig11" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2012.%20Myocardial%20infarction%20(%022641%20year).&p=BOOKS&id=565358_niceng185er6appef11.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565358/bin/niceng185er6appef11.jpg" alt="Figure 12. Myocardial infarction (≤1 year)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 12</span><span class="title">Myocardial infarction (≤1 year)</span></h3></div></article><article data-type="fig" id="figobniceng185er6appefig12"><div id="niceng185er6.appe.fig12" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2013.%20Myocardial%20infarction%20(%3E1-3%20years).&p=BOOKS&id=565358_niceng185er6appef12.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565358/bin/niceng185er6appef12.jpg" alt="Figure 13. Myocardial infarction (>1-3 years)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 13</span><span class="title">Myocardial infarction (>1-3 years)</span></h3></div></article><article data-type="fig" id="figobniceng185er6appefig13"><div id="niceng185er6.appe.fig13" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2014.%20Bleeding(%022641%20year).&p=BOOKS&id=565358_niceng185er6appef13.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565358/bin/niceng185er6appef13.jpg" alt="Figure 14. Bleeding(≤1 year)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 14</span><span class="title">Bleeding(≤1 year)</span></h3></div></article><article data-type="fig" id="figobniceng185er6appefig14"><div id="niceng185er6.appe.fig14" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2015.%20Bleeding%20(major)%20(%3E1-3%20years).&p=BOOKS&id=565358_niceng185er6appef14.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565358/bin/niceng185er6appef14.jpg" alt="Figure 15. Bleeding (major) (>1-3 years)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 15</span><span class="title">Bleeding (major) (>1-3 years)</span></h3></div></article><article data-type="fig" id="figobniceng185er6appefig15"><div id="niceng185er6.appe.fig15" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2016.%20Bleeding%20(minor)%20(%3E1-3%20years).&p=BOOKS&id=565358_niceng185er6appef15.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565358/bin/niceng185er6appef15.jpg" alt="Figure 16. Bleeding (minor) (>1-3 years)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 16</span><span class="title">Bleeding (minor) (>1-3 years)</span></h3></div></article><article data-type="fig" id="figobniceng185er6appefig16"><div id="niceng185er6.appe.fig16" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2017.%20Minimal%20luminal%20diameter%20(%022641%20year).&p=BOOKS&id=565358_niceng185er6appef16.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565358/bin/niceng185er6appef16.jpg" alt="Figure 17. Minimal luminal diameter (≤1 year)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 17</span><span class="title">Minimal luminal diameter (≤1 year)</span></h3></div></article><article data-type="fig" id="figobniceng185er6appefig17"><div id="niceng185er6.appe.fig17" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2018.%20Minimal%20luminal%20diameter%20%02013%20unspecified%20(%022641%20year).&p=BOOKS&id=565358_niceng185er6appef17.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565358/bin/niceng185er6appef17.jpg" alt="Figure 18. Minimal luminal diameter – unspecified (≤1 year)." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 18</span><span class="title">Minimal luminal diameter – unspecified (≤1 year)</span></h3></div></article><article data-type="table-wrap" id="figobniceng185er6appetab1"><div id="niceng185er6.appe.tab1" class="table"><h3><span class="label">Table 15</span><span class="title">Minimal important difference: DES versus BMS</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565358/table/niceng185er6.appe.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er6.appe.tab1_lrgtbl__"><table><thead><tr><th id="hd_h_niceng185er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Outcomes</th><th id="hd_h_niceng185er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Minimal important difference (MID)</th></tr></thead><tbody><tr><td headers="hd_h_niceng185er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Minimal luminal diameter (≤1 year) (in-segment)</td><td headers="hd_h_niceng185er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.35</td></tr><tr><td headers="hd_h_niceng185er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Minimal luminal diameter (≤1 year) (in-stent)</td><td headers="hd_h_niceng185er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.40</td></tr><tr><td headers="hd_h_niceng185er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Minimal luminal diameter (≤1 year) (in-lesion)</td><td headers="hd_h_niceng185er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.35</td></tr><tr><td headers="hd_h_niceng185er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Minimal luminal diameter (≤1 year) (proximal edge)</td><td headers="hd_h_niceng185er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.33</td></tr><tr><td headers="hd_h_niceng185er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Minimal luminal diameter (≤1 year) (distal edge)</td><td headers="hd_h_niceng185er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.36</td></tr><tr><td headers="hd_h_niceng185er6.appe.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Minimal luminal diameter - unspecified (≤1 year)</td><td headers="hd_h_niceng185er6.appe.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">0.33</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng185er6appftab1"><div id="niceng185er6.appf.tab1" class="table"><h3><span class="label">Table 16</span><span class="title">Clinical evidence profile: Drug eluting stents (DES) versus bare metal stents (BMS)</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565358/table/niceng185er6.appf.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er6.appf.tab1_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng185er6.appf.tab1_1_1_1_1" colspan="7" rowspan="1" style="text-align:center;vertical-align:middle;">Quality assessment</th><th id="hd_h_niceng185er6.appf.tab1_1_1_1_2" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">No of patients</th><th id="hd_h_niceng185er6.appf.tab1_1_1_1_3" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">Effect</th><th id="hd_h_niceng185er6.appf.tab1_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng185er6.appf.tab1_1_1_1_4" style="text-align:center;vertical-align:middle;">Quality</th><th id="hd_h_niceng185er6.appf.tab1_1_1_1_5" rowspan="2" colspan="1" headers="hd_h_niceng185er6.appf.tab1_1_1_1_5" style="text-align:center;vertical-align:middle;">Importance</th></tr><tr><th headers="hd_h_niceng185er6.appf.tab1_1_1_1_1" id="hd_h_niceng185er6.appf.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">No of studies</th><th headers="hd_h_niceng185er6.appf.tab1_1_1_1_1" id="hd_h_niceng185er6.appf.tab1_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Design</th><th headers="hd_h_niceng185er6.appf.tab1_1_1_1_1" id="hd_h_niceng185er6.appf.tab1_1_1_2_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk of bias</th><th headers="hd_h_niceng185er6.appf.tab1_1_1_1_1" id="hd_h_niceng185er6.appf.tab1_1_1_2_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Inconsistency</th><th headers="hd_h_niceng185er6.appf.tab1_1_1_1_1" id="hd_h_niceng185er6.appf.tab1_1_1_2_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Indirectness</th><th headers="hd_h_niceng185er6.appf.tab1_1_1_1_1" id="hd_h_niceng185er6.appf.tab1_1_1_2_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Imprecision</th><th headers="hd_h_niceng185er6.appf.tab1_1_1_1_1" id="hd_h_niceng185er6.appf.tab1_1_1_2_7" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Other considerations</th><th headers="hd_h_niceng185er6.appf.tab1_1_1_1_2" id="hd_h_niceng185er6.appf.tab1_1_1_2_8" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">DES</th><th headers="hd_h_niceng185er6.appf.tab1_1_1_1_2" id="hd_h_niceng185er6.appf.tab1_1_1_2_9" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">BMS</th><th headers="hd_h_niceng185er6.appf.tab1_1_1_1_3" id="hd_h_niceng185er6.appf.tab1_1_1_2_10" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Relative (95% CI)</th><th headers="hd_h_niceng185er6.appf.tab1_1_1_1_3" id="hd_h_niceng185er6.appf.tab1_1_1_2_11" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Absolute</th></tr></thead><tbody><tr><th headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_h_niceng185er6.appf.tab1_1_1_1_5" id="hd_b_niceng185er6.appf.tab1_1_1_1_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">All-cause mortality (follow-up up to1 year)</th></tr><tr><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_b_niceng185er6.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">22</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_b_niceng185er6.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_b_niceng185er6.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_b_niceng185er6.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_b_niceng185er6.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_b_niceng185er6.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>3</sup></td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_b_niceng185er6.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_b_niceng185er6.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>349/7800</p>
|
|
<p>(4.5%)</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_b_niceng185er6.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>309/6249</p>
|
|
<p>(4.9%)</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_b_niceng185er6.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">see comment<sup>5</sup></td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_b_niceng185er6.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2 fewer per 1000 (from 9 fewer to 5 more)</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_b_niceng185er6.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁◯◯</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_5 hd_b_niceng185er6.appf.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_h_niceng185er6.appf.tab1_1_1_1_5" id="hd_b_niceng185er6.appf.tab1_1_1_3_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">All-cause mortality (follow-up 1-3 years)</th></tr><tr><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_b_niceng185er6.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_b_niceng185er6.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_b_niceng185er6.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_b_niceng185er6.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_b_niceng185er6.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_b_niceng185er6.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_b_niceng185er6.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_b_niceng185er6.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>386/8032</p>
|
|
<p>(4.8%)</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_b_niceng185er6.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>284/4967</p>
|
|
<p>(5.7%)</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_b_niceng185er6.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.87 (0.75 to 1.01)</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_b_niceng185er6.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">7 fewer per 1000 (from 14 fewer to 1 more)</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_b_niceng185er6.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁◯◯</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_5 hd_b_niceng185er6.appf.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_h_niceng185er6.appf.tab1_1_1_1_5" id="hd_b_niceng185er6.appf.tab1_1_1_5_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Cardiac mortality (follow-up up to 1 year)</th></tr><tr><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_b_niceng185er6.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_b_niceng185er6.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_b_niceng185er6.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_b_niceng185er6.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_b_niceng185er6.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_b_niceng185er6.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_b_niceng185er6.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_b_niceng185er6.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>242/6786</p>
|
|
<p>(3.6%)</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_b_niceng185er6.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>210/5331</p>
|
|
<p>(3.9%)</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_b_niceng185er6.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.98 (0.82 to 1.17)</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_b_niceng185er6.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1 fewer per 1000 (from 7 fewer to 7 more)</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_b_niceng185er6.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁⨁◯</p>
|
|
<p>MODERATE</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_5 hd_b_niceng185er6.appf.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_h_niceng185er6.appf.tab1_1_1_1_5" id="hd_b_niceng185er6.appf.tab1_1_1_7_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Cardiac mortality (follow-up 1-3 years)</th></tr><tr><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_b_niceng185er6.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_b_niceng185er6.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_b_niceng185er6.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_b_niceng185er6.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_b_niceng185er6.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_b_niceng185er6.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_b_niceng185er6.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_b_niceng185er6.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>222/7695</p>
|
|
<p>(2.9%)</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_b_niceng185er6.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>176/4721</p>
|
|
<p>(3.7%)</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_b_niceng185er6.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.85 (0.70 to 1.03)</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_b_niceng185er6.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">6 fewer per 1000 (from 11 fewer to 1 more)</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_b_niceng185er6.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁◯◯</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_5 hd_b_niceng185er6.appf.tab1_1_1_7_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_h_niceng185er6.appf.tab1_1_1_1_5" id="hd_b_niceng185er6.appf.tab1_1_1_9_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Target vessel failure (follow-up up to 1 year)</th></tr><tr><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_b_niceng185er6.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_b_niceng185er6.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_b_niceng185er6.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_b_niceng185er6.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>4</sup></td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_b_niceng185er6.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_b_niceng185er6.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_b_niceng185er6.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_b_niceng185er6.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>108/1016</p>
|
|
<p>(10.6%)</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_b_niceng185er6.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>168/1025</p>
|
|
<p>(16.4%)</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_b_niceng185er6.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.62 (0.44 to 0.88)</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_b_niceng185er6.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">62 fewer per 1000 (from 20 fewer to 92 fewer)</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_b_niceng185er6.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_5 hd_b_niceng185er6.appf.tab1_1_1_9_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_h_niceng185er6.appf.tab1_1_1_1_5" id="hd_b_niceng185er6.appf.tab1_1_1_11_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Target vessel failure (follow-up 1-3 years)</th></tr><tr><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_b_niceng185er6.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_b_niceng185er6.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_b_niceng185er6.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_b_niceng185er6.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_b_niceng185er6.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_b_niceng185er6.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_b_niceng185er6.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_b_niceng185er6.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>51/356</p>
|
|
<p>(14.3%)</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_b_niceng185er6.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>90/347</p>
|
|
<p>(25.9%)</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_b_niceng185er6.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.55 (0.41 to 0.74)</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_b_niceng185er6.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">117 fewer per 1000 (from 67 fewer to 153 fewer)</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_b_niceng185er6.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁⨁◯</p>
|
|
<p>MODERATE</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_5 hd_b_niceng185er6.appf.tab1_1_1_11_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_h_niceng185er6.appf.tab1_1_1_1_5" id="hd_b_niceng185er6.appf.tab1_1_1_13_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Target vessel revascularisation (follow-up up to 1 year)</th></tr><tr><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_b_niceng185er6.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_b_niceng185er6.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_b_niceng185er6.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_b_niceng185er6.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_b_niceng185er6.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_b_niceng185er6.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_b_niceng185er6.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_b_niceng185er6.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>378/7205</p>
|
|
<p>(5.2%)</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_b_niceng185er6.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>565/5653</p>
|
|
<p>(10%)</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_b_niceng185er6.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.52 (0.46 to 0.59)</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_b_niceng185er6.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">48 fewer per 1000 (from 41 fewer to 54 fewer)</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_b_niceng185er6.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁⨁◯</p>
|
|
<p>MODERATE</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_5 hd_b_niceng185er6.appf.tab1_1_1_13_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_h_niceng185er6.appf.tab1_1_1_1_5" id="hd_b_niceng185er6.appf.tab1_1_1_15_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Target vessel revascularisation (follow-up 1-3 years)</th></tr><tr><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_b_niceng185er6.appf.tab1_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">13</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_b_niceng185er6.appf.tab1_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_b_niceng185er6.appf.tab1_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_b_niceng185er6.appf.tab1_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_b_niceng185er6.appf.tab1_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_b_niceng185er6.appf.tab1_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_b_niceng185er6.appf.tab1_1_1_15_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_b_niceng185er6.appf.tab1_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>703/9602</p>
|
|
<p>(7.3%)</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_b_niceng185er6.appf.tab1_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>713/5539</p>
|
|
<p>(12.9%)</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_b_niceng185er6.appf.tab1_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.52 (0.47 to 0.57)</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_b_niceng185er6.appf.tab1_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">62 fewer per 1000 (from 55 fewer to 68 fewer)</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_b_niceng185er6.appf.tab1_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁⨁◯</p>
|
|
<p>MODERATE</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_5 hd_b_niceng185er6.appf.tab1_1_1_15_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_h_niceng185er6.appf.tab1_1_1_1_5" id="hd_b_niceng185er6.appf.tab1_1_1_17_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Stent thrombosis – Definite or probable (follow-up up to 1 year)</th></tr><tr><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_b_niceng185er6.appf.tab1_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_b_niceng185er6.appf.tab1_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_b_niceng185er6.appf.tab1_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_b_niceng185er6.appf.tab1_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_b_niceng185er6.appf.tab1_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_b_niceng185er6.appf.tab1_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_b_niceng185er6.appf.tab1_1_1_17_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_b_niceng185er6.appf.tab1_1_1_17_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>163/6466</p>
|
|
<p>(2.5%)</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_b_niceng185er6.appf.tab1_1_1_17_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>168/4939</p>
|
|
<p>(3.4%)</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_b_niceng185er6.appf.tab1_1_1_17_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.71 (0.57 to 0.89)</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_b_niceng185er6.appf.tab1_1_1_17_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">10 fewer per 1000 (from 4 fewer to 15 fewer)</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_b_niceng185er6.appf.tab1_1_1_17_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁◯◯</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_5 hd_b_niceng185er6.appf.tab1_1_1_17_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_h_niceng185er6.appf.tab1_1_1_1_5" id="hd_b_niceng185er6.appf.tab1_1_1_19_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Stent thrombosis - Definite or probable (follow-up 1-3 years)</th></tr><tr><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_b_niceng185er6.appf.tab1_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_b_niceng185er6.appf.tab1_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_b_niceng185er6.appf.tab1_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_b_niceng185er6.appf.tab1_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_b_niceng185er6.appf.tab1_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_b_niceng185er6.appf.tab1_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_b_niceng185er6.appf.tab1_1_1_19_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_b_niceng185er6.appf.tab1_1_1_19_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>218/9228</p>
|
|
<p>(2.4%)</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_b_niceng185er6.appf.tab1_1_1_19_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>147/5162</p>
|
|
<p>(2.8%)</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_b_niceng185er6.appf.tab1_1_1_19_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.80 (0.64 to 0.99)</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_b_niceng185er6.appf.tab1_1_1_19_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">6 fewer per 1000 (from 0 fewer to 10 fewer)</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_b_niceng185er6.appf.tab1_1_1_19_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁◯◯</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_5 hd_b_niceng185er6.appf.tab1_1_1_19_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_h_niceng185er6.appf.tab1_1_1_1_5" id="hd_b_niceng185er6.appf.tab1_1_1_21_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Myocardial infarction (follow-up up to 1 year)</th></tr><tr><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_b_niceng185er6.appf.tab1_1_1_21_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_b_niceng185er6.appf.tab1_1_1_21_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_b_niceng185er6.appf.tab1_1_1_21_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_b_niceng185er6.appf.tab1_1_1_21_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_b_niceng185er6.appf.tab1_1_1_21_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_b_niceng185er6.appf.tab1_1_1_21_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_b_niceng185er6.appf.tab1_1_1_21_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_b_niceng185er6.appf.tab1_1_1_21_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>148/5438</p>
|
|
<p>(2.7%)</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_b_niceng185er6.appf.tab1_1_1_21_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>244/5342</p>
|
|
<p>(4.6%)</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_b_niceng185er6.appf.tab1_1_1_21_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">see comment<sup>5</sup></td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_b_niceng185er6.appf.tab1_1_1_21_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">18 fewer per 1000 (from 12 fewer to 23 fewer)</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_b_niceng185er6.appf.tab1_1_1_21_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁⨁◯</p>
|
|
<p>MODERATE</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_5 hd_b_niceng185er6.appf.tab1_1_1_21_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_h_niceng185er6.appf.tab1_1_1_1_5" id="hd_b_niceng185er6.appf.tab1_1_1_23_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Myocardial infarction (follow-up 1-3 years)</th></tr><tr><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_b_niceng185er6.appf.tab1_1_1_23_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">10</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_b_niceng185er6.appf.tab1_1_1_23_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_b_niceng185er6.appf.tab1_1_1_23_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_b_niceng185er6.appf.tab1_1_1_23_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_b_niceng185er6.appf.tab1_1_1_23_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_b_niceng185er6.appf.tab1_1_1_23_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_b_niceng185er6.appf.tab1_1_1_23_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_b_niceng185er6.appf.tab1_1_1_23_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>143/5552</p>
|
|
<p>(2.6%)</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_b_niceng185er6.appf.tab1_1_1_23_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>161/3904</p>
|
|
<p>(4.1%)</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_b_niceng185er6.appf.tab1_1_1_23_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.66 (0.53 to 0.83)</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_b_niceng185er6.appf.tab1_1_1_23_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">14 fewer per 1000 (from 7 fewer to 19 fewer)</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_b_niceng185er6.appf.tab1_1_1_23_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁◯◯</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_5 hd_b_niceng185er6.appf.tab1_1_1_23_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_h_niceng185er6.appf.tab1_1_1_1_5" id="hd_b_niceng185er6.appf.tab1_1_1_25_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Bleeding - Unspecified (follow-up up to 1 year)</th></tr><tr><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_b_niceng185er6.appf.tab1_1_1_25_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_b_niceng185er6.appf.tab1_1_1_25_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_b_niceng185er6.appf.tab1_1_1_25_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_b_niceng185er6.appf.tab1_1_1_25_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_b_niceng185er6.appf.tab1_1_1_25_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_b_niceng185er6.appf.tab1_1_1_25_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>2</sup></td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_b_niceng185er6.appf.tab1_1_1_25_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_b_niceng185er6.appf.tab1_1_1_25_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>18/716</p>
|
|
<p>(2.5%)</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_b_niceng185er6.appf.tab1_1_1_25_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>26/751</p>
|
|
<p>(3.5%)</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_b_niceng185er6.appf.tab1_1_1_25_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.73 (0.41 to 1.31)</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_b_niceng185er6.appf.tab1_1_1_25_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">9 fewer per 1000 (from 20 fewer to 11 more)</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_b_niceng185er6.appf.tab1_1_1_25_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_5 hd_b_niceng185er6.appf.tab1_1_1_25_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_h_niceng185er6.appf.tab1_1_1_1_5" id="hd_b_niceng185er6.appf.tab1_1_1_27_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Bleeding - Major (follow-up up to 1 year)</th></tr><tr><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_b_niceng185er6.appf.tab1_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_b_niceng185er6.appf.tab1_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_b_niceng185er6.appf.tab1_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_b_niceng185er6.appf.tab1_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_b_niceng185er6.appf.tab1_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_b_niceng185er6.appf.tab1_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_b_niceng185er6.appf.tab1_1_1_27_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_b_niceng185er6.appf.tab1_1_1_27_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>66/4090</p>
|
|
<p>(1.6%)</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_b_niceng185er6.appf.tab1_1_1_27_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>67/3305</p>
|
|
<p>(2%)</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_b_niceng185er6.appf.tab1_1_1_27_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.79 (0.56 to 1.11)</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_b_niceng185er6.appf.tab1_1_1_27_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4 fewer per 1000 (from 9 fewer to 2 more)</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_b_niceng185er6.appf.tab1_1_1_27_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁◯◯</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_5 hd_b_niceng185er6.appf.tab1_1_1_27_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_h_niceng185er6.appf.tab1_1_1_1_5" id="hd_b_niceng185er6.appf.tab1_1_1_29_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Bleeding - Minor (follow-up up to 1 year)</th></tr><tr><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_b_niceng185er6.appf.tab1_1_1_29_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_b_niceng185er6.appf.tab1_1_1_29_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_b_niceng185er6.appf.tab1_1_1_29_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_b_niceng185er6.appf.tab1_1_1_29_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_b_niceng185er6.appf.tab1_1_1_29_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_b_niceng185er6.appf.tab1_1_1_29_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_b_niceng185er6.appf.tab1_1_1_29_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_b_niceng185er6.appf.tab1_1_1_29_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>85/3691</p>
|
|
<p>(2.3%)</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_b_niceng185er6.appf.tab1_1_1_29_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>92/2904</p>
|
|
<p>(3.2%)</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_b_niceng185er6.appf.tab1_1_1_29_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.84 (0.63 to 1.12)</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_b_niceng185er6.appf.tab1_1_1_29_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">5 fewer per 1000 (from 12 fewer to 4 more)</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_b_niceng185er6.appf.tab1_1_1_29_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁◯◯</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_5 hd_b_niceng185er6.appf.tab1_1_1_29_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_h_niceng185er6.appf.tab1_1_1_1_5" id="hd_b_niceng185er6.appf.tab1_1_1_31_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Bleeding - Major (follow-up 1-3 years)</th></tr><tr><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_b_niceng185er6.appf.tab1_1_1_31_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_b_niceng185er6.appf.tab1_1_1_31_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_b_niceng185er6.appf.tab1_1_1_31_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_b_niceng185er6.appf.tab1_1_1_31_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>4</sup></td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_b_niceng185er6.appf.tab1_1_1_31_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_b_niceng185er6.appf.tab1_1_1_31_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>2</sup></td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_b_niceng185er6.appf.tab1_1_1_31_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_b_niceng185er6.appf.tab1_1_1_31_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>238/3652</p>
|
|
<p>(6.5%)</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_b_niceng185er6.appf.tab1_1_1_31_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>78/1452</p>
|
|
<p>(5.4%)</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_b_niceng185er6.appf.tab1_1_1_31_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.99 (0.63 to 1.57)</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_b_niceng185er6.appf.tab1_1_1_31_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1 fewer per 1000 (from 20 fewer to 31 more)</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_b_niceng185er6.appf.tab1_1_1_31_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_5 hd_b_niceng185er6.appf.tab1_1_1_31_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">CRITICAL</td></tr><tr><th headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_h_niceng185er6.appf.tab1_1_1_1_5" id="hd_b_niceng185er6.appf.tab1_1_1_33_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Bleeding - Minor (follow-up 1-3 years)</th></tr><tr><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_b_niceng185er6.appf.tab1_1_1_33_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_b_niceng185er6.appf.tab1_1_1_33_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_b_niceng185er6.appf.tab1_1_1_33_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_b_niceng185er6.appf.tab1_1_1_33_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_b_niceng185er6.appf.tab1_1_1_33_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_b_niceng185er6.appf.tab1_1_1_33_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>2</sup></td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_b_niceng185er6.appf.tab1_1_1_33_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_b_niceng185er6.appf.tab1_1_1_33_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>24/1549</p>
|
|
<p>(1.5%)</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_b_niceng185er6.appf.tab1_1_1_33_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>13/765</p>
|
|
<p>(1.7%)</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_b_niceng185er6.appf.tab1_1_1_33_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">RR 0.91 (0.47 to 1.78)</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_b_niceng185er6.appf.tab1_1_1_33_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">2 fewer per 1000 (from 9 fewer to 13 more)</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_b_niceng185er6.appf.tab1_1_1_33_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_5 hd_b_niceng185er6.appf.tab1_1_1_33_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_h_niceng185er6.appf.tab1_1_1_1_5" id="hd_b_niceng185er6.appf.tab1_1_1_35_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Minimal luminal diameter - In-segment (follow-up up to 1 year; Better indicated by lower values)</th></tr><tr><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_b_niceng185er6.appf.tab1_1_1_35_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_b_niceng185er6.appf.tab1_1_1_35_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_b_niceng185er6.appf.tab1_1_1_35_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_b_niceng185er6.appf.tab1_1_1_35_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_b_niceng185er6.appf.tab1_1_1_35_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_b_niceng185er6.appf.tab1_1_1_35_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_b_niceng185er6.appf.tab1_1_1_35_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_b_niceng185er6.appf.tab1_1_1_35_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">177</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_b_niceng185er6.appf.tab1_1_1_35_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">169</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_b_niceng185er6.appf.tab1_1_1_35_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_b_niceng185er6.appf.tab1_1_1_35_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 0.53 higher (0.4 to 0.65 higher)</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_b_niceng185er6.appf.tab1_1_1_35_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁⨁◯</p>
|
|
<p>MODERATE</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_5 hd_b_niceng185er6.appf.tab1_1_1_35_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_h_niceng185er6.appf.tab1_1_1_1_5" id="hd_b_niceng185er6.appf.tab1_1_1_37_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Minimal luminal diameter - In-stent (follow-up up to 1 year; Better indicated by lower values)</th></tr><tr><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_b_niceng185er6.appf.tab1_1_1_37_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_b_niceng185er6.appf.tab1_1_1_37_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_b_niceng185er6.appf.tab1_1_1_37_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_b_niceng185er6.appf.tab1_1_1_37_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_b_niceng185er6.appf.tab1_1_1_37_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_b_niceng185er6.appf.tab1_1_1_37_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious imprecision</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_b_niceng185er6.appf.tab1_1_1_37_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_b_niceng185er6.appf.tab1_1_1_37_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">554</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_b_niceng185er6.appf.tab1_1_1_37_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">549</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_b_niceng185er6.appf.tab1_1_1_37_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_b_niceng185er6.appf.tab1_1_1_37_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 0.68 higher (0.6 to 0.77 higher)</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_b_niceng185er6.appf.tab1_1_1_37_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁⨁◯</p>
|
|
<p>MODERATE</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_5 hd_b_niceng185er6.appf.tab1_1_1_37_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_h_niceng185er6.appf.tab1_1_1_1_5" id="hd_b_niceng185er6.appf.tab1_1_1_39_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Minimal luminal diameter - In-lesion (follow-up up to 1 year; Better indicated by lower values)</th></tr><tr><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_b_niceng185er6.appf.tab1_1_1_39_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_b_niceng185er6.appf.tab1_1_1_39_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_b_niceng185er6.appf.tab1_1_1_39_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_b_niceng185er6.appf.tab1_1_1_39_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_b_niceng185er6.appf.tab1_1_1_39_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_b_niceng185er6.appf.tab1_1_1_39_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_b_niceng185er6.appf.tab1_1_1_39_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_b_niceng185er6.appf.tab1_1_1_39_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">345</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_b_niceng185er6.appf.tab1_1_1_39_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">350</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_b_niceng185er6.appf.tab1_1_1_39_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_b_niceng185er6.appf.tab1_1_1_39_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 0.43 higher (0.32 to 0.53 higher)</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_b_niceng185er6.appf.tab1_1_1_39_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁◯◯</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_5 hd_b_niceng185er6.appf.tab1_1_1_39_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_h_niceng185er6.appf.tab1_1_1_1_5" id="hd_b_niceng185er6.appf.tab1_1_1_41_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Minimal luminal diameter - Proximal edge (follow-up up to 1 year; Better indicated by lower values)</th></tr><tr><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_b_niceng185er6.appf.tab1_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_b_niceng185er6.appf.tab1_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_b_niceng185er6.appf.tab1_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_b_niceng185er6.appf.tab1_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_b_niceng185er6.appf.tab1_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_b_niceng185er6.appf.tab1_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_b_niceng185er6.appf.tab1_1_1_41_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_b_niceng185er6.appf.tab1_1_1_41_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">19</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_b_niceng185er6.appf.tab1_1_1_41_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">18</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_b_niceng185er6.appf.tab1_1_1_41_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_b_niceng185er6.appf.tab1_1_1_41_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 0.12 lower (0.21 lower to 0.45 higher)</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_b_niceng185er6.appf.tab1_1_1_41_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁⨁◯◯</p>
|
|
<p>LOW</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_5 hd_b_niceng185er6.appf.tab1_1_1_41_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_h_niceng185er6.appf.tab1_1_1_1_5" id="hd_b_niceng185er6.appf.tab1_1_1_43_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Minimal luminal diameter - Distal edge (follow-up up to 1 year; Better indicated by lower values)</th></tr><tr><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_b_niceng185er6.appf.tab1_1_1_43_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_b_niceng185er6.appf.tab1_1_1_43_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_b_niceng185er6.appf.tab1_1_1_43_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_b_niceng185er6.appf.tab1_1_1_43_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious inconsistency</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_b_niceng185er6.appf.tab1_1_1_43_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_b_niceng185er6.appf.tab1_1_1_43_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>2</sup></td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_b_niceng185er6.appf.tab1_1_1_43_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_b_niceng185er6.appf.tab1_1_1_43_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">20</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_b_niceng185er6.appf.tab1_1_1_43_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">20</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_b_niceng185er6.appf.tab1_1_1_43_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_b_niceng185er6.appf.tab1_1_1_43_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 0.05 lower (0.39 lower to 0.29 higher)</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_b_niceng185er6.appf.tab1_1_1_43_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_5 hd_b_niceng185er6.appf.tab1_1_1_43_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr><tr><th headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_h_niceng185er6.appf.tab1_1_1_1_5" id="hd_b_niceng185er6.appf.tab1_1_1_45_1" colspan="13" rowspan="1" style="text-align:left;vertical-align:top;">Minimal luminal diameter - Unspecified (follow-up up to 1 year; Better indicated by lower values)</th></tr><tr><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_1 hd_b_niceng185er6.appf.tab1_1_1_45_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_2 hd_b_niceng185er6.appf.tab1_1_1_45_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">randomised trials</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_3 hd_b_niceng185er6.appf.tab1_1_1_45_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>1</sup></td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_4 hd_b_niceng185er6.appf.tab1_1_1_45_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">very serious<sup>4</sup></td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_5 hd_b_niceng185er6.appf.tab1_1_1_45_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">no serious indirectness</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_6 hd_b_niceng185er6.appf.tab1_1_1_45_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">serious<sup>2</sup></td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_1 hd_h_niceng185er6.appf.tab1_1_1_2_7 hd_b_niceng185er6.appf.tab1_1_1_45_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">none</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_8 hd_b_niceng185er6.appf.tab1_1_1_45_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">3369</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_2 hd_h_niceng185er6.appf.tab1_1_1_2_9 hd_b_niceng185er6.appf.tab1_1_1_45_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1904</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_10 hd_b_niceng185er6.appf.tab1_1_1_45_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">-</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_3 hd_h_niceng185er6.appf.tab1_1_1_2_11 hd_b_niceng185er6.appf.tab1_1_1_45_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">MD 0.18 higher (0.05 to 0.32 higher)</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_4 hd_b_niceng185er6.appf.tab1_1_1_45_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
|
<p>⨁◯◯◯</p>
|
|
<p>VERY LOW</p>
|
|
</td><td headers="hd_h_niceng185er6.appf.tab1_1_1_1_5 hd_b_niceng185er6.appf.tab1_1_1_45_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">IMPORTANT</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>1</dt><dd><div id="niceng185er6.appf.tab1_1"><p class="no_margin">Downgraded by 1 increment if the majority of the evidence was at high risk of bias, and downgraded by 2 increments if the majority of the evidence was at very high risk of bias</p></div></dd></dl><dl class="bkr_refwrap"><dt>2</dt><dd><div id="niceng185er6.appf.tab1_2"><p class="no_margin">Downgraded by 1 increment if the confidence interval crossed one MID or by 2 increments if the confidence interval crossed both MIDs.</p></div></dd></dl><dl class="bkr_refwrap"><dt>3</dt><dd><div id="niceng185er6.appf.tab1_3"><p class="no_margin">Imprecision was assessed by calculating the optimal information size and graded as follows: <80% - very serious imprecision, 80-90%- serious imprecision, >90%– no imprecision</p></div></dd></dl><dl class="bkr_refwrap"><dt>4</dt><dd><div id="niceng185er6.appf.tab1_4"><p class="no_margin">Downgraded by 1 or 2 increments because heterogeneity, I2= > 50%, p= > 0.04, unexplained by subgroup analysis</p></div></dd></dl><dl class="bkr_refwrap"><dt></dt><dd><div><p class="no_margin">No relative effect due to 0 events. Risk difference calculated in Review Manager</p></div></dd></dl></dl></div></div></div></article><article data-type="fig" id="figobniceng185er6appgfig1"><div id="niceng185er6.appg.fig1" class="figure bk_fig"><div class="graphic"><a href="/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Figure%2019.%20Flow%20chart%20of%20health%20economic%20study%20selection%20for%20the%20guideline.&p=BOOKS&id=565358_niceng185er6appgf1.jpg" target="tileshopwindow" class="inline_block pmc_inline_block ts_canvas img_link" title="Click on image to zoom"><div class="ts_bar small" title="Click on image to zoom"></div><img data-src="/books/NBK565358/bin/niceng185er6appgf1.jpg" alt="Figure 19. Flow chart of health economic study selection for the guideline." class="tileshop" title="Click on image to zoom" /></a></div><h3><span class="label">Figure 19</span><span class="title">Flow chart of health economic study selection for the guideline</span></h3><div class="caption"><p>* Non-relevant population, intervention, comparison, design or setting; non-English language</p><p>Review A = dual-antiplatelet therapy; Review B = early invasive investigation for UA/NSTEMI; Review C = antithrombins in UA/NSTEMI; Review D = bivalirudin in STEMI; Review E = multi-vessel PCI; Review F = drugeluting stents; Review G = combination of antiplatelets and anticoagulants; Review H = beta-blocker therapy.</p></div></div></article><article data-type="table-wrap" id="figobniceng185er6appitab1"><div id="niceng185er6.appi.tab1" class="table"><h3><span class="label">Table 17</span><span class="title">Studies excluded from the clinical review</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565358/table/niceng185er6.appi.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er6.appi.tab1_lrgtbl__"><table><thead><tr><th id="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Study</th><th id="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Exclusion reason</th></tr></thead><tbody><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ardissino 2004<a class="bibr" href="#niceng185er6.ref4" rid="niceng185er6.ref4"><sup>4</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect population (<50% ACS)</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ahmed 2012<a class="bibr" href="#niceng185er6.ref1" rid="niceng185er6.ref1"><sup>1</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect study design</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Alfonso 2008<a class="bibr" href="#niceng185er6.ref2" rid="niceng185er6.ref2"><sup>2</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect study design (pooled analysis)</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Aoki 2009<a class="bibr" href="#niceng185er6.ref3" rid="niceng185er6.ref3"><sup>3</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect comparison</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ariotti 2016<a class="bibr" href="#niceng185er6.ref5" rid="niceng185er6.ref5"><sup>5</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect study design (subgroup analysis)</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Arroyo 2014<a class="bibr" href="#niceng185er6.ref6" rid="niceng185er6.ref6"><sup>6</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Study protocol</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Belkacemi 2012<a class="bibr" href="#niceng185er6.ref11" rid="niceng185er6.ref11"><sup>11</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect intervention</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Belkacemi 2012<a class="bibr" href="#niceng185er6.ref12" rid="niceng185er6.ref12"><sup>12</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect intervention</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Bonaa 2016<a class="bibr" href="#niceng185er6.ref15" rid="niceng185er6.ref15"><sup>15</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No extractable outcome data</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Brener 2015<a class="bibr" href="#niceng185er6.ref16" rid="niceng185er6.ref16"><sup>16</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect comparison</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Brugaletta 2013<a class="bibr" href="#niceng185er6.ref23" rid="niceng185er6.ref23"><sup>23</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No extractable outcome data</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Carrier 2017<a class="bibr" href="#niceng185er6.ref25" rid="niceng185er6.ref25"><sup>25</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect study design (subgroup analysis)</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Chacko 2009<a class="bibr" href="#niceng185er6.ref26" rid="niceng185er6.ref26"><sup>26</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No relevant extractable outcome data</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Costa 2015<a class="bibr" href="#niceng185er6.ref29" rid="niceng185er6.ref29"><sup>29</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect comparison</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Crimi 2016<a class="bibr" href="#niceng185er6.ref30" rid="niceng185er6.ref30"><sup>30</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect study design (subgroup analysis)</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Darkahian 2014<a class="bibr" href="#niceng185er6.ref31" rid="niceng185er6.ref31"><sup>31</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect intervention</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Dominguez Franco 2008<a class="bibr" href="#niceng185er6.ref37" rid="niceng185er6.ref37"><sup>37</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect study design</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Dudek 2013<a class="bibr" href="#niceng185er6.ref38" rid="niceng185er6.ref38"><sup>38</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect study design (subgroup analysis)</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ellis 2009<a class="bibr" href="#niceng185er6.ref40" rid="niceng185er6.ref40"><sup>40</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No relevant extractable outcome data</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Erglis 2007<a class="bibr" href="#niceng185er6.ref41" rid="niceng185er6.ref41"><sup>41</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect population</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Garg 2011<a class="bibr" href="#niceng185er6.ref43" rid="niceng185er6.ref43"><sup>43</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect study design (subgroup analysis)</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Garot 2017<a class="bibr" href="#niceng185er6.ref44" rid="niceng185er6.ref44"><sup>44</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect population</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Holmvang 2013<a class="bibr" href="#niceng185er6.ref49" rid="niceng185er6.ref49"><sup>49</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No relevant extractable outcome data</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ielasi 2015<a class="bibr" href="#niceng185er6.ref50" rid="niceng185er6.ref50"><sup>50</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect comparison (subgroup analysis for age)</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ischinger 2006<a class="bibr" href="#niceng185er6.ref51" rid="niceng185er6.ref51"><sup>51</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No relevant extractable outcome data</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Jimenez-Quevedo, 2013<a class="bibr" href="#niceng185er6.ref53" rid="niceng185er6.ref53"><sup>53</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No relevant extractable outcome data</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Kaiser 2005<a class="bibr" href="#niceng185er6.ref54" rid="niceng185er6.ref54"><sup>54</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect population</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Kandzari 2013<a class="bibr" href="#niceng185er6.ref58" rid="niceng185er6.ref58"><sup>58</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect study design (pooled analysis)</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Kaul 2015<a class="bibr" href="#niceng185er6.ref59" rid="niceng185er6.ref59"><sup>59</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect comparison</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Kelbaek 2008<a class="bibr" href="#niceng185er6.ref60" rid="niceng185er6.ref60"><sup>60</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect population</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Kim 2010<a class="bibr" href="#niceng185er6.ref62" rid="niceng185er6.ref62"><sup>62</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect intervention</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Konig 2007<a class="bibr" href="#niceng185er6.ref63" rid="niceng185er6.ref63"><sup>63</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect intervention</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Kurz 2015<a class="bibr" href="#niceng185er6.ref64" rid="niceng185er6.ref64"><sup>64</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect study design (subgroup analysis)</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">La Manna 2011<a class="bibr" href="#niceng185er6.ref66" rid="niceng185er6.ref66"><sup>66</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect comparison</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ledwoch 2017<a class="bibr" href="#niceng185er6.ref68" rid="niceng185er6.ref68"><sup>68</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect study design</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Lemos 2012<a class="bibr" href="#niceng185er6.ref70" rid="niceng185er6.ref70"><sup>70</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect population</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Lemos 2009<a class="bibr" href="#niceng185er6.ref71" rid="niceng185er6.ref71"><sup>71</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect population</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Li 2004<a class="bibr" href="#niceng185er6.ref72" rid="niceng185er6.ref72"><sup>72</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Abstract only</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Mehilli 2011<a class="bibr" href="#niceng185er6.ref74" rid="niceng185er6.ref74"><sup>74</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect population</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Menozzi 2009<a class="bibr" href="#niceng185er6.ref77" rid="niceng185er6.ref77"><sup>77</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect population</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Morice 2017<a class="bibr" href="#niceng185er6.ref78" rid="niceng185er6.ref78"><sup>78</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect study design (subgroup analysis)</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Musto 2013<a class="bibr" href="#niceng185er6.ref79" rid="niceng185er6.ref79"><sup>79</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No relevant extractable outcome data</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Park 2013<a class="bibr" href="#niceng185er6.ref84" rid="niceng185er6.ref84"><sup>84</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Study protocol</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pedersen 2014<a class="bibr" href="#niceng185er6.ref85" rid="niceng185er6.ref85"><sup>85</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect study design (subgroup analysis)</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pitt 2007<a class="bibr" href="#niceng185er6.ref86" rid="niceng185er6.ref86"><sup>86</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Abstract only</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Raber 2016 <a class="bibr" href="#niceng185er6.ref88" rid="niceng185er6.ref88"><sup>88</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Abstract only</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Rebeiz 2009<a class="bibr" href="#niceng185er6.ref92" rid="niceng185er6.ref92"><sup>92</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No relevant extractable outcome data</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ribichini 2009<a class="bibr" href="#niceng185er6.ref97" rid="niceng185er6.ref97"><sup>97</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Study protocol</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ribichini, 2013<a class="bibr" href="#niceng185er6.ref98" rid="niceng185er6.ref98"><sup>98</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No relevant extractable outcome data</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Rodriguez 2009<a class="bibr" href="#niceng185er6.ref99" rid="niceng185er6.ref99"><sup>99</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect intervention</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Rubartelli 2010<a class="bibr" href="#niceng185er6.ref101" rid="niceng185er6.ref101"><sup>101</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect population</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Silber 2011<a class="bibr" href="#niceng185er6.ref107" rid="niceng185er6.ref107"><sup>107</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect population</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Sinning 2012<a class="bibr" href="#niceng185er6.ref108" rid="niceng185er6.ref108"><sup>108</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No relevant extractable outcome data</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Spaulding 2011<a class="bibr" href="#niceng185er6.ref110" rid="niceng185er6.ref110"><sup>110</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No relevant extractable outcome data</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Storger 2004<a class="bibr" href="#niceng185er6.ref115" rid="niceng185er6.ref115"><sup>115</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect population</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tierala 2006<a class="bibr" href="#niceng185er6.ref119" rid="niceng185er6.ref119"><sup>119</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Abstract only</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tomai 2014<a class="bibr" href="#niceng185er6.ref120" rid="niceng185er6.ref120"><sup>120</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No relevant extractable outcome data</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Van den Branden 2012<a class="bibr" href="#niceng185er6.ref127" rid="niceng185er6.ref127"><sup>127</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No relevant extractable outcome data</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Vink 2011<a class="bibr" href="#niceng185er6.ref130" rid="niceng185er6.ref130"><sup>130</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No relevant extractable outcome data</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Wiemer, 2010<a class="bibr" href="#niceng185er6.ref132" rid="niceng185er6.ref132"><sup>132</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No relevant extractable outcome data</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Wijnbergen 2014<a class="bibr" href="#niceng185er6.ref134" rid="niceng185er6.ref134"><sup>134</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No relevant extractable outcome data</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Witzenbichler 2011<a class="bibr" href="#niceng185er6.ref136" rid="niceng185er6.ref136"><sup>136</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect study design (subgroup analysis)</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Zellweger 2012<a class="bibr" href="#niceng185er6.ref139" rid="niceng185er6.ref139"><sup>139</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect comparison</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Zellweger 2008<a class="bibr" href="#niceng185er6.ref138" rid="niceng185er6.ref138"><sup>138</sup></a></td><td headers="hd_h_niceng185er6.appi.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Incorrect comparison</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng185er6appitab2"><div id="niceng185er6.appi.tab2" class="table"><h3><span class="label">Table 18</span><span class="title">Studies excluded from the health economic review</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK565358/table/niceng185er6.appi.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng185er6.appi.tab2_lrgtbl__"><table><thead><tr><th id="hd_h_niceng185er6.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Reference</th><th id="hd_h_niceng185er6.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Reason for exclusion</th></tr></thead><tbody><tr><td headers="hd_h_niceng185er6.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Bagust 2006<a class="bibr" href="#niceng185er6.ref8" rid="niceng185er6.ref8"><sup>8</sup></a></td><td headers="hd_h_niceng185er6.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">This study was assessed as partially applicable with potentially serious limitations. However, a more applicable UK analysis<a class="bibr" href="#niceng185er6.ref48" rid="niceng185er6.ref48"><sup>48</sup></a> was available that updated this analysis with more evidence therefore this study was selectively excluded.</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Baschet 2006<a class="bibr" href="#niceng185er6.ref9" rid="niceng185er6.ref9"><sup>9</sup></a></td><td headers="hd_h_niceng185er6.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">This study was rated as partially applicable with potentially serious limitations. However, given that a more applicable analysis<a class="bibr" href="#niceng185er6.ref135" rid="niceng185er6.ref135"><sup>135</sup></a> comparing drug-eluting with bare metal stents that included the same RCTs was available this study was selectively excluded.</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Baumler 2012<a class="bibr" href="#niceng185er6.ref10" rid="niceng185er6.ref10"><sup>10</sup></a></td><td headers="hd_h_niceng185er6.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Excluded as rated very serious limitations due to being a model where treatment effects are based on a study that does not meet clinical review inclusion criteria. Also partially applicable, reasons include: German setting may not reflect current NHS context.</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Brophy 2004<a class="bibr" href="#niceng185er6.ref20" rid="niceng185er6.ref20"><sup>20</sup></a></td><td headers="hd_h_niceng185er6.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">This study was assessed as partially applicable with potentially serious limitations. However, given that a more applicable UK analysis<a class="bibr" href="#niceng185er6.ref48" rid="niceng185er6.ref48"><sup>48</sup></a> comparing drug-eluting stents with bare-metal stents based on the same RCTs was available, this study was selectively excluded.</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Brophy 2005<a class="bibr" href="#niceng185er6.ref21" rid="niceng185er6.ref21"><sup>21</sup></a></td><td headers="hd_h_niceng185er6.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">This study was assessed as partially applicable with potentially serious limitations. However, given that a more applicable UK analysis<a class="bibr" href="#niceng185er6.ref48" rid="niceng185er6.ref48"><sup>48</sup></a> comparing drug-eluting stents with bare-metal stents based on the same RCTs was available, this study was selectively excluded.</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ekman 2006<a class="bibr" href="#niceng185er6.ref39" rid="niceng185er6.ref39"><sup>39</sup></a></td><td headers="hd_h_niceng185er6.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">This study was assessed as partially applicable with potentially serious limitations. However, a more applicable UK analysis<a class="bibr" href="#niceng185er6.ref48" rid="niceng185er6.ref48"><sup>48</sup></a> was available that included the same RCT; therefore this study was selectively excluded.</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Goeree 2009<a class="bibr" href="#niceng185er6.ref45" rid="niceng185er6.ref45"><sup>45</sup></a></td><td headers="hd_h_niceng185er6.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Excluded as rated very serious limitations due to being a model where treatment effects are based on a study that does not meet clinical review inclusion criteria. Also partially applicable, reasons include: Canadian setting may not reflect current NHS context.</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Jahn 2010<a class="bibr" href="#niceng185er6.ref52" rid="niceng185er6.ref52"><sup>52</sup></a></td><td headers="hd_h_niceng185er6.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Excluded as rated very serious limitations due to being a model where treatment effects are based on studies that do not meet clinical review inclusion criteria. Also partially applicable, reasons include: Austrian perspective may not reflect current NHS context.</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Kaiser 2005<a class="bibr" href="#niceng185er6.ref54" rid="niceng185er6.ref54"><sup>54</sup></a></td><td headers="hd_h_niceng185er6.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">This study was assessed as partially applicable with potentially serious limitations. However, a more applicable UK analysis was available that incorporated the same RCT;<a class="bibr" href="#niceng185er6.ref48" rid="niceng185er6.ref48"><sup>48</sup></a> therefore this study was selectively excluded.</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Kuukasjarvi 2007<a class="bibr" href="#niceng185er6.ref65" rid="niceng185er6.ref65"><sup>65</sup></a></td><td headers="hd_h_niceng185er6.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">This study was assessed as partially applicable with potentially serious limitations. However, given that a more applicable UK analysis comparing drug-eluting stents with bare-metal stents based on the same RCTs<a class="bibr" href="#niceng185er6.ref48" rid="niceng185er6.ref48"><sup>48</sup></a> was available, this study was selectively excluded.</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Lee 2014<a class="bibr" href="#niceng185er6.ref69" rid="niceng185er6.ref69"><sup>69</sup></a></td><td headers="hd_h_niceng185er6.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Excluded as rated very serious limitations due to being a model where treatment effects are based on a study that does not meet clinical review inclusion criteria. Also partially applicable, reasons include: Korean setting may not reflect current NHS context.</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Poder 2017<a class="bibr" href="#niceng185er6.ref87" rid="niceng185er6.ref87"><sup>87</sup></a></td><td headers="hd_h_niceng185er6.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">This study was assessed as partially applicable with potentially serious limitations. However, given there were more applicable analyses comparing drug-eluting stents with bare-metal stents with the relevant health outcomes this study was selectively excluded. The analysis was a cost-benefit analysis and did not use QALYs as the health outcome.</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Suh 2013<a class="bibr" href="#niceng185er6.ref117" rid="niceng185er6.ref117"><sup>117</sup></a></td><td headers="hd_h_niceng185er6.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">This study was assessed as partially applicable with potentially serious limitations. However, given there were more applicable analyses comparing drug-eluting stents with bare-metal stents with the relevant health outcomes this study was selectively excluded. The analysis was a cost-comparison and did not use QALYs as the health outcome.</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tarricone 2004<a class="bibr" href="#niceng185er6.ref118" rid="niceng185er6.ref118"><sup>118</sup></a></td><td headers="hd_h_niceng185er6.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">This study was assessed as partially applicable with potentially serious limitations. However, given that a more applicable UK analysis comparing drug-eluting stents with bare-metal stents based on the same RCTs<a class="bibr" href="#niceng185er6.ref48" rid="niceng185er6.ref48"><sup>48</sup></a> was available, this study was selectively excluded.</td></tr><tr><td headers="hd_h_niceng185er6.appi.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Van Hout 2005<a class="bibr" href="#niceng185er6.ref129" rid="niceng185er6.ref129"><sup>129</sup></a></td><td headers="hd_h_niceng185er6.appi.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">This study was assessed as partially applicable with potentially serious limitations. However, a more applicable UK analysis was available that incorporated the same RCT;<a class="bibr" href="#niceng185er6.ref48" rid="niceng185er6.ref48"><sup>48</sup></a> therefore this study was selectively excluded.</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal105 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|